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General Introduction 
Fatigue is a common symptom in a number of (chronic) neurological disorders such as multiple 
sclerosis, Parkinson’s disease and stroke (1-7). It was found in patients with these diseases that 
the experience of severe fatigue can be a major determinant of disability and influences the 
quality of life (8-9). Fatigue in neuromuscular disorders has received surprisingly little attention, 
although the clinical experience of our research group has indicated that many patients with 
neuromuscular disorders report fatigue and consider it an important problem (10).  
 
Expert Centre Chronic Fatigue 
The Expert Centre Chronic Fatigue is a multidisciplinary collaboration of internists, virologists, 
neurologists, neurophysiologists, neuroscientists, oncologists, and psychologists from several 
departments of the Radboud University Nijmegen Medical Centre. This centre has studied 
chronic fatigue since 1990, not only in chronic fatigue syndrome, but also in multiple sclerosis, 
after cancer, and in several other (chronic) diseases. A multidimensional assessment method was 
developed and used to create and test models of perpetuating factors in chronic fatigue syndrome 
and multiple sclerosis. These models served as guidelines for developing specific treatment 
interventions 
 
Neuromuscular Centre Nijmegen 
The Neuromuscular Centre Nijmegen investigates basic molecular, histological, genetic and 
physiological mechanisms underlying the common neuromuscular and neurometabolic disorders 
like myotonic dystrophy, facioscapulohumeral dystrophy, hereditary motor and sensory 
neuropathies, myositis, and mitochondrial myopathies, starting from the clinical phenotype. 
Research has been focused on various measurement methods and underlying aspects of muscle 
(physiological) fatigue in recent years.  
The collaboration between the Expert Centre Chronic Fatigue and the Neuromuscular Centre 
Nijmegen combines the expertise of two multidisciplinary research groups with predictors of 
fatigue in neuromuscular disorders. 
 
Experienced fatigue 
Asking patients to describe fatigue will lead to a variety of descriptions: e.g. exercise intolerance, 
weakness, sleepiness or exhaustion. This means that the term fatigue may be confusing, especially 
when used in the context of neuromuscular disorders - in which weakness is usually the main 
symptom - and so the definitions and assessment of the symptom of fatigue are complicated as a 
consequence. Krupp has defined experienced fatigue as an overwhelming sense of tiredness, lack 
of energy and feeling of exhaustion (1). It is not the same as muscle weakness or muscle 
fatigability.  
Fatigue as experienced by the patient is one of the symptoms most frequently presented to the 
treating physician, but most physicians do not know how to handle a symptom of this kind. 
Furthermore, they do not know how to estimate the severity of the problem and assessment 
instruments are useful as a consequence. Fatigue consists of several dimensions, which means it 
is also necessary to assess the other dimensions. A multidimensional assessment method was 
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developed, therefore, and was tested and validated in cross-sectional and prospective studies of 
several chronic disorders (11-15).  
The following relatively independent dimensions appeared to make a contribution to the 
experience of fatigue: functional impairment in daily life, physical activity, psychological distress, 
sleep disturbances, concentration problems, social functioning, social support, sense of control 
over fatigue (self-efficacy), attributions of the possible cause of fatigue, and pain. The question 
where each condition is concerned, is which dimension contributes to experienced fatigue and to 
what degree.  
Since different modes of assessment may yield different results, it is appropriate to measure each 
dimension by a variety of methods and different modalities of assessment are used within the 
multidimensional assessment method (16), including self-report questionnaires, standardised 
sleep and complaint diaries, neuropsychological and behavioural tests, and a motion-sensing 
device (actometer) (Table 1.1).  
This multidimensional assessment method made it possible to develop and test a model of 
perpetuating factors of fatigue in chronic fatigue syndrome (17), which model became the basis 
of the treatment of chronic fatigue syndrome. The same method enabled the development of a 
model and subsequently a treatment for fatigue in cancer survivors (13). 
 
 
TABLE 1.1. Types of fatigue and its assessment 
Type of fatigue  Assessment 
Experienced fatigue Fatigue severity Self-report 
 
Dimension: 
 
Functional impairment in daily life 
 
Self-report 
 Physical activity Self-report 
Actometer 
 Psychological distress Self-report 
 Sleep disturbances Self-report 
 Concentration problems Self-report 
Neuropsychological tasks 
 Social functioning  Self report 
 Social support Self report 
Report of relatives 
 Self-efficacy Self-report 
 Causal attribution Self-report 
 Pain Self-report 
   
Physiological fatigue Localization  Assessment 
 
Central fatigue 
 
Brain 
 
Twitch interpolation technique 
 Spinal cord Twitch interpolation technique 
 
Peripheral fatigue 
 
Peripheral nerve 
 
EMG 
 Neuromuscular junction EMG 
 Muscle EMG 
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Physiological fatigue 
Physiological fatigue has been defined as an exercise-induced reduction in maximal voluntary 
muscle force and is divided into peripheral and central components (18). The loss of force-
producing capacity can have both a peripheral and a central origin (and simultaneously), because 
muscles do not function automatically, but are activated by the central and peripheral nervous 
system (Table 1.1).  
Physiological measurements were used to determine peripheral fatigue and central fatigue. The 
experimental design was used in previous studies of peripheral and central aspects of fatigue in 
healthy subjects (19-20) and the assessment of the central part of fatigue was achieved by means 
of the twitch interpolation technique (21).  
In short, subjects made a 2-minute sustained maximal voluntary contraction of the biceps brachii 
muscle. Electrical stimulation was applied before, just after and every 15 seconds during maximal 
voluntary contraction (MVC). Each stimulus event consisted of 5 applications of a 5-pulse 100 
Hz stimulus train to the motor point. 
The difference in force response during rest before and after sustained MVC was used as a 
measure for peripheral fatigue and superimposed force responses during MVC indicated the level 
of central activation failure. It is a fact that if voluntary muscle activation is optimal, electrical 
stimulation on the muscle will not induce an increase in force. If a failure of voluntary central 
drive is present, however, electrical stimulation will lead to a superimposed force response. 
Despite increasing knowledge of the physiology of peripheral and central fatigue, most studies 
are conducted in healthy controls and so relatively little is known about these aspects of 
physiological fatigue in patients with neuromuscular disorders. This thesis provides the 
opportunity, therefore, to measure experienced fatigue and physiological fatigue simultaneously 
and to assess their interrelationships. 
 
Fatigue in neuromuscular disorders 
Although clinical research shows an increasing interest in aspects of quality of life, experienced 
fatigue is only included sporadically, which is also the case in studies of neuromuscular disorders 
unfortunately.  
Within the group of neuromuscular disorders, fatigue has mostly been described in patients with 
post-polio syndrome (22,23), myasthenia gravis (24), and immune mediated neuropathies like 
Guillain-Barré syndrome (25). Fatigue usually starts at the onset of the disease in the case of the 
last disorder and often stays present for months, in spite of recovery of the nervous system. 
Literature is lacking about the relationship between experienced fatigue and physiological fatigue. 
Now that reliable psychological and clinical neurophysiological techniques are available, a 
multidisciplinary approach may contribute to the elucidation of fatigue in patients with 
neuromuscular disorders and this is what we have tried to do in this thesis. 
This thesis concerns three genetically well defined, homogeneous, and large populations of 
patients with relatively common neuromuscular disorders, namely facioscapulohumeral muscular 
dystrophy (FSHD), adult-onset myotonic dystrophy (MD) and hereditary motor and sensory 
neuropathy type I (HMSN) (26-28). FSHD is an autosomal dominantly inherited myopathy, 
initially characterized by weakness and atrophy in facial, upper arm, and shoulder girdle muscles, 
often progressing to affect peroneal and pelvic girdle muscles (29). 
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MD is the most common form of muscular dystrophy and is also an autosomal dominant 
hereditary multisystemic disease characterized by myotonia, muscle weakness and atrophy, 
cataracts, cardiac abnormalities, excessive daytime sleepiness, and disorders of other systems such 
as the endocrine system, gastrointestinal tract, skin and bone (30). HMSN, also known as 
Charcot-Marie-Tooth disease, forms a heterogeneous group of slowly progressive heritable 
disorders of the peripheral nervous system (31).The most common form is type I, the clinical 
features of which include a symmetrical distal muscle weakness and atrophy, and areflexia and 
sensory impairment with distal loss of touch, pain, vibration and joint position sense. This thesis, 
therefore, compares patients with three different neuromuscular disorders, including a myopathy, 
a multisystem disorder and a neuropathy. 
 
Towards a model of fatigue in neuromuscular disorders 
In view of the fact that fatigue has several dimensions, it is important to find factors that 
perpetuate fatigue in the three neuromuscular disorders. Which factors are determinants of 
fatigue, and how are they related?  Patients with neuromuscular disorders perceive various 
symptoms produced by the pathophysiology of the disorder and affected either directly or 
indirectly via functional limitations or psychological distress, while patients’ perceptions or 
reports of symptoms can be influenced by different factors, such as psychiatric comorbidity and 
the support of close relatives. Functional status refers to the consequences of the disorder on a 
person’s ability to perform functions that are part of everyday life, including physical, social, role, 
and mental functions.  
If we know which factors have predictive value for continuation of the experience of fatigue, we 
can develop a model on which interventions can be based. A longitudinal design was used to 
investigate which factors may be predictors of fatigue and we also investigated whether 
psychiatric comorbidity has a place in the model of perpetuating factors, which we also did for 
the role of the support of close relatives and the relationship with patients’ experienced fatigue. 
The various dimensions and the contribution of each dimension to fatigue were investigated, to 
enable us to include or exclude a dimension in the final model of fatigue in these disorders. 
Structural equation techniques, also referred to as “causal modelling” were used to develop and 
test a model of fatigue in neuromuscular disorders, with the objective of developing a 
theoretically and data-driven model that can be used for the selection and development of 
treatment strategies to reduce fatigue. 
 
Outline of this thesis 
After the introduction of the problem of fatigue (Chapters 1 and 2), we assess the prevalence of 
experienced fatigue in large groups of patients with three relatively common neuromuscular 
disorders, namely FSHD, MD, and HMSN (Chapter 3). We used a validated fatigue questionnaire 
with an empirically derived cut-off score to assess experienced fatigue.  
In Chapter 4 we assess the relationship between psychiatric comorbidity, severe experienced 
fatigue, and muscle strength in these patients, as a consequence of which we investigated the 
presence of current and lifetime psychiatric comorbidity by the use of a structured clinical 
interview and self-reported questionnaires. Furthermore, we investigated the relationship 
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between experienced fatigue and ambulatory and mobility-related problems, and the use of 
walking aids (Chapter 5). 
The contribution of physiological factors to fatigue may be particularly relevant in neuromuscular 
disorders, however, and Chapters 6 and 7 present the relationship between experienced and 
physiological fatigue. We studied different types of fatigue (experienced fatigue and physiological 
fatigue) using a multidimensional assessment method to determine which dimensions were 
related to experienced fatigue and which to physiological fatigue.  
In Chapter 8 we explore the relationship between pain and experienced fatigue in FSHD, MD, 
and HMSN, investigating the presence, localization and other characteristics of pain in these 
disorders and its relationship with experienced fatigue. 
Chapter 9 addresses the influence of close relatives on the patient’s experienced fatigue, the 
responses of these relatives, and the relationship between the responses of the close relatives and 
the degree of the patient’s experienced fatigue. 
In Chapter 10 the focus is on the development of a model of perpetuating factors, using 
longitudinal data for a large cohort of patients with three neuromuscular disorders. The model is 
first tested in the group a whole and we subsequently attempt to develop separate models for the 
three neuromuscular disorders. 
In the final chapter of this thesis (Chapter 11), the general discussion addresses the main findings 
and clinical implications. 
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ABSTRACT 
 
Chronic fatigue is a symptom of diseases such as cancer, multiple sclerosis, Parkinson's disease 
and cerebrovascular disorders. Fatigue can also be present in people with no demonstrable 
somatic disease. If certain criteria are met, chronic fatigue syndrome can be diagnosed. Fatigue is 
a multi-dimensional concept with both physiological and psychological aspects. The 'Short 
Fatigue Questionnaire' consisting of 4 questions is a tool to measure the level of experienced 
fatigue with a high degree of reliability and validity. 
Within the group of patients with neuromuscular disorders, fatigue has been reported in patients 
with post-polio syndrome, myasthenia gravis and Guillain-Barré syndrome. The percentage of 
neuromuscular patients suffering from severe fatigue (64%) is similar to that of patients with 
multiple sclerosis, a disease in which fatigue is an acknowledged symptom. 
Now that reliable psychological and clinical neurophysiological techniques are available, a 
multidisciplinary approach to fatigue in patients with well-defined neuromuscular disorders may 
contribute towards the elucidation of the pathophysiological mechanisms of chronic fatigue, with 
the ultimate goal to develop methods of treatment for fatigue in neuromuscular patients.  
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INTRODUCTION 
 
Fatigue is a universal and daily phenomenon. In the general practitioner's office, symptoms of 
fatigue are ranked third on the list of most reported problems (1).The symptom of fatigue, 
however, covers a difficult multidimensional concept and therefore creates a complex problem 
for the physician. 
Fatigue as a chronic symptom is a well-known manifestation of a number of somatic disorders, 
like cancer, multiple sclerosis, Parkinson's disease and cerebrovascular disorders (Table 2.1). It 
also occurs as a side-effect of medication like β-blockers. Fatigue has been described in 
depression and during stress. There also is a group of severely fatigued patients that do not have 
a somatically demonstrable disease. If fatigue exists for more than 6 months and patients fulfill a 
number of additional criteria (Table 2.2), the disorder is diagnosed as chronic fatigue syndrome 
(CFS) (2). It is estimated that about 30,000 to 40,000 people suffer from CFS in the Netherlands 
(3). It is less well known that chronic fatigue also often occurs in neuromuscular disorders and 
that it has a considerable impact on these patients. Citing a neuromuscular patient: "Personally I 
consider fatigue as a more severe problem than the measurable somatic problems and handicaps. 
Fatigue makes me miss several things, whereas I could learn to live with the somatic handicaps. 
Despite my somatic problems I could fully function in society, if only the problem of fatigue was 
solved." 
 
 
TABLE 2.1. Percentage of patients with several disorders experiencing severe fatigue. 
Disorder Percentage of severely fatigued patients 
Cancer (during treatment) 75-99 4,5 
Multiple sclerosis 57-97 4,6 
After cerebrovascular accident 51 7 
Chronic pancreatitis 73 7 
Post polio syndrome 80 4 
Parkinson’s disease 65 4 
Systemic lupus erythematosus 80 4 
Myasthenia gravis 82 8 
Guillain-Barré syndrome 81-86 9 
 
In the fundamental sciences, especially neurobiology, fatigue has been defined as a time-related 
force decline (10,11). In clinical medicine fatigue has not been investigated thoroughly until 
recently, possibly because the term was regarded subjective and was not well-defined (12). Now 
that we have a better insight into different aspects of chronic fatigue and we can measure these 
reliably, subjective feelings can be studied scientifically. Therefore, researchers and clinicians 
more and more see that fatigue is a problem worth the study (4,7). 
This chapter describes the term fatigue and how it can be measured and reviews the literature 
about fatigue in neuromuscular disorders. 
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TABLE 2.2. Criteria for chronic fatigue syndrome (2) 
To diagnose chronic fatigue syndrome the following criteria should be fulfilled 
Clinically evaluated, unexplained, persistent or relapsing fatigue that is of new or  
definite onset (has not been lifelong) and lasts for 6 or more consecutive months 
Fatigue is not the result of ongoing exertions 
Fatigue is not substantially alleviated by rest 
Fatigue results in substantial reduction in previous levels of occupational, educational, social,  
or personal activities 
Four or more of the following symptoms are concurrently present for ≥ 6 months 
Impaired memory or concentration 
Sore throat 
Tender cervical or axillary lymph nodes 
Muscle pain 
Multi-joint pain 
New headaches 
Unrefreshing sleep 
Post-exertion malaise 
 
 
Experienced fatigue 
Asking patients or physicians to describe fatigue will lead to a variety of descriptions: e.g. 
sleepiness, weakness, exercise intolerance or exhaustion. Thus, the term fatigue may be 
confusing, especially when used in the context of neuromuscular disorders, in which weakness is 
usually a main symptom. This complicates the definition, diagnosis and treatment of the 
symptom of fatigue.  
Medical literature usually defines fatigue in the sense of 'experienced fatigue': an overwhelming 
sense of tiredness, lack of energy and feeling of exhaustion (4,7,13,14). A problem arises in 
discriminating the level of fatigue between different individuals. Everyone knows the feeling of 
fatigue, but do we mean the same thing? In order to compare levels of fatigue between subjects, 
fatigue should be quantified. For physicians this has practical implications, because they often 
need to evaluate the seriousness of the sign. This may be important to predict other symptoms or 
consequences of the disease, like the need for medical supplies or a reduction in working hours 
(15). Experienced fatigue is a concept with both psychological and physiological dimensions. For 
example the psychological factors well-being, concentration, attributions and social functioning 
may all influence experienced fatigue (16) (Table 2.3). 
Experienced fatigue can best be quantified with questionnaires. The Checklist Individual Strength 
(CIS) (17) contains an eight-item subscale fatigue. It is used both for scientific research and for 
patient care. For clinical practice also the Abbreviated Fatigue Questionnaire (AFQ) may be used 
(18,19). This is a shortened version of the CIS, which measures fatigue with four items. It has 
both a good reliability and validity and has been developed to use in the general practitioner's 
office. 
 
Physiological fatigue 
In physiology, fatigue is usually defined as the loss of voluntary force-producing capacity during 
exercise (20). Physiological fatigue is not necessarily accompanied by experienced fatigue, nor 
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vice versa. The loss of force producing capacity can both (and simultaneously) have a peripheral 
and a central origin because muscles do not function autonomically, but are activated by the 
nervous system (Table 2.3).  
Fatigue has mostly been studied at the peripheral level, that is in the muscle tissue. Peripheral 
fatigue is mainly ascribed to changing intracellular ion levels having a negative effect on 
contractile force (21-23). During peripheral fatigue, accumulation of lactate and extracellular 
potassium, together with a lowering of the pH, influence membrane excitability (24). Therefore, 
muscle fiber conduction velocity reflects the peripheral situation. With the multi-channel 
electrode grids developed at the Department of Clinical Neurophysiology in Nijmegen muscle 
fibre conduction velocity can be assessed quite easily (25). The most direct measure of peripheral 
fatigue, however, is the different force response to artificial electrical stimulation during rest after 
exercise compared to before. This directly shows the loss of force produced by the muscle tissue 
after constant input into the muscle. 
 
TABLE 2.3. Dimensions possibly influencing experienced fatigue. 
Type of fatigue Location 
Physiological  
Central fatigue Brain 
 Spinal cord 
 Peripheral nerve 
 
Peripheral fatigue 
 
Neuromuscular transition 
 Muscle 
Psychological  
Concentration  
Restrictions in daily functioning  
Physical activity  
Attributions about fatigue (e.g. attitude, self-efficacy)  
Social support  
Psychological well-being  
Sleep disturbances  
 
Central fatigue, the decrease of voluntary activation of the muscle by the nervous system, 
nowadays gains interest. A muscle receiving suboptimal input from the nervous system will not 
show its maximal force capacity. In the case of sub-maximal central activation, central activation 
failure (CAF) is said to be present. An increase of CAF during exercise is called central fatigue.  
Sub-maximal voluntary drive may have several causes, like a lack of motivation or exhaustion of 
cortical neurons in the motor cortex. Usually, CAF is determined with a version of the so called 
twitch-interpolation technique (26). Subjects are instructed to make a maximal voluntary 
contraction (MVC) of a specific muscle. During MVC, artificial electrical stimulation is applied 
on the motor nerve or motor endplate. If voluntary central drive is optimal, this will not lead to 
additional force production. However, if voluntary activation is sub-maximal, electrical 
stimulation results in an increase of force. Thus, in this case CAF can be shown. With this 
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technique, CAF can be quantified and its change over time (central fatigue) may be studied, but it 
cannot discriminate between the different causes of CAF.  
Combining data about central and peripheral aspects of fatigue will lead to a more profound 
insight into the relative contributions of these aspects to physiological fatigue.  
 
Fatigue in neuromuscular disorders 
Because experienced fatigue has direct consequences for the quality of life, questionnaires like the 
CIS can be used in studies in which the quality of life is the main research topic (18). Although 
clinical research shows an increasing interest in aspects of quality of life, experienced fatigue is 
only sporadically included. This unfortunately is also the case for studies into neuromuscular 
disorders. In a number of other neurological disorders, like multiple sclerosis or Parkinson's 
disease, however, fatigue is well-known and accepted as a disease related symptom(6,13,27,28) 
(Table 2.1).  
Despite the many different neuromuscular disorders, only a limited number of symptoms occurs. 
Muscle weakness is the most typical one. Other symptoms are pain, muscle loss, involuntary 
movements, myotonia, and contractures (29). Experienced fatigue is not the same as weakness; 
fatigue is an independent symptom. Patients having fatigue without weakness usually do not have 
a known neuromuscular disorder (30). In contrast, fatigue is not often recognized as a problem in 
neuromuscular disorders accompanied by weakness (31). 
A number of patients with specific neuromuscular disorders like metabolic or mitochondrial 
disorders, however, do not show muscle weakness, but do show fatigue in the sense of exercise 
intolerance. Besides, some types of patients experience both muscle weakness and fatigue, like for 
example the patient cited above. A possible explanation is that the weak or atrophic muscles have 
to function at their (e.g. metabolic) limits (30). For these patients, daily life is so demanding that 
we could consider them top sportsmen in daily life. This type of fatigue has not yet been studied 
well.  
Within the group of neuromuscular disorders, fatigue has mostly been described in patients with 
postpolio syndrome (32,33), myasthenia gravis (8), and immune mediated neuropathies like 
Guillain-Barré syndrome (9). In the last disorder, fatigue usually starts at the onset of the disease 
and often stays present for months in spite of total recovery of the peripheral nervous system. In 
myasthenia gravis peripheral fatigue has been studied and explained only part of the experienced 
fatigue (8). 
As a first investigation preceding the extensive study presented in the next chapter, our group has 
compared experienced fatigue, functional limitations, psychological well-being and depression in 
64 consecutive patients with a neuromuscular disorder visiting the outpatient clinic of our 
hospital and in 94 patients with multiple sclerosis (34). Sixty four % of the patients with a 
neuromuscular disorder and 57 % of those with multiple sclerosis experienced severe fatigue. 
Thus, experienced fatigue appears equally in patients with neuromuscular disorders and multiple 
sclerosis. Though, in multiple sclerosis fatigue is generally accepted, whereas it is not in 
neuromuscular disorders. To optimize care for patients with neuromuscular disorders it is 
important to recognize these high percentages of fatigue and to understand the underlying 
pathophysiological mechanisms.  
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Experienced fatigue in Facioscapulohumeral Dystrophy, Myotonic Dystrophy and 
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ABSTRACT 
 
Objectives 
The primary object of this study was to assess the prevalence of experienced severe fatigue and 
its relation with functional impairments in daily life in a large sample of patients with relatively 
common types of neuromuscular disorders.  
Methods 
598 patients with a neuromuscular disorder (139 Facioscapulohumeral Dystrophy, 322 adult-
onset Myotonic Dystrophy patients and 137 Hereditary Motor and Sensory Neuropathy type I  
patients) were studied. Fatigue severity was assessed with the Checklist Individual Strength (CIS-
fatigue). Functional impairments in daily life were measured with the SF-36 health survey 
questionnaire (SF-36). 
Results 
The three different neuromuscular patient groups were similar with respect to age and gender. 
Severe experienced fatigue was reported by 61-74 percent of the patients. Severely fatigued 
neuromuscular patients had more problems with physical functioning, social functioning, mental 
health, bodily pain, and general health perception.   
Conclusion 
Severe fatigue is reported by the majority of patients with relatively common types of 
neuromuscular disorders. Because experienced fatigue severity is associated with the severity of 
various functional impairments in daily life, it is a clinically and socially relevant problem in this 
group of patients. There appeared to be several differences in relation with fatigue between the 
three neuromuscular disorders. 
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INTRODUCTION 
 
Experienced fatigue has been defined as an overwhelming sense of tiredness, lack of energy and 
feeling of exhaustion and is not the same as weakness (1). Fatigue is a common symptom in 
different neurological disorders such as multiple sclerosis, Parkinson’s disease and stroke (1-7). 
In these patient populations it was found that the experience of severe fatigue can be a major 
determinant of disability and has influence on the quality of life.  Surprisingly, fatigue in 
neuromuscular disorders has received very little attention so far. There are some studies in 
patients with various neuromuscular disorders. Paul et al showed that 82% of a group of 
myasthenia gravis patients reported fatigue as a regular symptom of their disease (8). A study of 
Berlly et al showed that 68% of a group of post-polio patients reported daily fatigue. Half of 
these fatigued patients noted that their fatigue had led to the need for assistance in daily life (9). 
In a group of immune-mediated polyneuropathies it was found that fatigue was a prominent and 
highly disabling symptom (10). Herlofson et al showed that fatigued patients with Parkinson’s 
disease reported more problems in areas of functional limitations (11). Fisk et al found that 
fatigue has a significant effect on the general health status in patients with multiple sclerosis (12). 
The impact of fatigue in health related quality of life in patients with neuromuscular disorders 
has not been studied so far. 
Clinical experience and preliminary findings of our research group indicated that also many 
patients with a neuromuscular disorder experience severe fatigue and consider it an important 
problem (13). Most psychological studies in neuromuscular disorders, however, have focused 
mainly on disability or loss of quality of life, and did not address the problem of experienced 
fatigue among different neuromuscular disorders (14-16). Currently, no cross-sectional study has 
compared the presence and severity of fatigue in various neuromuscular disorders using 
validated instruments. 
This study concerns three genetically well defined, homogeneous, and large populations of 
patients with relatively common neuromuscular disorders, namely facioscapulohumeral muscular 
dystrophy (FSHD), adult-onset myotonic dystrophy (MD) and hereditary motor and sensory 
neuropathy type I (HMSN). FSHD is an autosomal dominantly inherited myopathy (17). MD is 
the most common form of muscular dystrophy and is an autosomal dominant hereditary 
multisystemic disease involving skeletal muscles, eye, heart, lungs, gastrointestinal tract, bone, 
skin, central nervous system and peripheral nervous system (18).  HMSN type I is the most 
common genetic disorder affecting the peripheral nervous system (19-21). Thus, this study 
compares experienced fatigue in three different neuromuscular patient populations, including a 
myopathy, a multisystem disorder and a neuropathy. 
Our research group has developed a multidimensional assessment method to measure fatigue in 
several chronic disorders (22-25). In this study we investigated besides fatigue severity the 
relation between fatigue and functional impairments in daily life.   
Health-related quality of life scales, like the Short Form 36 (SF-36), might be useful  to assess  
important domains of health and various aspects of impairment from the patient’s perspective 
(26). We chose the SF-36 as the most widely used generic health related scale to evaluate the 
potential impact of fatigue on different components of functional impairments in daily life in 
patients with a neuromuscular disorder. 
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In this article we will answer the following research questions. 1) How many patients with these 
neuromuscular disorders experience severe fatigue?; 2) Are there differences in fatigue severity, 
demographical variables and various functional impairments between the different 
neuromuscular disorders?; 3) What is the contribution of physical functioning, social 
functioning, mental health and bodily pain to fatigue severity in three different relatively 
common neuromuscular disorders? 
 
 
 
METHODS 
 
Patients 
Adult patients in the age of 18 to 65 years with a definite diagnosis of a neuromuscular disorder 
who could be classified into one of the following three diagnostic categories were asked to 
participate: (1) facioscapulohumeral muscular dystrophy (FSHD), (2) adult-onset myotonic 
dystrophy (MD) or (3) hereditary motor and sensory neuropathy type I (HMSN). Part of the 
patients was recruited from our Neuromuscular Centre, Radboud University Nijmegen Medical 
Centre in the Netherlands. The remaining part of the patients was recruited from the Dutch 
Neuromuscular Diseases Association (Vereniging Spierziekten Nederland, VSN).  
In total, 900 patients were informed by a letter and received a booklet with questionnaires 
(described below) at home. Subjects were asked which diagnosis was made and if this was done 
by a neurologist or clinical geneticist.  
The study used a cross-sectional design to assess fatigue in patients with a neuromuscular 
disorder. Written information about the purpose of the study was provided to all patients. The 
study was approved by the local ethics committee.  
 
Fatigue severity 
The Checklist Individual Strength (CIS) is a 20-item questionnaire and measures the following 
four separate aspects of fatigue during the previous two weeks: fatigue severity (8 items, range 8-
56), concentration problems (5 items, range 5-35), reduced motivation (4 items, range 4-28) and 
reduced activity (3 items, range 3-21). Each item was scored on a 7-point Likert scale. High 
scores indicated high levels of fatigue, high levels of concentration problems, low motivation 
and low levels of activity (22). The CIS had good internal consistency and split-half reliability 
(27). A CIS-fatigue score equal to or higher than 35 was used to identify severe fatigue (28). 
 
Functional impairment in daily life 
The following subscales of the Short Form-36 were used to assess different areas of functional 
impairments in daily life: physical functioning, social functioning, role limitations due to physical 
health problems, role limitations due to emotional problems, mental health, bodily pain and 
general health perception (29). The transformed scores for all SF-36 scales ranged from 0 to 100. 
For each subscale a higher score indicated better functioning or less pain. 
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Statistics 
Data analysis was performed using SPSS for Windows (version 11.0). Descriptive statistics were 
used to describe the sample. Normality was tested according to the Kolmogorov-Smirnov test. t-
tests, chi-square and one-way ANOVA’s  were performed to test differences between groups.  
In case of an overall significance, the Bonferonni correction was applied to compare the three 
patient groups. P values <= 0.05 were regarded as statistically significant. Correlations were 
calculated with the Pearson coefficient (r). In order to examine the contribution of physical 
functioning, social functioning, mental health and bodily pain in relation to fatigue severity, 
linear regression analyses (enter-method) were performed. 
 
 
RESULTS 
 
From the 647 adult patients who returned the questionnaires (72%), 49 patients were excluded. 
Excluded were patients without a diagnosis of FSHD, MD or HMSN type I (n=30), and 
incomplete booklets (n=19). A total of 598 patients fitted the inclusion criteria and completed 
the questionnaires (66%). This group consisted of 139 FSHD patients, 322 MD patients, and 
137 HMSN-I patients. Diagnoses of a quarter of these patients were made at our hospital 
according to established criteria (30). Results from this sub-group did not differ from the results 
of the total group of participants. Demographic characteristics of the complete groups are listed 
in Table 3.1. No significant differences were found in age, gender and marital status between the 
three groups. The MD group had a significantly lower level of education than the two other 
patient groups. 
 
TABLE 3.1. Demographic characteristics of patient groups  
  
FSHD 
N=139 
Mean (SD) 
MD 
N=322 
Mean (SD) 
HMSN 
N=137 
Mean (SD) 
Mean age  43.7 (10.1) 43 (10) 42.5 (10.7) 
Age range  22–61 18–63  19-63  
Gender (M/F)   49%/ 51%  47%/ 53% 41%/ 59% 
Marital status (%)     
   married/living together  74% 70% 69% 
   single  25% 30% 31% 
   missing information    1% --- --- 
Education level (%)*     
   lower  32% 53% 28% 
   intermediate  34% 28% 27% 
   upper  34% 19% 29% 
   missing information    1% --- --- 
* significantly different between MD and FSHD and between MD and HMSN (p-value < 0.05) 
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Fatigue and functional impairments in FSHD, MD and HMSN 
All patient groups experienced high levels of fatigue. The mean CIS-fatigue score in the FSHD 
group was 36.5 (SD 12.5), in the MD group 40.4 (SD 11.8) and in the HMSN group 37.4 (SD 
12.2). In the FSHD group 61% was severely fatigued, in the MD group 74% and in the HMSN 
group 64%. 
In Table 3.2, a comparison is made between the three patient groups (FSHD, MD, HMSN), 
with regard to functional impairments in daily life. The MD group reported having significantly 
more concentration problems, higher levels of reduced motivation and reduced levels of activity. 
The MD group perceived lower general health but experienced less bodily pain than the FSHD 
and HMSN patients.  
 
TABLE 3.2. Patient groups and their mean values on the main outcome measures 
  
FSHD 
N=139 
Mean (SD) 
MD 
N=322 
Mean (SD) 
HMSN 
N=137 
Mean (SD) 
p-value 
CIS      
CIS-fatigue  36.5 (12.5)b 40.4 (11.8)ac 37.4 (12.2)b 0.002 
CIS-concentration  12.3 (8.2)b 16.8 (8.3)ac 13.8 (8.7)b 0.000 
CIS-motivation  12    (5.9)b 16.8 (6.6)ac 12.2 (6.1)b 0.000 
CIS-activity  10.1 (5.5)b 13.2 (5.6)ac   9.4 (5.5)b 0.000 
      
SF-36      
physical functioning  45.2 (31.4) 48.4 (28.2) 53.1 (26.4) ns 
social functioning  71.6 (24.2) 69.9 (24.3) 67.5 (24.3) ns 
role limitations physical  47.9 (42) 48.2 (39.7) 48.9 (39) ns 
role limitations emotional  69.5 (41.6) 73.9 (37.6) 67.4 (41.6) ns 
mental health  72.6 (17) 72.7 (18) 68.9 (19.2) ns 
bodily pain  66.6 (23.8)b 75.4 (25.3)ac 68.5 (25.5)b 0.001 
general health perception  51.7 (21.6)b 40.5 (22.3)ac 52.5 (20.7)b 0.000 
A higher value indicates more complaints or impairments 
a Significantly different from FSHD, Bonferonni p<0.05 
b Significantly different from MD, Bonferonni p<0.05 
c Significantly different from HMSN, Bonferonni p<0.05 
 
 
Age related problems 
In the FSHD group and the MD group, age correlated significantly with fatigue severity (FSHD: 
r=0.19, p=0.002; MD: r=0.17, p=0.002). In all three patient groups, higher age is associated with 
more impairments in physical functioning and more bodily pain. Among the MD patients, age 
correlated significantly with all subscales of the SF-36 and with reduced motivation and reduced 
activity of the CIS. 
 
Severely fatigued patients 
Severely fatigued patients (CIS-fatigue >= 35) were compared with less fatigued patients (CIS-
fatigue < 35) within the three neuromuscular disorders. Severely fatigued FSHD patients, MD 
patients and HMSN patients had significantly more concentration problems, higher scores on 
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reduced motivation and reduced levels of physical activity. Severely fatigued neuromuscular 
patients also had significantly lower scores at all subscales of the SF-36.   
 
Contribution of different dimensions to fatigue severity 
Regression analyses have been performed to examine the contribution of different dimensions in 
relation to fatigue severity (Table 3.3). For each group separate analyses were carried out, with 
CIS-fatigue as the dependent variable. In none of the groups did age contribute to fatigue 
severity. In the FSHD group, physical functioning, social functioning and bodily pain 
contributed significantly to fatigue severity. In the MD group physical functioning and social 
functioning contributed significantly to fatigue severity. In the HMSN group none of the 
independent variables contributed significantly to fatigue severity. The correlations between CIS-
fatigue and the SF-36 sub-scales are weaker in the HMSN group than in the FSHD and MD 
group. 
 
TABLE 3.3. Linear regression analysis to predict fatigue severity 
  Dependent variable CIS-fatigue severity 
  FSHD 
Beta 
FSHD 
P 
MD 
Beta 
MD 
p 
HMSN 
Beta 
HMSN 
p 
Independent variables          
physical functioning  -.228 0.010 -.398 0.000 -.188 0.056 
social functioning  -.219 0.038 -.157 0.015 -.107 0.358 
mental health  -.031 0.725 -.112 0.048 -.166 0.121 
bodily pain  -.195 0.042 -.062 0.284 -.146 0.121 
age  .022 0.900 -.087 0.114 -.148 0.083 
Total R2  (adjusted)  .238  .270  .143  
 
 
 
DISCUSSION 
 
This is the first cross-sectional study in which experienced fatigue has been investigated in three 
large homogeneous groups of neuromuscular disorders with validated measurements, as far as 
we know. This study demonstrated that in the investigated patient groups of FSHD, MD and 
HMSN-I 61-74% were severely fatigued. This finding means that the experience of severe 
fatigue is a major complaint in most patients with these neuromuscular disorders. In all three 
patient groups, being severely fatigued was associated with higher levels of functional 
impairments in daily life.   
Further, results showed that patients with MD have significantly higher scores of severe fatigue, 
reported significantly more problems with concentration (CIS-concentration), and have 
significantly more difficulties with initiating and planning (CIS-reduced motivation) than the 
other two patient groups. Daytime sleepiness is an established clinical manifestation of MD 
(18,31-32). It is possible that MD patients confuse the experience of fatigue with daytime 
sleepiness, which may have affected the CIS-fatigue scores of the MD patient group. However, 
van der Werf et al showed that experienced fatigue, measured with the CIS-fatigue, and daytime 
sleepiness are different clinical manifestations in MD (33). 
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In addition, we found that MD patients have a significantly lower education level than the 
FSHD and HMSN patients. These differences could be explained by disease-specific problems 
associated with a multisystem disorder like MD. Mental dysfunction in MD, such as reduced 
intelligence, lower levels of concentration and initiation have been recognised, in contrast to the 
lack of such defects in other disabling neuromuscular disorders (18, 31).  FSHD patients and 
HMSN patients turned out to have higher scores of bodily pain than the MD patients. These 
results are consistent with reports of presence of pain in other studies in FSHD and HMSN 
patients (14-16). Pain, particularly back pain, is often cited as a problem but is poorly studied in 
MD patients (31). 
In all groups age and fatigue severity do not seem related, as no contribution of age and fatigue 
severity was found in the regression analyses. Karlsen showed that fatigue severity is not 
regarded as part of the normal aging process (5).  
Significant correlations between age and functional impairments in daily life suggest that higher 
age is associated with more  impairments in physical functioning and bodily pain in all three 
patient groups. This result is in accordance with the fact that these disorders are progressive. 
Literature already described an increase of physical limitations with age (17-19). In MD, age also 
correlated with all other functional impairments. These results were in line with the differences 
between the three neuromuscular disorders (18,31). 
Compared with healthy controls, mentioned in the manual of the Dutch version of the SF-36, 
the mean scores of all three neuromuscular patient groups were lower on all SF-36 subscales 
(26). In addition, the severely fatigued patients in all three neuromuscular disorders scored lower 
than the non-severely fatigued patients, suggesting a relation between fatigue and functional 
impairments. Herlofson et al showed that fatigued patients with Parkinson’s disease reported 
more problems in areas of functional limitations and the patients with fatigue had a more 
advanced disease than those without fatigue, measured by a disease severity scale for Parkinson’s 
disease (11). A study of Fisk et al found that fatigue has a significant effect on the general health 
status in patients with multiple sclerosis (12). They found that disease classification and 
neurological impairment had little bearing on fatigue in patients with multiple sclerosis. In our 
study we have not used a disease severity scale, so we can not investigate the relation between 
fatigue severity and disease severity in these disorders. 
Regression analyses suggest that in FSHD patients physical functioning, bodily pain and social 
functioning are related to fatigue severity. In MD patients only physical functioning and social 
functioning were related to fatigue severity. In HMSN patients none of the dimensions 
contributed independently to fatigue severity. Thus, in this group fatigue is less clearly related to 
functional impairments. Possibly, factors that we did not measure, play a more prominent role in 
the contribution of fatigue. 
The impact of fatigue in health related quality of life in patients with neuromuscular disorders 
has not been studied so far. 
Our findings must, however, be interpreted in the context of methodological limitations. Firstly, 
the cross-sectional design of this study makes it impossible to draw conclusions on the direction 
of the association. Secondly, not all diagnoses were made at our hospital. About a quarter of the 
patients in this study come from our hospital and the diagnoses of those patients were checked. 
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Nevertheless, this group of patients did not differ in all main outcome variables from the 
remaining patients recruited from the Dutch Neuromuscular Diseases Association. 
In conclusion, the present study shows that the majority of a large sample of patients with 
relatively common types of neuromuscular disorders experienced severe fatigue. Which factors 
are related to fatigue severity, appears to be different in the three neuromuscular disorders. 
Severe fatigue is associated with serious impairments in daily life. Therefore, experienced fatigue 
is a clinically and socially relevant problem in patients with a neuromuscular disorder.  
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ABSTRACT 
 
Objectives 
To study the presence of psychiatric comorbidity assessed by the use of a structured clinical 
interview and self-reported questionnaires in a large sample of patients with adult-onset DM, 
FSHD, and HMSN-I, and to assess whether psychiatric comorbidity is related to fatigue severity 
and/or muscle strength.  
Methods 
In a cohort of 217 patients with a neuromuscular disorder (79 DM, 65 FSHD and 73 HMSN-I 
patients) overall psychiatric comorbidity was studied cross-sectionally with the structured clinical 
interview (SCID) for DSM-IV axis I disorders. Self-reported psychopathology, fatigue severity 
and muscle strength were assessed with the Beck Depression Inventory, SCL-90, General Health 
Questionnaire-12, Checklist Individual Strength, and muscle strength (MRC-scale). 
Results 
In all three neuromuscular disorders (DM, FSHD and HMSN), 10 to 12% of the patients met 
DSM IV clinical criteria for current psychiatric disorders. Lifetime psychiatric disorders were 
found in 32% of patients in all three patient groups. The most common psychiatric disorders 
were depression and phobias. A comparison of patients with and without current psychiatric 
disorder showed that fatigue severity and muscle strength (MRC) were not related to psychiatric 
comorbidity.  
Conclusion 
Psychiatric disorders appear equally in patients with DM, FSHD and HMSN-I and are not related 
to fatigue or muscle strength in these patients. 
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INTRODUCTION 
 
Previous studies have documented the presence of psychiatric comorbidity in neurological 
disorders. These studies found high prevalence of depression (40%) in neurological patients (1,2). 
Similar findings have been described for depressive disorders comorbidity with specific 
neurological disorders such as Parkinson’s disease, stroke and multiple sclerosis (3-7). Carson et 
al conclude that patients with various neurological diseases are at risk for developing depressive 
disorders (1). It has been recognised that mood disorders and anxiety disorders contribute to well 
being and improvement in patient’s disability (8). 
Only few studies have examined levels of depression and anxiety in patients with various 
neuromuscular disorders. The largest study of patients with various neuromuscular disorders 
examined psychopathology of 36 DM patients and 13 HMSN patients (9). Current diagnosis of 
major depression was found in 6% of patients with DM and in none of the HMSN patients. Half 
of the DM patients and one third of HMSN patients met the diagnosis for lifetime history of 
major depression. Substance related disorders has not been studied systematically in patients with 
neuromuscular disorders. 
Fatigue is a common complaint of patients with neurological disorders, including neuromuscular 
disorders (3,10). An association between fatigue and psychiatric disorders has been reported in a 
number of neurological disorders, including Parkinson’s disease and multiple sclerosis (6,8).  
Fatigue is a major component of a number of affective disorders, including major depression and 
dysthymia. We have found no studies examining the association of psychiatric disorders and 
fatigue in neuromuscular disorders.  
The present study concerns three genetically well-defined and homogeneous populations of 
patients with relatively common neuromuscular disorders, namely adult-onset myotonic 
dystrophy (DM), facioscapulohumeral muscular dystrophy (FSHD), and hereditary motor and 
sensory neuropathy type I (HMSN). DM is the most common form of muscular dystrophy and is 
an autosomal dominantly inherited multisystemic disease characterized by myotonia, muscular 
weakness, cardiac abnormalities, cataract, and disorders of other systems such as the endocrine 
system, gastrointestinal tract , and the central nervous system, the known abnormalities of which 
concern cognitive processes, and affective status (11). FSHD is an autosomal dominantly 
inherited myopathy (12). HMSN type I is the most common genetic disorder affecting the 
peripheral nervous system (13-15). Thus, this study compares psychiatric comorbidity in three 
different neuromuscular patient populations, including a multisystem disorder, a myopathy and a 
neuropathy. To date, no study has compared psychiatric comorbidity in large groups of patients 
with DM, FSHD and HMSN using a standardized psychiatric interview and self-report 
questionnaires. 
The aims of this study were to determine the presence of psychiatric disorders, specifically mood 
disorders, anxiety disorders and substance related disorders, (lifetime and current) in patients with 
DM, FSHD and HMSN patients, and to assess if psychiatric comorbidity was related to fatigue 
severity and/or muscle strength. 
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METHODS 
 
Patients 
Adult patients in the age of 18 to 60 years with a definite diagnosis of a neuromuscular disorder 
who could be classified into one of the following three diagnostic categories were asked to 
participate: (1) adult-onset myotonic dystrophy (DM), (2) facioscapulohumeral muscular 
dystrophy (FSHD) or (3) hereditary motor and sensory neuropathy type I (HMSN). Patients were 
recruited from the outpatient clinic of the Neuromuscular Centre of the Radboud University 
Nijmegen Medical Centre and the database of the Dutch Neuromuscular Diseases Association. 
Patients are a subgroup of patients described earlier (10). 
Only ambulatory patients were included. From the 527 patients that were eligible 331 patients 
were willing to participate in the research project. We invited 240 patients (for each 
neuromuscular disorder at least 70 patients) and 217 patients (79 DM, 65 FSHD and 73 HMSN 
patients) complete data could be collected. Patients dropped out (n=23) for several reasons: high 
travel distance, inability to take a day off or personal reasons.  Written informed consent was 
obtained from all participating patients. The following demographic features were collected: age, 
gender, marital status, and highest level of education and current status of employment. The 
Committee on Research Involving Human Subjects approved the study. 
 
Psychiatric comorbidity based on a structured clinical interview 
Psychiatric disorders were valuated using the Structured Clinical Interview for DSM-IV (SCID-I-
R) axis 1 disorders (16). The Dutch translation of the SCID was used, by which post-interview 
diagnoses based on DSM-IV criteria can be generated (17). Three broad categories of psychiatric 
disorders were assessed: mood disorders (depression and dysthymic disorder), anxiety disorders 
(panic disorder, simple phobia, PTSD, general anxiety disorder and obsessive compulsive 
disorder), and substance related disorders (alcohol and drugs abuse).  According to DSM IV 
guidelines a distinction was made between current (disease manifest in the past 30 days) and 
lifetime (disease not manifest in the past 30 days) diagnoses.  
 
Psychiatric comorbidity based on self-reported questionnaires 
The Beck Depression Inventory (BDI) is a 21-item standardised self-report questionnaire 
measuring depression on a 4-point scale ranging from 0 to 3 (18). 
The Symptom Checklist-90 (SCL-90) measures self-reported psychopathology. This 
questionnaire asks for anxiety, agoraphobia, depression, somatisation, obsessive-compulsive 
behaviour, interpersonal sensitivity, hostility and sleep disturbances (e.g., light and fragmented 
sleep, difficulties with sleep initiating) (19). The total score can be considered as a general 
measure of psychological distress. 
The 12-item version of the General Health Questionnaire (GHQ-12) was used as a screening tool 
for psychiatric disorders within the general population (20). Higher scores indicate increasing 
levels of psychiatric morbidity. 
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Fatigue severity 
The Checklist Individual Strength (CIS) is a 20-item questionnaire and measures the following 
four aspects of fatigue during the previous two weeks: fatigue severity (8 items, range 8-56), 
concentration problems (5 items, range 5-35), reduced motivation (4 items, range 4-28) and 
reduced activity (3 items, range 3-21). Each item was scored on a 7-point Likert scale. High 
scores indicate high levels of fatigue, high levels of concentration problems, low motivation and 
low levels of activity (21,22). The CIS questionnaire has good reliability and validity, including 
discriminative validity (22,23). A CIS-fatigue score of 35 or more was used to identify severe 
fatigue (21).  
 
Muscle strength 
Muscle strength was determined using the Medical Research Council (MRC) grading scale (MRC; 
0 to 5) investigating the strength of the shoulder abductors, grip force, foot extensors and knee 
extensors (24). These eight values (both left and right) were averaged. 
 
Statistics 
Data analysis was performed using SPSS for Windows (version 11.0). Descriptive statistics were 
used to describe the sample. Chi-square, t-test and one-way ANOVAs were performed to test 
differences between groups. In case of an overall significance, the Bonferroni correction was 
applied to test differences between groups. For comparison between patients with and without 
psychiatric disorder the Mann-Whitney test was used. Significance level was set at p < 0.05 (two-
tailed). Correlations were calculated with the Spearman coefficient (r) correlation.   
 
 
RESULTS 
 
The patient sample consisted of 79 DM patients, 65 FSHD patients, and 73 HMSN patients. 
Neuromuscular diagnoses of the patients were verified according to established criteria (25). In 
order to verify the diagnoses, the patients neurologist were contacted. The diagnoses of all 
patients were genetically confirmed in the patient, or in a first degree family member. 
Demographic characteristics of the groups are summarized in Table 1. No significant differences 
were found in age, gender, marital status, level of education, and employment between the three 
groups. The patients who refused to take part in the study did not differ from the participating 
subjects with regard to age, gender, marital status, level of education, employment status, fatigue 
severity and GHQ-12 score in each neuromuscular disorder. 
 
Psychiatric comorbidity 
We found no significant differences in current and lifetime psychiatric comorbidity between the 
three neuromuscular disorders. The presence of at least one lifetime psychiatric disorder was 
found in 33% of the DM patients, 31% of the FSHD patients and in 34% of the HMSN patients  
(Table 4.2). A current psychiatric disorder (1-month) was reported in 11% of the DM patients, 
12% of the FSHD patients and in 11% of the HMSN patients. The most common psychiatric 
disorders were depression and phobias.  
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TABLE 4.1. Demographic characteristics of the three neuromuscular patient groups 
  
DM 
N=79 
mean (sd) 
FSHD 
N=65 
mean (sd) 
HMSN-I 
N=73 
mean (sd) 
Mean age  41 (9.9) 43.1 (10.3) 42.4 (9.8) 
Age range  22-56 22-60 20-58 
Gender (male/female)  56% / 44% 59% / 41% 41% / 59% 
Marital status     
married/living together  53   (67%) 52   (80%) 49   (68%) 
divorced    4   (5%)   3   (5%)   4   (5%) 
widowed  ---   2   (3%)   4   (5%) 
living independently  13   (17%)   6   (9%) 11   (15%) 
living with parents    9   (11%)   2   (3%)   5   (7%) 
Higher education (>= 12 years)  17   (21%) 18   (28%) 20   (27%) 
Employment     
work outside home  50   (63%) 41   (63%) 45   (62%) 
household  10   (13%)   7   (11%)   3   (4%) 
study/school    2   (3%) ---   8   (11%) 
disablement insurance act  17   (22%) 20   (31%) 19   (26%) 
partial disablement insurance act  16   (20%)   6   (9%)   9   (12%) 
sick leave    3   (4%)   3   (6%)   5   (7%) 
 
 
TABLE 4.2. Proportions of lifetime and 1-month prevalence of DSM-IV diagnoses in the three 
neuromuscular patient groups (DM, FSHD and HMSN)  
 DM 
N=79 
FSHD 
N=65 
HMSN 
N=73 
 Lifetime 
% 
1-month 
% 
Lifetime 
% 
1-month 
% 
Lifetime 
% 
1-month 
% 
Mood disorders 19   2.5 16.9   4.6 19.2   2.7 
depression 15.2   2.5 13.8   3.1 16.4   2.7 
dysthymic   3.8   ---   3.1   1.5   2.7   --- 
Anxiety disorders 17.7   7.6 15.4   6.1 19.2   5.5 
panic disorder   ---   ---   1.5   ---   2.7   --- 
simple phobia 12.7   3.8 10.8   3.1 12.3   2.7 
PTSD   ---   ---   ---   ---   2.7   --- 
gen. anxiety disorder   2.5   2.5   3.1   1.5   1.4   1.4 
obs. comp. disorder   2.5   1.3   ---   ---   ---   1.4 
Alcohol abuse   1.3   1.3   1.5   ---   1.4   --- 
Drugs abuse   2.5   1.3   ---   ---   ---   --- 
       
One or more DSM-IV diagnoses 32.9 10.7 30.8 12.3 34.2 10.6 
 
 
No significant differences were found between the three groups on self-reported 
psychopathology (Table 4.3), fatigue severity and muscle strength. However, DM patients 
reported to have significantly higher scores on concentration problems and reduced motivation, 
while HMSN patients reported significantly more sleep problems (Table 4.3). DM patients had 
significantly higher score on reduced activity than HMSN patients (Table 4.3). 
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Current psychiatric comorbidity in relation to fatigue severity and muscle strength 
Comparisons have been made between patients with and without current psychiatric disorder in 
each neuromuscular disorder (DM, FSHD and HMSN). No significant differences were found in 
age, gender, fatigue severity and muscle strength (MRC).  
 
Lifetime psychiatric comorbidity in relation to fatigue severity and disease severity 
No significant differences were found in age, gender, fatigue severity and muscle strength 
between patients with and without a lifetime psychiatric disorder in each neuromuscular disorder. 
 
 
TABLE 4.3. Complaints and symptom characteristics of the three neuromuscular patient groups 
 
DM 
N=79 
mean (sd) 
FSHD 
N=65 
mean (sd) 
HMSN-I 
N=73 
mean (sd) 
p-value 
BDI-total   6.2 (4.7)   5.3 (5.8)   6.1 (6.6) ns 
SCL-90     
anxiety 12.0 (3.9) 12.3 (4.4) 13.5 (5.3) ns 
agoraphobia   7.7 (1.4)   8.3 (3.4)   7.8 (2.0) ns 
depression 21.6 (5.3) 21.4 (8.5) 23.1 (9.8) ns 
somatisation 18.9 (5.1) 19.0 (6.6) 20.4 (6.2) ns 
obsessive-compulsive behaviour 14.9 (4.7) 13.5 (6.2) 13.9 (5.0) ns 
interpersonal sensitivity 24.3 (6.8) 23.3 (8.7) 24.6 (8.7) ns 
hostility   6.9 (1.6)   7.0 (2.0)   7.2 (2.1) ns 
sleep   4.0 (1.6)c   4.4 (2.1)c   5.3 (2.4)ab 0.001 
total 121.7 (27.2) 120.1 (41.0) 126.9 (37.5) ns 
GHQ-12 total   1.9 (2.6)   2.4 (3.2)   2.6 (3.8) ns 
CIS 
fatigue severity 
 
32.1 (11.7) 
 
34.1 (10.5) 
 
34.9 (12.9) 
 
ns 
concentration problems 16.3 (7,3)bc 12.0 (7.4)a 13.1 (8.7)a 0.003 
reduced motivation 14.0 (5.7)bc 10.6 (4.9)a 10.7 (5.0)a 0.000 
reduced activity 10.7 (4.8)c   8.9 (5.1)   8.3 (4.9)a 0.01 
Muscle strength (MRC)   3.6 (0.9)   3.7 (0.9)   3.7 (0.9) ns 
A higher value indicates more complaints or symptoms 
a Significantly different from DM, Bonferonni p<0.05 
b Significantly different from FSHD, Bonferonni p<0.05 
c Significantly different from HMSN, Bonferonni p<0.05 
 
 
DISCUSSION 
  
In this prospective study, lifetime and current psychiatric disorders (mood disorders, anxiety 
disorders and substance related disorders) were equally prevalent in a large cohort of DM, FSHD 
and HMSN-I patients. Approximately 11% of the 217 patients we studied had a current 
psychiatric disorder and 32% had lifetime psychiatric comorbidity. The most common psychiatric 
disorders were depression and phobias. Psychiatric comorbidity was not associated with fatigue 
severity or muscle strength in the various neuromuscular disorders. 
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These results concur with those of Phillips et al. who found that DM patients had higher 
depression scores than HMSN patients or healthy controls (26). This difference may in part  be 
explained by the smaller sample size of DM patients in their study and differences in the study 
methodology (self-report versus structured interview). However, Bungener et al. showed that 
DM patients did not present significant depressive  disorders according to DSM-III-R criteria in 
comparison with FSHD patients, although DM patients did present symptoms of mild 
depression (27). Furthermore, they found that FSHD patients presented significantly greater 
symptoms of depression and anxiety than control subjects (27). In a study of Meola et al. none of 
the DM patients fulfilled DSM IV criteria for axis I and II disorders (28). However, Winblad et a. 
indicates deviant personality in classical DM-1 in comparison to healthy controls and to patients 
with other muscle disorders with known brain disorder (29). 
Bungener et al showed that DM patients have more emotional disorders than FSHD patients and 
healthy controls (27). These disorders are manifestated as anhedonia and lack of expressiveness 
as evidenced by monotonous mood, apathy, and inability to anticipate pleasure. Other studies 
found a range of mental disturbances in patients with DM: moodiness, apathy, excessive 
somnolence, lack of motivation and diminished mental capacity (11,33). Myotonic dystrophy is a 
multi-system disorder, including the brain. Although neuropathological and neuroradiological 
abnormalities have been reported in the literature, we found only few studies that investigated 
neuropathological and neuroradiological abnormalities and cognitive impairment, (30-32). 
However, in our study we investigated the presence of psychiatric morbidity and not cognitive 
impairment. 
We found a higher score on reduced motivation in patients with myotonic dystrophy than in 
patients with FSHD and HMSN. However, we found no more psychiatric disorders in DM 
patients than in the other two groups. In addition, most patients with myotonic dystrophy did 
not have clinical depression when interviewed and therefore the higher reduced motivation in 
these patients cannot be explained in these terms. It is possible that features like ptosis, 
myopathic faces and dysarthric speech noted in DM can give a false impression of affective state.  
 Comparing our data with the general population, as many as 41% of the Dutch adult population 
under 65 year reported having experienced one or more psychiatric disorders at some time in 
their lives (34). Among them were 19% who had experienced a mood disorder and 19.3% an 
anxiety disorder. The 1-month rates were 3.9% for mood disorders and 9.7% for anxiety 
disorders. So, the presence of psychiatric comorbidity in patients with a neuromuscular disorder 
seems to be similar to the prevalence of psychiatric morbidity in the general Dutch population. 
The most common psychiatric disorders were depression and phobias. Fear of heights was the 
most represented type of single phobia, followed by those of animals and insects, closed spaces, 
and blood. There was no difference in type of simple phobia between the three neuromuscular 
disorders. We do not find studies demonstrating an association between neuromuscular disorders 
and simple phobia.  
Our study might have the following methodological limitations. Firstly, a selection bias is 
possible, because we only investigated ambulant patients. However, we have GHQ scores from 
381 non-participating patients with neuromuscular disorders (243 DM, 74 FSHD and 64 HMSN 
patients), an instrument that has been validated as a screening tool for psychiatric disorder. We 
found that the investigated groups did not differ in GHQ-12 scores from the not included 
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patients in this study. So it is unlikely that there is a systematic bias in our sample. Secondly, the 
investigators seeing the patients were not blinded to their diagnosis. This is not an easy problem 
to overcome, as many patients with DM have characteristics faces. Thirdly, a well known 
methodological problem in studying psychiatric comorbidity in the context of chronic diseases is 
that symptoms of somatic illness, for instance reduced appetite, lack of energy, weight changes, 
and insomnia, partly overlap with symptoms of psychiatric disorders, thus creating diagnostic 
difficulties. However, this problem is less serious in neuromuscular disorders, as the symptoms of 
the majority of neuromuscular disorders do not overlap with somatic disturbances that may be 
found in psychiatric disorders. Finally, in the absence of validated objective disease severity scales 
in neuromuscular disorders is a methodological problem in studying disease severity in various 
neuromuscular disorders. 
In conclusion, the present study shows that psychiatric comorbidity occurs equally in patients 
with DM, FSHD and HMSN. Current and lifetime psychiatric comorbidity is not associated with 
experienced fatigue and/or muscle strength. 
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ABSTRACT 
 
Objectives 
To determine the level of ambulatory disability in well ambulant patients with Hereditary Motor 
and Sensory Neuropathy type I (HMSN I), and to identify the related demographic, physical and 
psychological variables.  
Methods 
Seventy-five ambulatory HMSN I patients, aged 20 to 58 years, were measured in a cross-
sectional assessment, addressing demographics, disability of ambulation and mobility (Sickness 
Impact Profile), muscle strength (Medical Research Council (MRC)), use of walking aids, physical 
activity (actometer), fatigue (Checklist Individual Strength), and quality of life (EuroQoL). 
Results 
Seventy-two percent of the patients perceived significant amount of ambulatory disability. These 
patients were less active, and more fatigued compared to patients without ambulatory disability, 
and healthy reference groups. The total patient sample showed distal paresis (mean MRC = 3.3), 
a high level of pain- discomfort (76%), but normal levels of employment (62.7%) and anxiety- 
depression (20%). Walking aids were used by 49% of the patients. These patients were older, less 
active, more fatigued, had less muscle strength, and perceived more disabilities of ambulation, 
and mobility than non-users. Of the patients without walking aids, 41% perceived a significant 
amount of ambulatory disability. 
Conclusion  
Ambulatory disability frequently occurs in well ambulant HMSN I patients. The use of walking 
aids is not completely in accordance with the perceived ambulatory disability.  
Therefore prescription requires specific attention as well as complaints about pain and fatigue. 
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INTRODUCTION 
 
Hereditary motor and sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth disease 
(CMT), is among the most commonly inherited neuropathies, with a prevalence of 1 in 2.500 
people(1). The most common form, type IA, is caused by a duplication of the peripheral myelin 
protein 22 gene (PMP22) on chromosome 17 (2). The duplication causes an initial 
hypermyelination of the distal large myelinated fibres, followed by a demyelination when the 
disease progresses.  The clinical characteristics of HMSN I are  progressive and include muscle 
weakness and atrophy of the distal lower leg muscles, and areflexia and sensory impairment with 
loss of touch, pain, vibration and joint position sense (3-7). Due to the muscular imbalance, 
patients develop foot deformities such clawing of the toes, hammertoes, pes cavus and ultimately 
per eyuinovarus(8). The patients mainly complain about spraining, stumbling, poor balance and 
clumsy gait, as well as difficulty with running, jumping and climbing stairs (7,8). Then 
neurological and orthopaedic impairments may lead to problems at the level of activities and 
participation. 
Ambulatory disability has been addressed in HMSN I patients before: Birouk et al. and Holmberg 
et al. used a 4-point scale to address functional disability of ambulation and graded ambulatory 
problems as mild or moderate when patients were still able to walk unaided (6,9). Since HMSN I 
patients are usually not totally wheelchair confined, many young and middle-aged HMSN I 
patients who walk independently are thus regarded as non- or only mildly- disabled in the 
literature. This seems equivocal when looking at the patients’ complaints in clinical practice. 
Therefore, the level of perceived ambulatory disability in HMSN I patients needs further 
attention. 
The level of experienced ambulatory disabilities and patients’ participation is likely to be 
determined by several demographic, physical and psychological factors (10). Not the actual 
physical impairments of HMSN patients, but their perceived disability appeared to affect the level 
of patients’ participation (15). The extent to which HMSN I patients perceive themselves as 
ambulatory disabled, has not been studied systematically in well ambulant HMSN I patients 
before. Pfeiffer et al. measured experienced ambulation and mobility problems in a sample of 50 
middle-aged HMSN I patients and found no significant differences compared to healthy elderly 
and persons with stroke (10). However, a comparison with healthy subjects of similar age was not 
made. Other studies did not use validated measurements for scoring disability (11) or were 
performed in non-homogeneous patient samples (12-14). The use of walking aids, such as 
insoles, orthotics, walkers and wheelchairs can alleviate patients’ complaints, but has not been 
studied in this context as well. 
Therefore, in this study the following questions will be addressed: (1) What is the level of 
ambulatory disability in well ambulant HMSN I patients, and (2) which demographic, physical 
and psychological variables differ between patients, based on the presence of ambulatory 
disability and the use of walking aids? 
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METHODS 
 
Participants 
Patients, aged 18 to 60 years, were recruited from databases of the Dutch Neuromuscular 
Diseases Association. A total of 220 HMSN type I patients were informed by a letter and asked 
to fill out and return a booklet of questionnaires. The booklets were returned by 158 patients, of 
which 135 met the eligibility criteria. The eligibility criteria consisted of a positive diagnosis of 
HMSN I,  absence of other neurological or movement disorders, and the ability to walk 
unassisted over 10 minutes. Eighty six patients willing to take part in the study were invited to the 
hospital for further assessment, of which 75 completed the measurements. A total of 11 patients 
dropped out due to the length of travel time, the inability to take a day off, or for personal 
reasons.  
The patients’ neurologist or clinical geneticist received a letter verifying the diagnosis. The 
diagnosis was based on family history, electromyographic (EMG) data, and histological or DNA 
proof, if available. The patients that refused to take part in the study did not differ from the 
research subjects with regard to age, estimated maximum walking duration, use of walking aids or 
employment status. Written informed consent was obtained from all patients. The regional ethics 
committee approved the study.  
 
Outcome variables  
Information was gathered by means of a cross-sectional assessment. Demographic features were 
collected through a self-reported general questionnaire and included age, marital status, level of 
education, and current status of employment. The demographic features were compared with the 
population statistics available from the Central Bureau of Statistics (CBS 2002®).   
 
Muscle strength (ankle plantar flexion, knee extension, and grip strength) was measured bilaterally 
on an ordinal 6-point scale (0-5) according to the Medical Research Council (MRC) (16). Mean 
MRC scores were calculated for the combined ankle and knee strength, and the ankle and grip 
strength, as HMSN preferentially affects the distal body parts.  
  
Two subscales of the Sickness Impact Profile (SIP) addressed the perceived disability of 
ambulation (SIP-A) and mobility (SIP-M) (17,18). The SIP-A score (12 items) assessed the need 
for walking aids, personal assistance or resting while walking normally, up the stairs, or up a hill. 
The SIP-M score (10 items) addressed the ability to get out of the room or the house, and the 
ability to travel. Affirmative answers were summed up and weighted for each category.  The SIP-
scores were compared with the scores of a reference group of 90 healthy people, consisting of 35 
men and 55 women (mean age 37.1 years, sd 10.9), who participated as controls in previous 
studies at the Expert Centre Chronic Fatigue. Based on the SIP-A score, the patients were 
divided in two groups: a group with and a group without significant ambulatory disability. The 
mean and two times the standard deviation of the reference population (2.3 + 2* 12.6= 27.5) was 
used as a cut-off point.  
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The subscale CIS-fatigue of the Checklist Individual Strength (CIS) was used to address the level 
of fatigue severity (22,23). The score on this 8-item questionnaire ranged from 8 (no fatigue at all) 
to 56 (maximally fatigued). Each item was scored on a 7-point Likert scale. High scores indicate 
high level of fatigue severity, a score of ≥ 35 indicates that a patient is severely fatigued (22).  
 
The level of physical activity was assessed using an actometer, a device worn by the patients 
around the ankle for 12 consecutive days (19). The actometer measured the number of 
accelerations over a 5-minute period. A general physical activity score was calculated by averaging 
the number of accelerations over the 12-day period. The mean actometer scores were compared 
with the scores of a reference group consisting of 24 males and 23 females (mean age 40.1 years, 
range 19-63 years), who participated in previous studies at the Expert Centre Chronic Fatigue 
(19). Furthermore, patients were asked to estimate their maximum walking duration on a 3-point 
scale (< 10 min, 10 min-1 hr, >1 hr). The use of walking aids was defined as a single or multiple 
positive score on a list of items consisting of: electrical wheelchair, hand rim propulsed 
wheelchair, walker, cane, orthopaedic shoes, and other orthopaedic orthoses.  
 
We used 3 domains of the EuroQol questionnaire to address the patients’ deterioration in quality 
of life: self care, pain- discomfort, and anxiety- depression (20). Each of the domain was scored 
on a 3-point scale ranging from 1-3, increasing with the severity of the complaints. For example, 
the item pain- discomfort distinguished between 1) no, 2) moderate, and 3) severe pain or 
discomfort. The percentage of patients that reported a score of 2 or 3 was calculated for each 
domain. Furthermore, patients were asked to mark  their current health state on a visual analogue 
scale (VAS) calibrated from zero (‘worst imaginable health state’) to 100 (‘best imaginable health 
state’). The VAS has recently been proven to be a valid, reliable, and responsive measure of 
global quality of life (21). 
 
Statistical analysis 
Patients were divided in two groups based on the presence of significant ambulatory disability 
(SIP-A > 27.5). Patients were also stratified according to whether or not they used walking aids. 
A student’s t-test was used to test group differences for continuous variables. Associations 
between dichotomous variables and walking aids  were tested using the Chi-square test. 
Spearmann correlation coefficients were calculated to test correlations between non-parametric 
parameters. Linear multiple regression was used to calculate the explained variance of ambulatory 
disability. Statistical significance was tested at two levels, p < 0.05 (*) and p < 0.01 (**), by using 
SPSS software (SPSS 11.0, Inc., Chicago, IL).  
 
 
RESULTS 
 
The patient characteristics are shown in table 5.1. The age ranged from 20 to 58 years (mean ± 
standard deviation is 41.5 ± 9.9 yrs). No differences between men (n=32) and women (n=43) 
were found for any of the characteristics. The demographic features of this population did not 
differ from the reference population. Despite the normal level of employment in the patient 
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group (62.7% had work outside home), 13% and 25% of the patients were declared partially or 
completely incapacitated for work,  in comparison with a total incapacity percentage of 9% 
within the reference population. This discrepancy is caused by the fact that 10 of the subjects 
who were declared  partially or completely incapacitated for work were simultaneously involved 
in a pain occupation, and 2 were studying.  
 
TABLE 5.1.  Demographic patient characteristics  
 HMSN patients (N=75) 
Mean age (mean ± sd) 41.5 (9.9) 
Gender (N, %)   
male 32 42.7 
female 43 57.3 
Marital status (N, %)   
married/living together 50 66.7 
living independently  20 26.6 
living with parents   5   6.7 
Higher education (>12 yrs) ( N,%) 21 28.0 
Current status of employment (N,%)   
work outside home 47 62.7 
household   3   4.0 
study/school    8 10.7 
 
 
The mean values of the SIP-A, SIP-M and CIS-fatigue were significantly different for the patients 
compared to the healthy reference groups (p< 0.05). Patients experienced more ambulatory and 
mobility related disability and were less physically active, as measured by the actometer. The 
mean MRC scores of the lower extremity and the distal body-parts (both 3.3) showed a marked 
paresis and a high level of pain- discomfort (76%).  
 
Twenty-one patients reported no ambulatory disabilities and 54 patients reported ambulatory 
disability scores ranging from 35 to 393 (table 5.2). The mean CIS fatigue score of the patients 
without ambulatory disability (28.5) indicated no severe fatigue. The mean actometer score of 
these patients (89.5) was comparable with the activity score of the healthy reference group (90.6). 
 
The patient group which reported ambulatory disability was significantly older, had more mobility 
related disabilities, had less muscle strength, was less physically  active, more fatigued and had a 
lower current perceived health state (VAS) compared to the group without ambulatory disability 
(table 5.2). No significant group differences were found for the self care, anxiety- depression, and 
pain- complaints items. A total of 71% of the patients without disability were involved in a paid 
occupation compared to 51% of the patients with ambulatory disability, which was not 
significantly different. The use of walking aids also differed: 24% of the patients without 
ambulatory disability used walking aids compared to 59% of the patients within the disability 
group.   
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TABLE 5.2. Outcome variables for the total patient sample (N=75) according to level of ambulatory 
disability  
    Total  
(N=75) 
No ambulatory 
disability  
(N=21) 
Ambulatory 
disability  
(N=54) 
p-Value* 
Age  41.5  (9.9) 36.5  (10.9) 44.6  (8.3) 0.001 
Walking aids (%) 49 24 59 0.006 
Employed (%)  62.7 71 51.9 ns 
MRC Lower extremity (knee and 
ankle) 
  3.3  (1.2)   4.3  (1.0)   2.9  (1.1) 0.000 
MRC Distal (ankle and hand)   3.3  (1.2)    4.2  (1.0)   2.9  (1.0) 0.000     
SIP Mobility 22     (55) †   0     (0) 62.6  (8.5) 0.001 
CIS Fatigue 35.0  (12.7) 28.6  (13.0) 37.5  (11.8) 0.006 
Actometer  69.8  (22.4) † 89.5  (19.1) 62.1  (18.6) 0.000 
Max walking duration ‡ 41.3% 76% 29% 0.000  
EuroQoL Self-care ║ 11%   0% 15% ns 
EuroQoL Pain- discomfort ║ 76% 62% 82% ns 
EuroQoL Anxiety- depression ║ 20% 19% 20% ns 
EuroQoL General Health status 
(VAS)  
66.1 (19.7) 73.3 (18.0) 63.2  (19.9) 0.048 
Data is presented as mean (± standard deviation), unless otherwise specified 
* = Level of significance for group difference  
† = Significantly different from reference group of healthy controls 
‡ = Percentage of patients with an estimated maximum walking duration of > 1hr 
║ = Percentage of patients with a EuroQoL score of 2 or 3 
ns = not significant, MRC= Medical Research Council, SIP= Sickness Impact Profile, CIS= Checklist Individual Strength, 
VAS=Visual Analogue Scale 
 
 
By means of multiple linear regression analyses a total of 21.6% of the ambulatory disability in 
the patients with ambulatory disability was predicted. Of the variables that were entered 
(actometer score, CIS fatigue score, age, MRC distal, maximum walking duration), only the 
variables MRC distal and maximum walking duration had a significant contribution to the 
explained variance in ambulatory disability (p=0.03 and p=0.005, respectively). To verify the 
reported (dis)abilities (including estimated maximum walking duration) we assessed the actual 
level of physical activity by actometer. These variables showed a significant correlation of 0.452 
(p < 0.001)). 
 
 
Forty-nine percent of the total patient sample used walking aids (table 5.3). When analysing the 
mean scores, this group of patients was significantly older, had less muscle strength, was less 
physically  active, more fatigued and reported more ambulatory and mobility related disabilities 
compared to the group of non-users. In contrast, no significant group differences were found for 
the participation and quality of life variables.  
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TABLE 5.3 Outcome variables for the total patient sample (N=75) according to the use of walking aids 
      Total  
(N=75)  
No walking 
aids (N=38) 
Walking aids 
(N=37) 
p-
Value* 
Age  41.5  (9.9) 38.8  (10.3) 46.0  (7.8) 0.001 
Employed (%)  62.7 63.2 62.2 ns 
MRC Lower extremity (knee and 
ankle) 
  3.3  (1.2)   3.7  (1.2)   2.8  (1.1) 0.001 
MRC Distal (ankle and hand)   3.3  (1.2)    3.7  (1.2)   2.8  (1.0) 0.001     
SIP Ambulation 109     (101) † 72     (93) 147     (94) 0.001 
SIP Mobility 22     (55) †   6     (31) 38     (68) 0.011 
CIS Fatigue 35.0  (12.7) 31.3  (13.8) 38.8  (10.4) 0.009 
Actometer  69.8  (22.4)† 75.8  (21.7) 63.6  (21.6) 0.018 
Max walking duration  ‡ 41.3% 57.9% 24.3% 0.006 
EuroQoL Self-care ║ 11% 5% 16% ns 
EuroQoL Pain- discomfort ║ 76% 68% 84% ns 
EuroQoL Anxiety- depression ║ 20% 18% 22% ns 
EuroQoL General Health status 
(VAS)  
66.1   (19.7) 69.9  (20.7) 62.1  (18.4) ns 
Data is presented as mean (± standard deviation), unless otherwise specified 
* = Level of significance for group difference  
† = Significantly different from reference group of healthy controls 
‡ = Percentage of patients with an estimated maximum walking duration of > 1hr 
║ = Percentage of patients with a EuroQoL score of 2 or 3 
ns = not significant, MRC= Medical Research Council, SIP= Sickness Impact Profile, CIS= Checklist Individual 
Strength, VAS=Visual Analogue Scale 
 
 
The relationship between ambulatory disability and the use of walking aids is further specified in 
table 5.4.  In general, orthopedic shoes and canes were reported most often as a walking aid. The 
use of wheelchairs and walkers was limited and confined to the group of patients with 
ambulatory disability. For longer distances, 3 patients with ambulatory disability used an electrical 
wheelchair, 5 used a hand-rim propulsed wheelchair, and 2 used a walker. 
 
 
TABLE 5.4. Specification of the use of walking aids 
 Use of walking aids (N) Total 
 No Yes  
No ambulatory disability * 16 5 21 
Ambulatory disability  22 32 54 
Total 38 37 75 
 
 Ambulatory disability  
 No  Yes 
Electrical wheelchair 0 3 
Handrim propulsed wheelchair 0 5 
Walker 1 2 
Cane 1 12 
Orthopaedic shoes 3 12 
Total 5 32 
 
N= number of patients, * Ambulatory disability is defined as SIP-A > 27.5 
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DISCUSSION 
 
From this study we show that ambulatory and mobility related disabilities frequently occur within 
a large homogeneous population of HMSN I patients. Compared to healthy subjects, patients 
were more fatigued and experienced high levels of pain- discomfort. Actometer scores 
unequivocally showed that they were less physically active.  
The patients with ambulatory disability had increased age, fatigue, degree of paresis, decreased 
physical activity, and a decreased general health status, compared to the patients without 
ambulatory disability. The patients who used walking aids were generally more severely affected 
compared to the patients without walking aids, according to their muscle strength, fatigue, 
physical activity and disability scores.  
The use of walking aids in our patient sample (49%) was comparable with the percentage 
mentioned by Pfeiffer et al. (52%) (11). Although we found a higher use of walking aids in the 
group of patients who perceived ambulatory disability, the presence of perceived ambulatory 
disability did not distinguish walking aids users from non-users. Walking aids may have 
eliminated ambulatory problems in the group of users without perceived 
ambulatory disability. However, 41% of the patients that perceived ambulatory disability did not 
use any form of walking aids, suggesting that the use of walking aids is currently not optimal. 
This could be explained, partly, by a lack of adequate prescription by practioners or by 
disacceptance and feelings of shame regarding the use walking aids within the patient group.  
The patients’ scores on perceived disability of both ambulation and mobility were significantly 
higher than the scores of the reference group of 90 healthy people. As for the perceived 
disabilities, our patient population reported more ambulatory than mobility related disabilities. 
Apparently, HMSN I patients mainly experience a deterioration of gait, whereas they are not so 
much limited in their ability to leave the house and join social activities. Probably, they are able to 
compensate adequately for their mobility problems, rather than for their walking problems. 
  
The estimated walking duration was surprisingly consistent with the actometer score in our 
patient sample, as was shown by the correlation coefficient. It seems that HMSN I patients were 
able to judge their activities and capabilities rather well, which is in contrast with previous 
findings in other patient categories, such as survivors of cancer (24). Since HMSN is a genetic 
disorder, which progresses very slowly, it is suggested that these patients are able to adjust to 
their limitations very gradually, which enables them to make a rather accurate estimation about 
their current physical capabilities. The actometer score solely represents the physical activity of 
the lower extremity, so it is possible that the actometer score has slightly underestimated the 
physical activity of the patients who incidentally used a handrim propulsed wheelchair for longer 
distances (N=5). 
   
The mean percentage of patients suffering from anxiety- depression, and the high level of pain- 
complaints (20% and 76%) were comparable to the percentages measured by Pfeiffer et al. (18% 
and 68%), and were not related to ambulatory disability or the use of walking aids (11). We also 
found a high level of fatigue, which is imaginable since HMSN patients have to compensate 
continuously in their postural control by extra muscular, visual and cognitive efforts. The mean 
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level of paid employment (63%) in our patient sample did not differ from the reference 
population and was not significantly related to the use of walking aids There was a trend, 
however, that patients without ambulatory disability were more often involved in a paid 
occupation compared to patients with significant ambulatory disability (71% vs 51%).  
  
We found that the variables strength loss, physical activity and general health state differed 
between patients, based on the presence of ambulatory disability. However, we were not able to 
detect differences for the emotional aspects of quality of life, as shown by Teunissen et al. and 
Piccininni et al. in related patient groups suffering from an axonal polyneuropathy or hereditary 
neuromuscular disease in general (13,15). In the present study, the only measurement of 
emotional status was the item anxiety- depression of the EuroQoL. The mean score of our 
patient sample was low on this item, and there was small intersubject variability. The absence of 
substantial emotional suffering may explain the lack of significant differences between the patient 
groups.   
 
Multiple regression analyses revealed the variables that were able to explain part of the reported 
ambulatory disability. Estimated maximum walking duration, which was also a self-reported 
measure, partly explained the level of perceived ambulatory disability. Apparently, patients were 
consistent in reporting their perceived (dis)abilities. The other variable that was able to explain 
part of the perceived ambulatory disability was the amount of strength loss on the distal body 
parts, as measured by the MRC. Future long-term follow-up research, with greater power, might 
shed more light on the main causes of ambulatory related disabilities. The high levels of pain-
discomfort and fatigue need further scientific attention as well. Fatigue was recently investigated 
by Kalkman et al. in a study comparing patients with facioscapulohumeral dystrophy, myotonic 
dystrophy and HMSN-I patients (25). They found that the perceived fatigue in HMSN-I patients 
was not clearly related to their functional impairments. 
  
In conclusion, ambulatory disability frequently occurs, even in HMSN I patients who appear to 
walk relatively well.  The presence of ambulatory disability is associated with increased age and 
fatigue, and decreased muscle strength, physical activity and perceived health state. Walking aids 
are generally administered to the more severely affected patients, however, the use of walking 
aids is not completely in accordance with the perceived disability. Thus, with respect to walking 
aids, counseling and prescription require specific care. In addition, physicians who attend to 
HMSN I patients should be observant to pain- discomfort and fatigue.  
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ABSTRACT 
 
Objectives 
Fatigue has been described as a typical symptom of various neurological diseases. It might be 
caused both by changes at the peripheral and at the central level. This study measured the level of 
experienced fatigue and physiological correlates of fatigue in three genetically defined 
neuromuscular disorders. 
Methods 
65 Facioscapulohumeral dystrophy (FSHD), 79 classical myotonic dystrophy (MD), 73 hereditary 
motor and sensory neuropathy type I (HMSN) patients and 24 age-matched healthy controls 
made a 2-min sustained maximal voluntary contraction of the biceps brachii muscle. Experienced 
fatigue at the current moment was assessed with the abbreviated fatigue questionnaire just before 
the physiological measurement. Peripheral fatigue was quantified by comparing the amplitudes of 
an initial and a final stimulated force response during rest. Muscle fibre conduction velocity was 
determined from a 5-channel surface EMG recording in order to show peripheral changes during 
the contraction. Central aspects of fatigue were measured using superimposed electrical endplate 
stimulation. Two weeks later, the Checklist Individual Strength subscale fatigue (CIS-fatigue) was 
used to determine the level of experienced fatigue of the past two weeks. 
Results 
Patients showed an increased level of experienced fatigue. Total physiological and peripheral 
fatigue were smaller in patients compared to controls, and central fatigue was normal. The most 
interesting result of this study was the presence of a large central activation failure (CAF) in all 
groups of neuromuscular patients; they showed CAF values of 36 - 41% already directly at the 
start of sustained contraction, whereas the control group showed only 12%. CAF slightly 
correlated with the level of experienced fatigue just before the test.  
Conclusion 
The cause of the large CAF in patients is unclear. Reduced concentration, motivation or effort 
can lead to lower central activation. In neuromuscular patients especially fear of physical activity 
or fear to damage the muscle or nerve tissue may contribute. Besides, also physiological feedback 
mechanisms or changes at the motocortical level may be a cause of reduced central activation.  
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INTRODUCTION 
 
Fatigue is a typical symptom of various neurological diseases(9). It is present in more than 60% 
of patients with a neuromuscular disorder(21,32,41). In Parkinson’s disease, more fatigue is 
associated with less physical activity, worse physical function, and lower functional capacity (17). 
In current literature, the term fatigue indicates both experienced fatigue and types of 
physiological fatigue. 
Experienced fatigue has been defined as a difficulty in initiation of or sustaining voluntary 
activities (9). Krupp and Polina have described it to be an overwhelming sense of tiredness, lack 
of energy, and feeling of exhaustion (27). The symptom is distinguished from weakness and does 
not necessarily correlate with signs of physiological fatigue (26,27).  
Physiological fatigue has been defined as an exercise-induced reduction in maximal voluntary 
muscle force (15). It is divided into peripheral and central components, a division based on 
whether a loss of capacity to generate a maximum force originates in the muscle tissue or in the 
nervous system, respectively. During a sustained maximal voluntary contraction (MVC), healthy 
subjects develop both peripheral and central fatigue (23,46). The occurrence of central fatigue 
means that central activation worsens during the contraction. However, central activation is sub 
optimal already at the start of a sustained MVC (46). 
Literature about physiological fatigability in neuromuscular patients is scarce. It is an interesting 
phenomenon, because the muscle itself - the motor of movement and force - is affected. 
McComas and co-workers have described that increased fatigability inevitably occurs in patients 
with muscle weakness, regardless whether the latter is due to a central or a peripheral 
neurological disorder (31). Not only (possibly indirect) peripheral changes, but also central 
changes could be responsible for this. Recently, alterations in the central nervous system have 
been described in neuromuscular disorders (10,11,14,28,36,40,53), but their influence on fatigue 
has not yet been studied.  
The aim of the present study was to investigate both peripheral and central aspects of 
physiological fatigue during a sustained MVC in neuromuscular patients. We correlate these 
factors of physiological fatigue to the level of experienced fatigue just before the test. To get a 
broad overview of different types of neuromuscular disorders and to find possible disease 
specific mechanisms playing a role in the development of fatigue, we studied three genetically 
characterised neuromuscular disorders: facioscapulohumeral muscular dystrophy (FSHD), a 
myogenic disorder; hereditary motor and sensory neuropathy type Ia (HMSN), a neurogenic 
disorder; and myotonic dystrophy (MD), a multisystem disorder. 
 
 
METHODS 
 
Subjects 
Age-matched groups of 65 FSHD-, 79 classical DM-, 73 HMSN-patients and 24 neurologically 
healthy controls participated in the study (Table 6.1). Patients registered in our hospital or at the 
Dutch Neuromuscular Diseases Association (Vereniging Spierziekten Nederland, VSN) were 
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recruited. Only ambulant patients, age 18-60 years, able of passive abduction of the left shoulder 
to 900  were included. 
Disease severity was determined with the Medical Research Council grading scale (MRC; 0 to 5) 
investigating the strength of the shoulder abductors, grip force, foot extensors and knee 
extensors. In order to characterise the patients, these eight values (both left and right) were 
averaged (Table 6.1). In order to verify the diagnoses, the patients' neurologists were contacted. 
In part of the patients, the diagnosis was genetically confirmed (Table 6.1). 
The protocol was approved by the Committee on Research Involving Human Subjects Region 
Arnhem-Nijmegen. All subjects gave their written informed consent before participation. 
 
 
TABLE 6.1 Details of subject groups 
    Age Mean MRC DNA 
 N total men women mean SD range mean SD range confirmed 
FSHD 65 58.5% 41.5% 43.1 10.3 22.5-60.9 3.6 0.8 1.9-5.0 83.1% 
MD 79 55.7% 44.3% 41.0  9.8 22.5-56.6 3.7 0.8 2.0-5.0 62.0% 
HMSN 73 41.1% 58.9% 42.4  9.8 20.0-58.0 3.7 0.9 1.5-5.0 45.2% 
control 24 50.0% 50.0% 42.1 13.5 21.7-59.3 5.0 0.0 5.0-5.0  
 
Experienced fatigue 
Just before the start of the physiological protocol, all patients and 16 controls filled out the 4-
item abbreviated fatigue questionnaire (AFQ) (1) referring to the level of experienced fatigue at 
the current moment. Scores range from 4 to 28; higher scores indicate higher levels of fatigue. 
Fourteen days later, patients filled out the Checklist Individual Strength subscale fatigue (CIS-
fatigue) evaluating the level of experienced fatigue during the past two weeks (43,55).  Scores of 
this 8-item questionnaire range from 8 to 56. Values ≥ 35 indicate severe fatigue (49). Controls 
only answered the AFQ. 
 
Physiological factors of fatigue 
Experimental set-up 
The experimental design has been used earlier in studies into peripheral and central aspects of 
fatigue in healthy subjects (46) and in patients with chronic fatigue syndrome (47). It is based on 
the twitch interpolation technique (35).  
Subjects sat in a chair with their left arm fixed in a dynamometer in a horizontal position with the 
shoulder in abduction, the elbow in a right angle and the forearm supinated. Trunk and elbow 
were stabilised using common made pads. The force of elbow flexion was measured at the wrist. 
Force was sampled at a rate of 2 kHz and low-pass filtered (1 kHz). The maximal resolution of 
force measurement was 0.1 N bit (1). 
Surface EMG (sEMG) was measured using a multi-electrode array of five gold-coated serrated 
electrodes (5) that were placed in line (electrode diameter 2 mm; inter electrode distance 3 mm) 
parallel to the fibre direction of the biceps brachii muscle, distal to the motor points. A reference 
electrode was placed at the elbow joint. Monopolar signals were amplified using a 64-channel 
amplifier system (MARK 6, Biosemi, Amsterdam, The Netherlands), band-pass filtered (3.2-800 
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Hz) and A/D-converted (16 bits with a resolution of 0.5 mV bit-1 at a rate of 4 kHz/channel). A 
custom-made time code generator synchronised force- and sEMG-data. 
Using self-adhesive surface electrodes (Teca NCS2000 disposable surface electrode system) and a 
general-purpose electrical bio-stimulator (designed and manufactured by the local Department of 
Technical Engineering), electrical endplate stimulation was applied over the motor points of the 
medial and lateral head of the biceps brachii muscle (5). A stimulus event consisted of five times 
a 5-pulse 100-Hz train (duration 40ms). Pulse duration usually was 100µs. In 6 FSHD, 6 MD, 32 
HMSN, and 1 control subject duration was set at 200 µs, because force responses to shorter 
stimulation were very low. The average of the five responses to these short trains is referred to as 
'the force response' and is used for analysis. During voluntary contraction the inter-train interval 
was 300ms, during rest the inter-train interval was 1000ms. Pilot experiments had shown that 
these inter-train intervals were appropriate to avoid fusion of the single force responses.  
Stimulus intensity was determined by increasing the current until the force did not rise anymore 
or until pain limited further increase. All SEs were given at this intensity level (FSHD: intensity 
mean 41.5, SD 10.5, range 20.0-72.9 mA; force mean 9.4, SD 4.6, range 1.9-18.4 N; MD: intensity 
mean 37.4, SD 11.0, range 19.9-88.4 mA; force mean 9.4, SD 5.0, range 1.4-25.9 N; HMSN: 
intensity mean 46.9, SD 9.7, range 26.0-65.7; force mean 7.2, SD 4.3, range 1.3-21.7 N; controls: 
intensity mean 44.0, SD 12.2, range 21.0-70.0; force mean 15.7, SD 6.5, range 8.2-31.3 N). The 
initial stimulus event was not preceded by a short voluntary contraction, because pilot 
experiments showed that potentiation did not occur with this type of stimulus event.  
 
Protocol 
The electrophysiological protocol has been described and visualised earlier (46,47). First, subjects 
made three short MVCs of the biceps brachii muscle with a 1-minute interval. After a 10-minute 
rest, an initial SE was applied while the subject’s biceps brachii muscle was relaxed, resulting in 
the initial force response. Then, the subject performed a 2-minute sustained MVC of the biceps 
brachii muscle. SEs were given every 15s, leading to superimposed force responses. Verbal 
encouragement was given throughout and real-time visual feedback of the force was provided. 
Immediately after the sustained contraction, a final SE was applied while the muscle was relaxed, 
resulting in the final force response. 
 
Force analysis 
Voluntary force values are mean values over 2s of data just before stimulation, except for the 
value of MVC before the sustained contraction (MVCi), which is the true maximum. Values were 
obtained via Matlab6.5 (The Mathworks Inc., USA).  
Physiological fatigue indicated the total amount of voluntary force lost during the sustained 
MVC: physiological fatigue = (1 - F120/F0) * 100%, in which F120 is the voluntary force at the 
end and F0 at the start of sustained MVC. A higher score indicates more fatigue. 
Peripheral fatigue was determined by: peripheral fatigue = (1 – Fs
e/Fs
b) * 100%, where Fs
b is the 
amplitude of the initial (before sustained MVC) and Fs
e the amplitude of the final (after sustained 
MVC) force response during rest. A higher score indicates a higher loss of force due to peripheral 
changes, and thus more peripheral fatigue. 
Central activation failure (CAF) after t s of sustained MVC was calculated by: 
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CAFt = Fsx
t / (Fs
b – t/120 * (Fs
b – Fs
e)) * 100%, where Fsx
t is the amplitude of the superimposed 
force response after t s from the start of sustained MVC. In calculating CAFt, the influence of 
changing peripheral fatigue on the size of the superimposed force responses during MVC is taken 
into account, as described earlier(46). CAF was determined using Excel2000 (Microsoft 
Corporation®). A higher value of CAF indicates less central activation. 
Central fatigue is defined as the change of CAF during the sustained MVC, thus: 
central fatigue = CAF120 – CAF0. A higher score means that more fatigue occurs due to 
changes at the central level. 
 
SEMG analysis 
SEMG values used were calculated with Matlab6.5 (The Mathworks Inc., USA) from 2 s of data 
just before stimulation. As described in more detail before (46,47), muscle fibre conduction 
velocity (MFCV) was determined from four out of five electrodes. The upper limit of MFCV was 
set at 8 m s-1, based on physiological limits. MFCV is known to decrease with peripheral fatigue 
(35,56) and therefore used as a measure of peripheral fatigue during sustained MVC.  
 
Statistical analysis 
Differences between controls and the total group of patients were tested with an independent 
samples t-test. Possible differences between the three patient groups were analysed with one-way 
ANOVA (analysis of variance). The possible change of a variable during the sustained 
contraction was determined by linear regression. Slopes as well as the amount of peripheral 
fatigue were tested by one-sample t-tests.  
In correlations in which MRC values were involved, Spearman's ρ was used. These were not 
calculated for healthy controls, because mean MRC is 5.0 in any control by definition. In other 
correlations, we used Pearson's coefficient (r). All statistical tests were performed with the 
Statistical Package for the Social Sciences (SPSS 12.0.1). Significance level was set at p < 0.05 
(two-tailed). All values presented are means ± standard deviations. 
 
 
RESULTS 
 
Three subjects (2 HMSN and 1 DM) did not sustain the 2-minute MVC. Measurements of two 
FSHD subjects were stopped because the subjects fainted during detection of the motor points. 
Measurements of 1 FSHD and 1 DM patient failed because of technical problems. Of these 
seven subjects no force data was analysed. Electrical stimulation did not result in a sufficient 
force response in 4 FSHD, 6 DM and 17 HMSN patients. Although no stimulation data was 
available, other data of this group was used in further analyses.  
 
Experienced fatigue 
Answering the AFQ, patients reported a significantly higher level of current experienced fatigue 
than controls [Table 6.2, Fig. 6.1, AFQ: t = 8.4; P < 0.001]. There were no significant differences 
between the three patient groups. CIS-fatigue revealed high mean scores in patients for the level 
of experienced fatigue during the past two weeks [FSHD: 32.1 ± 11.7; DM: 34.1 ± 10.5; HMSN: 
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34.9 ± 12.9]. More than half of the patients showed CIS-fatigue ≥ 35, which is considered 
severely fatigued (49) [FSHD: 50.8%; DM: 53.2%; HMSN: 54.8%]. In all patient groups, AFQ 
values concerning the current fatigue level correlated significantly with the level of experienced 
fatigue during the past two weeks (CIS-fatigue) [FSHD: r = 0.68, P < 0.001; DM: r = 0.53, P < 
0.001; HMSN: r = 0.78, P < 0.001]. 
 
 
TABLE 6.2. Force and fatigue values 
 MVC, (N) Experienced fatigue (AFQ) 
Physiological 
fatigue (%) 
Peripheral 
fatigue (%) 
Central 
fatigue (%) 
CAF0 (%) 
FSHD 133.5 ± 66.0 14.2 ± 5.7 29.3 ± 48.1 27.4 ± 24.0   4.5 ± 26.6 33.9 ± 23.7 
MD 130.6 ± 64.9 16.1 ± 5.8 37.3 ± 33.4 29.5 ± 26.1   1.7 ± 26.6 41.4 ± 25.7 
HMSN 148.3 ± 79.0 16.6 ± 6.3 36.3 ± 32.6 34.2 ± 24.8 15.1 ± 46.0 36.4 ± 23.4 
control 209.8 ± 64.5   7.1 ± 3.7 54.3 ± 10.9 50.8 ± 13.7   3.9 ± 13.4 12.4 ± 10.7 
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FIGURE 6.1. Level of experienced fatigue at the current moment measured with the AFQ just 
before the physiological protocol. Scores can range from 4 to 28. Higher scores indicate higher levels of 
experienced fatigue. Each symbol represents an individual subject. Horizontal lines show group averages. 
Patient groups clearly show higher mean values than the control group, although individual patients 
might have normal values. 
 
 
Physiological fatigue 
MVC of the biceps brachii muscle before sustained contraction (MVCi) was significantly [t = -4.8; 
P < 0.001] lower in patients than in controls (Table 6.2). ANOVA showed no difference between 
the three patient groups. MVC at the start of sustained contraction (MVC0) differed in the same 
way between the groups [t = -5.9; P < 0.001] (Fig. 6.2A). MVC0 correlated negatively with AFQ 
scores in FSHD and HMSN  [FSHD: r = -0.29, P = 0.031; HMSN: r = -0.28, P = 0.024].  
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In all groups, MVC declined significantly during the sustained contraction (FSHD: slope = -0.24 
± 0.39 %s-1, t = -4.7, P < 0.001; MD: slope = -0.27 ± 0.27 %s-1, t = -8.9, P < 0.001; HMSN: 
slope = -0.26 ± 0.23 %s-1, t = -8.9, P < 0.001; controls: slope = -0.44 ± 0.12 %s-1, t = -18.2, P 
< 0.001). This decline was slower in patients than in controls [t = 3.0; P = 0.003], but did not 
differ between the patient groups (Fig. 6.2A). Physiological fatigue, which is the size of the 
decline of voluntary force, was significantly larger in controls than in patients [t = -5.6; P < 0.001] 
and did not differ between the three patient groups. It correlated positively with mean MRC in all 
patient groups [FSHD: ρ = 0.34, P = 0.010; MD: ρ = 0.24, P = 0.035; HMSN: ρ = 0.45, P < 
0.001], and with AFQ in the HMSN group only [HMSN: r = -0.25, P = 0.043]. 
 
Peripheral fatigue 
In all groups, the relative amplitude of the final force response - compared with the amplitude of 
the initial force response - showed that peripheral fatigue had occurred  [FSHD: t = 8.7, P < 
0.001; DM: t = 9.7, P < 0.001; HMSN: t = 10.3, P < 0.001, controls: t = 18.2, P < 0.001] (Table 
6.2). Less peripheral fatigue occurred in patients than in controls [t = -6.2; P < 0.001], whereas 
the three patient groups did not differ. 
The course of peripheral fatigue development during the sustained MVC, represented by MFCV 
values, is shown in Fig. 6.2B. All groups showed a negative slope not different between the 
groups (FSHD: slope = -0.013 ± 0.013 ms-2, t = -6.1, P < 0.001; MD: slope = -0.010 ± 0.008 
ms-2, t = -9.7, P < 0.001; HMSN: slope = -0.011 ± 0.009 ms-2, t = -9.4, P < 0.001; controls: 
slope = -0.012 ± 0.008 ms-2, t = -7.1, P < 0.001). Peripheral fatigue correlated positively with 
mean MRC in FSHD [FSHD: ρ = 0.27, P = 0.041]. It did not correlate with AFQ, neither in  
patients nor in controls. 
 
Central activation failure and fatigue 
At the start of the sustained MVC, patients showed higher CAF values than controls [t = 8.9; P < 
0.001] (Fig. 6.2C, Fig. 3, Table 6.2). Values in the three patient groups were similar. CAF0 
correlated negatively with mean MRC in FSHD and HMSN [FSHD: ρ = -0.27, P = 0.038; 
HMSN: ρ = -0.39, P = 0.004]. It correlated positively with AFQ in HMSN [r = 0.31, P = 0.022], 
but not in the other patient groups nor in the control group. Taking an average CAF of the first 
30s MVC slightly reduced the variance of CAF values in controls, FSHD and MD. This CAF0-30 
did correlate with AFQ scores in all three patient groups but not in controls, although P-values in 
FSHD were borderline [FSHD: r = 0.26, P = 0.051; MD: r = 0.27, P = 0.022; HMSN: r = 0.32, P 
= 0.019].  
Only in the HMSN-group, the slope of CAF during the sustained contraction was significantly 
positive [slope = 0.10 ± 0.34 %s-1, t = 2.0, P = 0.046]. However, ANOVA did not show a 
difference between this slope and the slopes of the other patient groups. Slopes of patients and 
controls did not differ significantly. Central fatigue, measured as the difference of CAF120 and 
CAF0, was significantly positive in HMSN [t = 2.4, P = 0.019], and not in the other groups. 
Though, again ANOVA did not reveal a difference between the three patient groups and central 
fatigue was not different between patients and controls. In none of the groups central fatigue 
correlated with mean MRC or AFQ. 
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FIGURE 6.2.  Voluntary force (A), muscle fibre conduction velocity (B) and central activation failure (C) 
during a 2-minute sustained MVC. At the start of the contraction, patients show lower voluntary force and 
higher central activation failure than controls. Voluntary force declines slower in patients than in controls.  
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FIGURE 6.3. Central activation failure in FSHD-, DM-, and HMSN-patients, and healthy controls at the 
start of sustained MVC. Each symbol represents a mean CAF of the first 30 s MVC within one individual. 
Horizontal lines show group averages. Patient groups clearly show higher mean values than the control 
group, although individual patients might have normal values. Theoretically, CAF values lie between 0 and 
100 %. In both DM and HMSN one artificially high value has been found, which must be ascribed to 
inaccuracy of the measurements.  
 
 
DISCUSSION 
 
This study shows that more than 50% of the neuromuscular patients has severe experienced 
fatigue. In a sustained MVC protocol, total physiological fatigue and peripheral fatigue are smaller 
in neuromuscular patients, but central fatigue is similar in patients and controls. Activation of the 
muscle by the central nervous system was shown to be less efficient in patients than in controls. 
The level of central activation failure correlated positively with the level of experienced fatigue. A 
remarkable similarity is present in all aspects of fatigue in the three groups of neuromuscular 
patients. 
 
Experienced fatigue 
Neuromuscular patients experience a high level of fatigue: patients' mean AFQ values were 
clearly higher than normal, both if compared to values measured in our control group and to 
reference values reported in literature (1). Correspondingly, CIS-fatigue scores of the 
neuromuscular patients were much higher than in the normal working population (4). The 
correlation between AFQ and CIS-fatigue showed that the level of experienced fatigue at the 
current moment parallels the level of long-term fatigue. 
 
Peripheral fatigue 
Smaller peripheral fatigability was present in patients compared to controls. This contrasts with 
the increased fatigability that was found during intermittent exercise in patients with amyotrophic 
lateral sclerosis (51), postpoliomyelitis syndrome (2,50) and multiple sclerosis (31,54). Schulte-
Mattler and coworkers (48)described excessive peripheral fatigue during repetitive electrical 
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stimulation in mitochondrial encephalomyopathies and a hodgepodge of other neuromuscular 
disorders, among which FSHD, MD and a polyneuropathy. In contrast to our work, both the 
intermittent exercise tasks and the non-tetanic contractions after electrical stimulation avoid 
vascular occlusion.  
In our protocol, blood flow will have been occluded less in the majority of patients than in the 
controls. This results from the lower intramuscular pressure, due to the smaller MVC in patients 
(56). The ongoing blood flow keeps the intracellular state in patients better than in controls. If 
our protocol had avoided vascular occlusion in both patients and controls, results on peripheral 
fatigability possibly would have been more in line with the literature. 
Peripheral fatigue was not related to the current level of experienced fatigue. 
 
Central activation failure and fatigue 
Central fatigue was minimal in all groups. In contrast to our former studies (46,47), even healthy 
controls did show no central fatigue. This may have to do with the higher age of the newly 
studied group. How central fatigue relates to age, seems to be task-dependent and possibly also 
depends on the methodology used for CAF assessment (3). Our results do not show any relation 
between central and experienced fatigue, which is not surprising seen the very low central fatigue 
in all groups.  
In contrast, CAF at the start of sustained MVC is enlarged in patients, and does relate to the level 
of experienced fatigue.  
Of importance for the discrepancy between physiological fatigue measures and the level of 
experienced fatigue is the difference in concepts. Physiological fatigue has been defined as an 
exercise-induced reduction in maximal voluntary muscle force(15). In contrast, experienced 
fatigue has been characterised as a difficulty in initiation of or sustaining voluntary activities (9). It 
is a state not necessarily induced by exercise. CAF at the start of sustained contraction is neither 
influenced by exercise. This may explain why CAF correlates better to the level of experienced 
fatigue than the exercise-dependent physiological, peripheral and central fatigue. 
As written above, CAF is higher in neuromuscular patients than in controls. This result seems to 
be in accordance with one of the findings of Di Lazzaro et al.(11).They showed an increased 
resting motor threshold in FSHD using transcranial magnetic stimulation (TMS), which might 
indicate lower resting membrane potentials of the cortical and/or spinal motoneurons (7). In 
contrast, Liepert and co-workers (28) did not observe a different motor threshold in a group of 
10 myopathic patients, under whom 6 FSHD patients. TMS in MD patients neither showed a 
significant resting motor threshold alteration (40). Though, it demonstrated a prolongation of 
central motor conduction time in patients, which was related to motor threshold value (40). 
Increased CAF also seems to contradict the lowered intracortical inhibition observed with TMS 
in FSHD and other myopathies (11,28). Enhanced excitability of α-motoneurons and increased 
amplitudes of motor-evoked potentials, described in myopathies by Liepert et al. (28), neither 
seem to be consistent with our results. However, the translation of results of isolated short-pulse 
TMS experiments into the behaviour of the brain in a more natural situation remains difficult. 
Apparently, although some systems possibly promote enhanced activation, in neuromuscular 
patients the output from the total chain of motor activation is reduced. 
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It is unclear which factors cause the reduced central activation in FSHD, MD and HMSN. In 
general, reduced concentration, motivation and effort increase CAFvalues (16,24,26,30). We tried 
to diminish the contribution of these factors by actively encouraging the subjects and by 
providing real-time visual feedback of the performance (52). Pain, described as a symptom of 
these neuromuscular disorders (6,8,42) or other feedback from muscles, joints and tendons may 
have reduced central activation (16, 18,44).  
Although FSHD, MD and HMSN are most obviously characterized by muscle weakness, it 
cannot be excluded that other systems, including the (central) nervous system, are affected. In 
FSHD, the peripheral afferent sensory pathways (12), and in MD functioning of the sensory 
cortex have been shown to be altered (36). Functional changes at the motor cortical level have 
been described in several neuromuscular disorders (10.11.28,40). These may be a consequence of 
deconditioning or the relatively large demands on the affected neuromuscular system in daily life. 
It is well known that recruitment of motor units in neuromuscular disorders is abnormal. In 
myopathies more motor units are recruited already at low force levels; in neuropathies on the 
other hand, force is mainly regulated by control of firing rate (45). In both circumstances the 
activation pattern of the central nervous system may not be suited to counteract the peripheral 
problems, resulting in suboptimal drive. 
The level of experienced fatigue and CAF are correlated, although explained variance is limited. 
This suggests that experienced fatigue influences CAF. Though, we cannot exclude the causality 
to be vice versa: CAF may (partly) control the experience of fatigue. In this light, it is interesting 
that patients with chronic fatigue syndrome, whose main complaint is the experience of severe 
fatigue, show enlarged CAF as well (26,47). 
Finally, some pharmaceutical agents may influence CAF (22) by changing neuronal functioning. 
While about a third of our neuromuscular patients used any form of medication, we checked if 
this could explain the higher values of CAF in our group of patients. Sub group analyses, 
however, showed that CAF values of only medication-free patients were also increased. 
Considering clinical practice, it is important to notice that MRC and MVC values can be strongly 
influenced by the amount of CAF. Reduced central activation further decreases the maximal 
voluntary force in neuromuscular patients who generally already have reduced muscle force 
because of changes in the muscle and/or nerve tissue. Therefore, these measures do not make an 
objective evaluation of neuromuscular functioning. Especially in weaker patients conclusions 
about muscle functioning should be drawn with great care, because CAF and mean MRC turned 
out to be negatively correlated in two of the three patient groups. How it influences the daily life 
of patients is unclear. Compared to controls, patients will more often need a higher percentage of 
MVC to perform daily tasks. However, a task, like the one we used, is uncommon in daily life. If 
central activation is also diminished during short contraction is formally unknown, but seems to 
be likely considering the large CAF at the start of sustained contraction. Resistance training has 
been suggested as a way to reduce CAF, but conclusive evidence has not yet been provided 
(reviewed by 62). However, results of Lindeman et al. (29) indeed strongly suggest a reduction of 
CAF during a training program in HMSN patients. 
In conclusion, this paper shows that although neuromuscular patients experience considerably 
more fatigue than healthy controls, neither central nor peripheral fatigue is increased. Already at 
the start of sustained MVC, neuromuscular patients show diminished central activation, which is 
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correlated to the level of experienced fatigue. Right now, we can only speculate about the cause 
of this central activation failure. For clinical practice, it is important to bear the consequences in 
mind. 
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ABSTRACT 
 
Objectives 
Fatigue is a common symptom in neuromuscular disorders. Little is known about different types 
of fatigue among patients with various neuromuscular disorders. Therefore, various determinants 
of experienced fatigue and physiological fatigue were assessed in three relatively common types 
of neuromuscular disorders 
Methods 
217 patients (65 Facioscapulohumeral Dystrophy, 79 adult-onset Myotonic Dystrophy, and 73 
Hereditary Motor and Sensory Neuropathy type I patients) were studied. Experienced fatigue 
severity was assessed with the Checklist Individual Strength (CIS-fatigue). Physiological fatigue 
was measured during a 2-minute sustained maximal voluntary contraction of the biceps brachii 
muscle using the twitch interpolation technique to assess peripheral fatigue and central activation 
failure (CAF). A multidimensional assessment method was used including self-report 
questionnaires, a daily Self Observation List, physical activity (actometer), and neuro-
psychological tasks. Muscle strength was determined with the Medical Research Council (MRC) 
scale. 
Results 
Experienced fatigue was significantly related to CAF, but not to peripheral fatigue. Regression 
analyses indicated that in FSHD psychological distress and sleep disturbances, in MD sleep 
disturbances, and in HMSN sleep disturbances and concentration problems significantly 
contributed to experienced fatigue. In FSHD pain contributed significantly to CAF. In FSHD 
and HMSN functional impairments in daily life contributed significantly to peripheral fatigue, in 
MD sleep disturbances and pain.  
Conclusion 
Fatigue in neuromuscular disorders is a complex concept with involvement of dimensions. Even 
between the various neuromuscular diseases studied, different variables contributed to its 
presence. 
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INTRODUCTION 
 
Fatigue has been described with various definitions and descriptions that range from tiredness, 
sleepiness, and weakness to exhaustion(1). In current literature, the term fatigue refers both to 
experienced fatigue and to physiological fatigue.  
Experienced fatigue has been defined as an overwhelming sense of tiredness, lack of energy, and 
feeling of exhaustion. It is not the same as muscle weakness or muscle fatigability (1). This type 
of fatigue is a common symptom of various neurological disorders and is most studied in 
multiple sclerosis, Parkinson’s disease, and after a stroke2-6. Experienced fatigue is present in 
more than 60% of patients with various neuromuscular disorders and was associated with higher 
levels of functional impairments in daily life (7-11).  
Our research group has developed a multidimensional assessment method to measure 
experienced fatigue in several chronic disorders (12-15). This multidimensional assessment 
method identifies various dimensions relevant for fatigue: functional impairment in daily life, 
physical activities, psychological distress, sleep disturbances, concentration problems, social 
functioning/social support, self-efficacy, and causal attributions. In chronic disorders like 
neuromuscular disorders also pain and muscle strength are assessed.  
Physiological fatigue has been defined as an exercise-induced reduction in maximal voluntary 
muscle force and is divided into peripheral and central components (16). This division is based 
on whether a loss of capacity to generate a maximum force is found to originate in the muscle 
tissue or in the nervous system, respectively. During a sustained maximal voluntary contraction, 
healthy subjects develop both peripheral and central fatigue (17,18). The occurrence of central 
fatigue means that central activation worsens during the contraction. In healthy subjects central 
activation is sub optimal already at the start of a sustained maximal voluntary contraction (17).  
Literature about the relation between experienced fatigue and physiological fatigue is lacking. 
Especially in neuromuscular disorders fatigue may be caused by peripheral and/or central 
dysfunction. Although there is an increasing knowledge of the physiology of peripheral and 
central fatigue, most studies are conducted in healthy controls. In this study we investigated 
besides experienced fatigue the relation between experienced fatigue, and physiological fatigue in 
neuromuscular patients. Physiological fatigue was divided in central activation failure (CAF) and 
peripheral fatigue.   
In this study the contribution of the dimensions of experienced fatigue and disease severity was 
assessed in three homogeneous populations of patients with three relatively common, genetically 
well-defined neuromuscular disorders, namely: facioscapulohumeral muscular dystrophy (FSHD), 
a myogenic disorder; adult-onset myotonic dystrophy (MD), a multisystem disorder; and 
hereditary motor and sensory neuropathy type I (HMSN), a neurogenic disorder. To get an 
overview of different types of fatigue, we studied the determinants of experienced fatigue and of 
physiological fatigue. 
As far as we know these different types of fatigue have never been studied simultaneously in 
neuromuscular disorders.  
The first aim of the present study was to investigate the strength of the relationship between 
experienced fatigue, CAF and peripheral fatigue. The second aim was to examine the 
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determinants of the different types of fatigue (experienced fatigue, CAF, and peripheral fatigue) 
in the various neuromuscular disorders. 
 
 
METHODS 
 
Patients 
Adult patients with a definite diagnosis of a neuromuscular disorder who could be classified into 
one of the following diagnostic categories were asked to participate: (1) facioscapulohumeral 
muscular dystrophy (FSHD), (2) adult-onset myotonic dystrophy (MD) or (3) hereditary motor 
and sensory neuropathy type I (HMSN-I). They were recruited from the outpatient clinic of the 
Neuromuscular Centre, based at the Institute of Neurology of the Radboud University Nijmegen 
Medical Centre and from the Dutch Neuromuscular Diseases Association (Vereniging 
Spierziekten Nederland, VSN).  
In total, 900 patients were informed by a letter and received a booklet with questionnaires at 
home. From the 647 adult patients (72%) who returned the questionnaires, 49 patients were 
excluded. In all, 598 patients fitted the diagnostic inclusion criteria and completed the 
questionnaires (66%). This group consisted of 139 patients with FSHD, 322 with MD, and 137 
with HMSN-I. 
For this study only ambulatory patients with age between 18-60 years were included. For the 
physiological measurement it was necessary that patients were able of passive abduction of the 
left shoulder to 900. From the 527 patients that were eligible 331 patients were willing to 
participate in this research project, but ultimately from 217 patients (65 FSHD, 79 MD and 73 
HMSN patients) complete data could be collected. Patients dropped out for several reasons: large 
travel distance, inability to take a day off or personal reasons. The patients who refused to take 
part in the study did not differ from the participating subjects with regard to age, gender, marital 
status, level of education, and employment status and level of experienced fatigue in each 
neuromuscular disorder. Written informed consent was obtained from all participating patients. 
The regional ethics committee approved the study. 
 
Procedure 
The patients who agreed to take part in the study were invited to the Radboud University 
Nijmegen Medical Centre for the assessments. On the first day the physiological measurement 
was carried out. At home, they started with the daily Self Observation List (SOL) during a period 
of 12 days. Severity of experienced fatigue was reported four times a day in this list. Furthermore, 
quality of sleep, level of activity, hours of household activities and hours of work outside the 
house were reported once a day. During this period the patients were wearing an actometer. After 
this 12-day period, patients filled out several computerised questionnaires.  
 
Physiological fatigue (CAF and peripheral fatigue) 
Physiological measurements were used to determine peripheral fatigue and central activation 
failure (CAF). The experimental design was used earlier in studies into peripheral and central 
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aspects of fatigue in healthy subjects (18) and in patients with chronic fatigue syndrome (19). It 
was based on the twitch interpolation technique(16-20).  
In short, subjects made a 2-minute sustained maximal voluntary contraction of the biceps brachii 
muscle. Electrical stimulation was applied before, just after and every 15 seconds during MVC. 
Each stimulus event consisted of 5 times a 5-pulse 100 Hz stimulustrain applied to the motor 
points. The average force response was used in analysis.  
The difference in force response during rest before and after sustained MVC is used as a measure 
for peripheral fatigue. Superimposed force responses during MVC indicated the level of central 
activation failure. Namely, if voluntary muscle activation is optimal, electrical stimulation will not 
induce a force increase. If, however, a failure of voluntary central drive is present, electrical 
stimulation will lead to a superimposed force response. 
 
Experienced fatigue  
The Checklist Individual Strength (CIS) is a 20-item questionnaire and measures the following 
four aspects of fatigue during the previous two weeks: fatigue severity (8 items, range 8-56), 
concentration problems (5 items, range 5-35), reduced motivation (4 items, range 4-28) and 
reduced activity (3 items, range 3-21). Each item was scored on a 7-point Likert scale. High 
scores indicate high level of experienced fatigue, a high level of concentration problems, low 
motivation and low levels of activity (13,21). A CIS-fatigue score equal or higher 35 was used to 
identify severe fatigue (22). In addition, fatigue was measured with the Daily Observed Fatigue 
(DOF) score of the Self Observation List (SOL). Severity of fatigue was reported four times a 
day on a 5-point scale (0-4). Total scores range from 0 to 16.  
 
Functional Impairment 
The Sickness Impact Profile (SIP) was used to assess functional disability in the following 12 
areas: sleep/rest, emotional behaviour, body care and movement home management, mobility, 
social interactions, ambulation, alertness behaviour, communication, work limitations, recreation 
and pastimes and eating (23,24). Higher score indicate a higher level of functional disability. In 
addition, daily worked hours (outside the home and household activities) were registered in the 
SOL. 
 
Physical activity  
The level of physical activity was assessed using an actometer (Actilog V3.0), a device worn by 
the patients around the ankle for 12 consecutive days (25). The actometer measures the number 
of accelerations over a 5-minute period. A general physical activity score is calculated by 
averaging the number of accelerations over the 12-day period (25). During this period of 12 days 
the patients filled out daily Self Observation List (SOL). Physical activity was registered once a 
day in the SOL. In addition, the subscales mobility and ambulation of the SIP were used. 
 
Psychological distress 
Psychological distress was measured with the Beck Depression Inventory for primary care (BDI-
pc), and the Symptom Checklist-90 (SCL-90). The BDI-pc instead of the complete BDI, was 
used in order to prevent an overlap between physical aspects of fatigue with the somatic 
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symptoms of depression (26,27). This shortened version of the BDI has 7 items and is including 
cognitive and affective symptoms. A score of 4 or more is indicative of clinical depression. The 
SCL-90 indicates psychological distress for anxiety, agoraphobia, depression, somatisation, 
obsessive-compulsive behaviour, interpersonal sensitivity, hostility and sleep disturbances (28). 
Higher SCL-subscale scores indicate more distress. 
 
Sleep disturbances 
Sleep disturbances were measured with the sleep/rest scale of the SIP and the sleep subscale of 
the SCL-90. Finally, quality of sleep (general quality of sleep, difficulties falling asleep, restless 
sleep, non restorative sleep, and early awakening) was registered daily in the SOL. 
 
Concentration problems 
Experienced concentration problems were measured with the concentration subscale of the CIS 
and the alertness behaviour subscale of the SIP. Neuropsychological performance was measured 
with the Complex Reaction Time Task (CRT) and the Symbol Digit subtest of the Dutch version 
of the Wechsler Adult Intelligence Scale (WAIS) (29,30). The CRT measures the speed of 
information processing and is comprised of three succeeding tasks, each providing a reaction 
time (RT) and movement time (MT). RT reflects speed of information processing and MT 
reflects motor speed. The Symbol Digit subtest (SDT) of the WAIS assesses the ability to 
concentrate. This test consists of pairing numbers with nonsense symbols as quickly as possible. 
The higher the score on this test, the better a person is able to concentrate. 
 
Social functioning and social support 
Social functioning was measured with the social interaction subscale of the SIP. Social support 
was measured by the van Sonderen Social Support Inventory (SSL) (31). The SSL was divided 
into the SSL-I (amount of social support), the SSL-D (discrepancies between amount of social 
support and desired amount of social support), and the SSL-N (amount of negative interactions).  
Total scores of SSL-I and SSL-D range from 34-136, total score of SSL-N from 7-28.  
 
Self-efficacy  
Self-efficacy, a sense of control over fatigue symptoms, was measured with the Self-efficacy Scale. 
The SES consisted of seven questions that measured sense of control with respect to fatigue (32). 
The total score ranges from 7 to 28, a higher score reflecting more sense of control. 
 
Causal attribution  
Causal Attribution with regard to fatigue complaints was measured with the Causal Attribution 
List (CAL). This questionnaire consisted of 4 items divided over two subscales; psychological 
related attributions and neuromuscular disorder related attributions. For each item, patients were 
asked to indicate their opinion regarding the cause of their fatigue complaints on a 4-point scale, 
a higher score indicating stronger causal attributions (32). 
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Muscle strength 
Muscle strength was determined using the Medical Research Council (MRC) grading scale (MRC; 
0 to 5) investigating the strength of the shoulder abductors, grip force, foot extensors and knee 
extensors (33). In order to characterise the patients, these eight values (both left and right) were 
averaged. 
 
Pain 
Pain intensity was assessed by a 0 – 100 rating Visual Analogue Scale (VAS) of average pain 
intensity on current moment, where 0 = no pain and 100 = pain as bad as could be. In addition, 
pain was measured with the daily-observed pain score of the SOL. Severity of pain was reported 
four times a day on a 5-point scale (0-4). Total scores range from 0 to 16. 
 
Statistics 
Data analysis was performed using SPSS (version 12.0). Descriptive statistics were used for 
description of the sample. T-tests, chi-square, analyses of variance (ANOVA) with correction 
according to Bonferroni multiple-comparison test and general linear model (GLM)-general 
factorial were performed to test differences between groups.  P values < 0.05 were regarded as 
statistically significant. Correlations were calculated with the Spearman coefficient (r) correlation. 
In order to examine the contribution of the various dimensions of fatigue to the dimension of 
fatigue severity, linear regression analyses (enter-method) were performed. Regression analyses 
have been performed to examine the contribution of CAF and peripheral fatigue to experienced 
fatigue severity. Furthermore, regression analyses have been performed to examine the 
contribution of the dimensions and pain and disease severity to experienced fatigue severity. Two 
analyses were performed, one with the CIS-fatigue severity score as the dependent variable, and 
the other using the DOF score as the dependent variable. Independent variables were those 
questionnaires or subscales within the various dimensions that correlated strongest and 
significant with the dependent variable. 
Finally, regression analyses have been performed to examine the contribution of the dimensions 
to physiological fatigue. Two analyses were carried out, one with the CAF score as the dependent 
variable, and the other using the peripheral fatigue score as the dependent variable. 
 
 
RESULTS 
 
The patient sample consisted of 65 FSHD patients, 79 MD patients, and 73 HMSN patients. 
Neuromuscular diagnoses of the patients were verified according to established criteria [34]. 
Demographic characteristics of the groups are summarized in Table 7.1. No significant 
differences were found in age, gender, marital status and level of education between the three 
groups. 
 
 
 
 
80 Chapter 7 
 
 
 
TABLE 7.1. Demographic characteristics of the three neuromuscular patient groups 
 FSHD 
n=65 
mean (sd) 
MD 
n=79 
mean (sd) 
HMSN-I 
n=73 
mean (sd) 
Mean age 43.1 (10.3) 41   (9.9) 42.4 (9.8) 
Age range 22-60 22-56 20-58 
Gender (male/female) 59% / 41% 56% / 44% 41% / 59% 
Marital status    
    married/living together 52   (80%) 53   (67%) 49   (68%) 
    divorced 3   (5%) 4   (5%) 4   (5%) 
    widowed 2   (3%) --- 4   (5%) 
    living independent 6   (9%) 13   (17%) 11   (15%) 
    living with parents 2   (3%) 9   (11%) 5   (7%) 
Higher education (>= 12 years) 18   (28%) 17   (21%) 20   (27%) 
 
 
Relation between experienced fatigue and physiological fatigue (CAF and peripheral 
fatigue) 
In all patients (n=217) regression analyses showed that with the CIS-fatigue as dependent 
variable the CAF contributed significantly (beta=0.129, p=0.005), but peripheral fatigue did not 
contribute significantly (beta=0.075, p=0.396) to the experienced fatigue severity. In total, 4% of 
the experienced fatigue severity was predicted. In the analysis with the daily-observed fatigue 
(DOF) as dependent variable, the CAF contributed also significantly to the experienced fatigue 
(beta=0.314, p=0.000) and peripheral fatigue did not (beta= -0,032, p=0.711). In total, 10% of 
the DOF was predicted. No differences in physiological fatigue were found between severely 
fatigued and non-severely fatigued patients (Table 7.2). 
 
Differences and similarities between the three neuromuscular disorders 
The three groups were comparable concerning their functional limitations, psychological distress, 
and muscle force. However, MD patients reported more communication problems and more 
limitations in sleep and rest, while HMSN patients reported more sleep problems. The HMSN 
patients had significant higher levels of physical activity (mean actometer) than the two other 
groups. The MD patients reported more discrepancies between the amount of social support and 
desired amount social support (SSL-D) than the two other groups. Further, the MD patients 
reported significantly lower sense of control of fatigue symptoms (self-efficacy) and reported 
significantly less pain than FSHD and HMSN patients. 
 
Determinants of experienced fatigue 
Being severely experienced fatigued was associated with more problems in all dimensions (Table 
7.2). The less fatigued FSHD, MD and HMSN patients had comparable scores, while the fatigued 
MD patients reported more limitations in sleep and rest, and reported more problems with 
communication. In the MD group, there were no differences in activity level between the 
experienced fatigued and non-experienced fatigued patients. 
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In all three groups, regression analyses showed that the model with the CIS-fatigue as dependent 
variable the dimension sleep disturbances (non restorative sleep) contributed significantly to 
fatigue severity. In FSHD also psychological distress (SCL-depression), and in HMSN patients 
concentration problems (SIP-alertness behaviour) contributed significantly to CIS-fatigue. In 
total, 32.5% of the fatigue severity subscale of the CIS was predicted in the FSHD group, 26.6% 
in the MD group and 53% in the HMSN group (Table 7.3a). Only in HMSN muscle strength 
(MRC) was included in the model but it did not contributed significantly. 
 
In the analysis with the DOF as dependent variable only the dimension pain (VAS score) 
contributed significantly in FSHD patients, the dimension sleep disturbances (non restorative 
sleep) in MD patients, and the dimensions psychological distress (SCL-somatisation) and sleep 
disturbances (non restorative sleep) contributed significantly to the DOF score in HMSN 
patients. In total, 45.1% of the DOF score was predicted in the FSHD group, 25% in the MD 
group and 51.6% in the HMSN group (Table 7.3b). In none of the three neuromuscular disorders 
muscle strength (MRC) was included in the model. 
 
 
TABLE 7.3a. Linear regression analysis to predict experienced fatigue (CIS-fatigue) 
 Dependent variable 
CIS-fatigue 
 FSHD MD HMSN 
 Beta Beta Beta p Beta p 
Independent variables       
1) SIP-recreation and pastime 0.227 0.161 0.097 0.476 0.120 0.295 
2) SIP-ambulation 0.063 0.623 -0.106 0.442 ---  
3) SCL-depression 0.539 0.041 0.191 0.120 ---  
4) non restorative sleep 0.272 0.026 0.298 0.007 0.321 0.003 
5) SIP-alertness behaviour -0.168 0.400 0.223 0.127 0.274 0.013 
6) SIP-social functioning -0.51 0.537 0.086 0.552 0.018 0.873 
7) Self-efficacy ---  -0.149 0.246 ---  
III) MRC ---  ---  -0.206 0.061 
Total R2 (adjusted) 0.325  0.266  0.530  
Dimensions: 1) functional impairment in daily life; 2) physical activities; 3) psychological distress;  
4) sleep disturbances; 5) concentration problems; 6) social functioning; 7) self-efficacy; III) disease severity.  
 
Determinants of physiological fatigue (CAF and peripheral fatigue) 
Regression analyses showed that with the CAF as dependent variable only pain (VAS score) 
contributed significantly in FSHD patients and none of the dimensions contributed significantly 
in HMSN patients. In total, 24% of the peripheral fatigue was predicted in the FSHD group and 
15.5% in the HMSN group (Table 7.4a). In MD a model of contributing dimensions could not be 
developed, as none of the dimensions correlated significantly with the CAF. 
 
The analysis with peripheral fatigue as dependent variable showed that only functional 
impairment in daily life (daily worked hours) contributed significantly in FSHD patients, sleep 
disturbances (daily general quality of sleep) and pain (daily observed pain) in MD patients, and 
only functional impairment in daily life (daily worked hours) contributed significantly in HMSN 
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patients. In total, 10.9% of the peripheral fatigue was predicted in the FSHD group, 13.3% in the 
MD group and 12.6% in the HMSN group (Table 7.4b). 
 
 
TABLE 7.3b. Linear regression analysis to predict experienced fatigue (daily observed fatigue) 
 Dependent variable    CIS-fatigue 
 FSHD MD HMSN 
 Beta p Beta p Beta p 
Independent variables       
1) SIP-eating 0.159 0.192 ---  0.172 0.072 
1) SIP-body care and  movement ---  -0.149 0.247 ---  
2) SIP-mobility ---  -0.085 0.510 ---  
3) SCL-anxiety ---  ---  0.208 0.045 
3) SCL-depression ---  0.152 0.139 ---  
4) non restorative sleep 0.073 0.493 0.405 0.000 0.403 0.000 
5) SIP-alertness behaviour 0.251 0.099 ---  -0.027 0.773 
6) SIP-social functioning 0.021 0.880 ---  -0.017 0.864 
6) SSL-I ---  0.126 0.214 ---  
9) VAS (pain) 0.418 0.000 ---  0.328 0.000 
Total R2 (adjusted) 0.451  0.250  0.516  
Dimensions: 1) functional impairment in daily life; 2) physical activities; 3) psychological distress;  4) sleep disturbances; 5) 
concentration problems; 6) social functioning; 9) pain. 
 
 
TABLE 7.4a. Linear regression analysis to predict CAF 
 Dependent variable    CAF 
 FSHD HMSN 
 Beta p Beta p 
Independent variables     
1) SIP-ambulation ---  0.215 0.098 
3) SIP-emotional behaviour 0.114 0.344 ---  
3) SCL-anxiety ---  0.239 0.129 
4) SCL-sleep ---  0.175 0.269 
9) daily observed pain (SOL) 0.476 0.000 ---  
Total R2 (adjusted) 0.242  0.155  
In MD patients, none of the dimensions were significant 
Dimensions: 1) functional impairment in daily life; 3) psychological distress; 4) sleep disturbances; 9) pain. 
 
 
TABLE 7.4b. Linear regression analysis to predict peripheral fatigue 
 Dependent variable   Peripheral fatigue 
 FSHD MD HMSN 
 Beta p Beta P Beta p 
Independent variables       
1) daily worked hours (SOL) 0.280 0.046 0.220 0.052 0.388 0.004 
4) daily general quality of sleep (SOL) 0.009 0.947 0.253 0.029 -0.154 0.235 
9) daily observed pain (SOL) -0.185 0.193 0.247 0.032 -0.161 0.218 
Total R2 (adjusted) 0.109  0.133  0.126  
Dimensions: 1) functional impairment in daily life; 4) sleep disturbances; 9) pain. 
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DISCUSSION 
 
As far as we know this is the first study in which both experienced fatigue and physiological 
fatigue were studied in three relatively common neuromuscular disorders. 
This study showed that experienced fatigue is related to central activation failure (CAF), but not 
to peripheral fatigue in a large cohort of patients with FSHD, adult-onset MD, and HMSN type 
I. However, CAF explained only a small amount of the variance of experienced fatigue. There 
was no significant difference in CAF, peripheral fatigue or disease severity between patients with 
severely experienced fatigue and non-severely experienced fatigue. Experienced fatigue, CAF, and 
peripheral fatigue appeared to be separate types of fatigue. Although the respective determinants 
of experienced fatigue appear to be quite similar in the three neuromuscular disorders, the 
amount of explained variance differed considerably. 
In the three neuromuscular disorders, severe experienced fatigued was associated with more 
symptoms on the various dimensions: more functional impairment in daily life, more 
psychological distress, more sleep disturbances, more concentration problems, less social 
functioning, and higher levels of pain.  
In patients with MD, the severely fatigued patients have higher scores than the  
non-severely fatigued patients of communication problems and these scores were significantly 
higher than in the two other patient groups. This difference is understandable by the disease-
specific problems associated with a multisystem disorder like MD. Myotonic dystrophy often 
leads to nasal and dysarthic speech, which possibly causes communication difficulties (35). 
As far as we know, the relation between experienced fatigue and actual physical activity 
(actimetry) in patients with neuromuscular disorders has not been investigated before. Patients 
with FSHD and HMSN with severe experienced fatigue appeared to have lower levels of actual 
physical activity. Thus, patients who are more fatigued move less, compared with patients 
without experienced fatigue. Whether fatigue is the cause or the result of the physical inactivity, 
and/or muscle weakness cannot be concluded from these cross-sectional data. Remarkably, in 
MD patients we found no difference in actual physical activity between severely fatigued and 
non-severely fatigued. This means that actual physical activity has no relationship with fatigue in 
this patient group. 
Severely fatigued patients reported higher level of psychological distress than non-severely 
fatigued patients in all three groups. No significant differences were found between the three 
neuromuscular disorders on psychological distress. We cannot say whether distress is an 
antecedent or consequent of fatigue, because of the cross-sectional data. 
 In all three disorders, sleep disturbances showed an important relation with experienced fatigue.  
According to previous reports, sleep disturbances are very common in (chronic) neurological 
disorders (35). Various sleep disruptions may result from impaired motor functions, nocturnal 
pain and (muscle) cramps, restless legs and periodic limb movement disorders. These disruptions 
might lead to excessive daytime sleepiness and fatigue (36). HMSN patients reported significantly 
more sleep problems than the two other groups. Dematteis et al found an association between 
HMSN and sleep apnoea (37). Experienced fatigue is common to a wide range of sleep disorders 
and might leads to insomnia (37). Additional studies are needed to analyse the specific sleep 
disturbance in patients with neuromuscular disorders and the specific relation with fatigue. 
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We found a relation between concentration problems (SIP-alertness behaviour) and experienced 
fatigue in the three disorders. Pfeiffer et al showed that the statements of the SIP alertness 
behaviour (‘I have minor accidents’, or “I react slowly to things that are said or done”) are 
statements which illustrate typical problems of patients with neuromuscular disorders, who 
behave clumsily and are slow in important activities (38). 
In all three groups, severely fatigued patients reported more impairment in social interaction than 
non-severely fatigued patients. Severely fatigued patients had a lower sense of control with 
respect to their fatigue symptoms than non-severely fatigued patients. No differences were found 
between severely fatigued and non-severely fatigued patients of causal attribution. However, 
those patients who report that they never experience fatigue have not filled out the self-efficacy 
and causal attribution questionnaires. Finally, we found that patients with FSHD and HMSN 
turned out to report more often pain than MD patients. Pain is a significant problem for these 
disorders interrupting activities of daily living (39,40). The relationship between experienced 
fatigue and pain is weak.  
We used two measurements for experienced fatigue as dependent variable: the CIS-fatigue, a 
general self-report measure, and the daily-observed fatigue (DOF) score. For both experienced 
fatigue measures about the same dimensions explained the variance in all tested models. 
 
In this study physiological fatigue was divided in central activation failure, as measure of central 
fatigue, and peripheral fatigue. Determinants of the CAF were different for the three 
neuromuscular disorders and were different from the dimensions contributing to experienced 
fatigue. In FSHD patients CAF could be significantly explained by pain. This means that pain in 
FSHD has a great influence on the level of central activation. This was also found by Graven-
Nielsen (41). In contrast, in HMSN none of the tested variables was significantly related to CAF 
explaining only a small amount of variance. In MD none of the variables of the dimensions could 
be put in the regression model.  
There is a remarkable similarity in the three neuromuscular disorders in the variables that 
explained the variance of peripheral fatigue. Peripheral fatigue is defined as the ability of muscle 
to produce force declines during exercise. We found that daily worked hours, daily general quality 
of sleep and daily observed pain contributed to peripheral fatigue. However, these determinants 
explained only a small amount of the variance.  
All determinants were measured with the self-observation list, filled out during two weeks after 
the experiment. Chaudhuri and Behan considered peripheral fatigue as a term for muscle 
fatigability due to disorders of muscle and neuromuscular junction (2). However, we found no 
relation between peripheral fatigue, muscle strength and disabilities.  
Our data are cross-sectional, which affected the ability to make any definite conclusions about 
the cause and effect relationships between variables. Further work evaluating the causal pathways 
for the different types of fatigue and the role of determinants in moderating or mediating fatigue 
in patients with neuromuscular disorders is necessary.  A longitudinal study of such factors might 
reveal which determinants can predict different types of fatigue. 
In conclusion, results from this study indicate that fatigue in neuromuscular disorders should be 
distinguished in experienced fatigue and physiological fatigue (CAF and peripheral fatigue). 
Experienced fatigue is significantly but very modestly associated with central activation failure. 
Determinants of fatigue       87 
 
 
 
 
Experienced fatigue is not related with peripheral fatigue. The identification of different types of 
fatigue and the causally related determinants of the different types in these disorders can help us 
to develop specific interventions to reduce fatigue in patients with neuromuscular disorders. 
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Pain and the relation with fatigue in patients with Facioscapulohumeral Dystrophy, 
Myotonic Dystrophy and HMSN-I 
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ABSTRACT 
 
Objectives 
To determine the presence, localization and other characteristics of pain and its relation with 
fatigue in patients with relatively common types of neuromuscular disorders. 
Methods 
In total, 217 patients (65 Facioscapulohumeral Dystrophy, 79 adult-onset Myotonic Dystrophy 
and 73 Hereditary Motor and Sensory Neuropathy type I patients) were studied.  
Pain was investigated with the McGill Pain Questionnaire, functional disability was measured 
with the Sickness Impact Profile, physical activity with an actometer, and muscle strength with 
the Medical Research Council (MRC) scale. Fatigue severity was assessed with the Checklist 
Individual Strength (CIS-fatigue). 
Results 
Pain complaints were reported by 77% of FSHD, 47% of MD, and 75% of HMSN patients. The 
main values of pain scores were significantly higher for the patients compared to a healthy 
reference group. The localization of pain is specific for each neuromuscular disorder. Pain was 
most frequently localized in body regions most affected by the neuromuscular disorder and 
localization thus differed between the three disorders.  No significant difference were found in 
levels of functional disability, physical activity, and muscle strength between patients with and 
without pain in each neuromuscular disorder. 
Conclusion 
Pain is an important feature in the studied neuromuscular disorders and its distribution is related 
to the weakness and differs from fatigue in these disorders. 
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INTRODUCTION 
 
Severe fatigue has been reported  by the majority of patients with relatively common 
neuromuscular disorders (1). Clinical experience of our research group indicated that many 
patients with these disorders also report pain and consider it an important problem. Surprisingly, 
pain in neuromuscular disorders has received little attention: only a few studies have investigated 
pain complaints in patients with neuromuscular disorders (2-5).  
The present study concerns three homogeneous populations of patients with relatively common, 
genetically well-defined neuromuscular disorders, namely: facioscapulohumeral muscular 
dystrophy (FSHD), a myogenic disorder; adult-onset myotonic dystrophy (MD), a multisystem 
disorder; and hereditary motor and sensory neuropathy type I (HMSN), a neurogenic disorder. 
The first aim of the present study was to investigate the presence, the localization and other 
characteristics of pain in FSHD, MD, and HMSN and its relation with functional disability, 
physical activity, and muscle strength. The second aim was to examine the strength of the 
relationship between pain and fatigue in these disorders.  
 
 
METHODS 
 
Patients 
Adult patients with a definite diagnosis of a neuromuscular disorder who could be classified into 
one of the following diagnostic categories were asked to participate: (1) facioscapulohumeral 
muscular dystrophy (FSHD), (2) adult-onset myotonic dystrophy (MD) or (3) hereditary motor 
and sensory neuropathy type I (HMSN-I). Patients are a subgroup of patients describes earlier 
(1). Written informed consent was obtained from all participating patients. The study was 
approved by the local ethics committee. 
 
Pain 
The McGill Pain Questionnaire (MPQ) was used for the assessment of different aspects of pain 
(6,7).The main outcome measure is the magnitude of pain at the current moment marked on the 
visual analogue scale (VAS): a score of 0 mm indicates no pain, and 100 mm indicates unbearable 
pain. During 12 days, patients filled pain complaints in a daily Self Observation List (SOL). Pain 
severity was rated four times a day on a scale of 0 (no pain) to 4 (severe pain). This daily observed 
pain  (DOP) score could range from 0 to 16, and the twelve daily pain scores were averaged into 
one DOP score (8). The DOP score was compared with the scores of a reference group of 90 
healthy people, consisting of 35 men and 55 women (mean age 37.1 years, sd 10.9), who 
participated as controls in previous studies at the Expert Centre Chronic Fatigue. Furthermore, 
four times a day patients were asked to mark in the SOL types of pain that applied best for that 
moment (muscle pain, joint pain, back pain, abdominal pain, headache, and sore throat) (8). 
 
Functional disability 
Functional disability was assessed using the Dutch version of the Sickness Impact Profile (SIP-
12) (8,9). A higher score means more functional disability.  
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Physical activity  
The level of physical activity was assessed using an actometer (Actilog V3.0), a device worn by 
the patients around the ankle for 12 consecutive days 10). During this period of 12 days the 
patients filled out the daily Self Observation List (SOL) (8).  
 
Muscle strength 
Muscle strength was determined using the Medical Research Council (MRC) grading scale (MRC; 
0 to 5) investigating the strength of the shoulder abductors, grip force, foot extensors and knee 
extensors (11). These eight values (both left and right) were averaged. 
 
Fatigue severity  
Fatigue severity was assessed using a subscale of the Checklist Individual Strength (CIS) (13-15). 
 
Statistics 
Data analysis was performed using SPSS (version 12.0). Descriptive statistics were used for 
description of the sample. T-tests, chi-square, analyses of variance (ANOVA) with correction 
according to the Bonferroni multiple-comparison test and general linear model (GLM)-analyses 
were performed to test differences between groups. For comparison between patients with and 
without pain the Mann-Whitney test was used. Correlations were calculated with the Spearman 
coefficient (r) correlation.  P values < 0.05 were regarded as statistically significant. In order to 
examine the contribution of the pain scores (DOP and VAS) to fatigue, linear regression analyses 
(enter-method) were performed. 
 
 
TABLE 8.1. Pain characteristics of patients with pain of each neuromuscular disorder 
 FSHD 
N=50 
mean (sd) 
MD 
N=37 
mean (sd) 
HMSN-I 
N=55 
mean (sd) 
p-value 
MPQ:     
VAS-momentary pain 26.2 (22.1) 24.4 (19.8) 34.8 (22.8) ns 
Range VAS-momentary pain (0-100) 0 – 87 0 - 83 0 - 81  
Self Observation List:     
Daily Observed Pain (DOP)   3.6 (2.6) b   2.0 (1.8) ac   4.0 (2.8) b 0.001 
Range DOP (0-16) 0 – 10.8 0 – 7.6 0 – 14.3  
% muscle pain 40.6 (38.8) 24.8 (33.3) 41.5 (37.8) ns 
% joint pain 21.6 (33.5)   8.2 (15.8) c 30.7 (35.4) b 0.003 
% backache 22.5 (28.8) 13.5 (18.5) c 34.9 (39.0) b 0.005 
% abdominal pain   2.3 (7.9)   3.5 (5.2)   4.6 (10.1) ns 
% headache 12.1 (23.0)   5.6 (10.5)   9.3 (17.2) ns 
% sore throat   5.7 (14.9)   1.0 (2.5)   2.6 (8.2) ns 
a Significantly different from FSHD, Bonferonni p<0.05 
b Significantly different from MD, Bonferonni p<0.05 
c Significantly different from HMSN, Bonferonni p<0.05  
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RESULTS 
 
The patient sample consisted of 65 FSHD patients, 79 MD patients, and 73 HMSN patients. The 
mean (sd) age was 43.1 (10.3) in the FSHD group, 41.0 (9.9) in the MD group, and 42.4 (9.8) in 
the HMSN group. In the FSHD group 59% were female, in the MD group 56%, and in the 
HMSN group 41%. No significant differences were found in age, gender, marital status and level 
of education between the three groups. 
 
Pain 
Pain complaints were reported by 50 of the 65 FSHD patients (77%), by 37 of the 79 MD 
patients (47%), and by 55 of the 73 HMSN patients (75%)(Table 8.1).  
 
Pain was present for more than 4 years in the majority of the patients (68% of the FSHD, 62% 
MD, and 55% HMSN patients). Pain had started gradually in 94% of the FSHD, 84% MD, and 
in 80% of the HMSN patients with pain. In 62% in FSHD, 81% MD, and 78% HMSN patients 
with pain the complaints were always localized in the same body regions. The localizations of 
pain indicated on the bodily outline of the MPQ are presented in Figure 1.  
 
Frequently used adjectives to characterize the pain in all three groups were stabbing, nagging, 
stiff, and sore. Pain intensity was mostly described as mild to moderate. 
Only 22% FSHD, 16% MD,  and 20% HMSN patients used analgesics regularly.  
 
The mean values of the daily-observed pain score were significantly higher for the patients (in 
FSHD 2.9, sd 2.6; in MD 1.5, sd 1.6; in HMSN 3.2, sd 2.9) compared to the healthy reference 
group (mean DOP 1.0, sd 1.3). 
 
In none of the groups, we found significant differences in age, gender, QoL, physical activity, and 
muscle strength between patients with and without pain. 
 
 
Relation between pain and fatigue 
The severely fatigued FSHD and HMSN patients had significantly higher pain scores  (DOP and 
VAS) than the non-severely fatigued patients. We found no differences in pain scores in the MD 
group. 
 
With regression analyses we investigated the relation between CIS-fatigue (as dependent variable) 
and the pain scores (DOP and VAS) (as independent variables). In total, 16.4% of the 
experienced fatigue was predicted in the FSHD group, 3% in the MD group and 21.5% in the 
HMSN group. 
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FIGURE 8.1. Localization of pain in front and back in each neuromuscular disorder (%) 
FSHD: 
MD: 
HMSN: 
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DISCUSSION 
 
This study shows that a high percentage of patients with homogeneous well-defined 
neuromuscular disorders report pain symptoms. About three quart of the FSHD and HMSN 
patients, and nearly half of the MD patients reported pain. Pain was most frequently localized in 
body regions generally known to be affected most by the neuromuscular disorder and thus 
localization differed between the three disorders. In none of the disorders was a statistically 
significant relationship between the presence of pain and age, gender, functional impairment, 
physical activity, or muscle strength.  
In all three disorders, the Daily Observed Pain scores were higher than the scores of the 
reference group of 90 healthy people. This means that the reported pain is a clinically relevant 
phenomenon in these disorders.  
Pain was most frequently localized in body regions mostly affected by the neuromuscular 
disorder and localization thus differed between the three disorders. Bushby attributed the pain in 
FSHD to postural problems in shoulders, hips and low back (2). Harper et al described that 
particularly back pain is often reported as a problem but was poorly studied in myotonic 
dystrophy so far (16). In HMSN patients, pain was most frequently present in lower back, feets 
and legs. This finding agreed with the clinical features of HMSN. In HMSN, muscle weakness 
and atrophy usually start in the foot and leg muscles. The rate of pain in HMSN patients is 
consistent with the findings of Carter et al (3).  
In all three neuromuscular disorders we found a high presence of pain in the lower back. We 
know that back pain, especially pain in the lower back, is one of the most common health 
problems in adults.  
Remarkable is the low consumptions of first-line analgesics in all three disorders. It may be 
possible that conventional first-line analgesics or anti-inflammatory therapy provide little effect in 
these patients. Or prescribing analgesics more frequently could be useful, further studies can give 
a definite answer. 
In all three neuromuscular disorders pain appeared to be poorly related to fatigue. Severely 
fatigued FSHD and HMSN patients reported significantly more often pain than non-severely 
fatigued patients. We found no differences in pain between severely fatigued and non-severely 
fatigued MD patients. 
Our study might have the following methodological limitations. Firstly, a selection bias is 
possible, because we only investigated ambulant patients. However, we have pain scores and 
experienced fatigue scores from 381 non-participating patients with neuromuscular disorders (74 
FSHD, 243 MD, and 64 HMSN patients)(1). We found that the investigated group and the 
patients not included in this study did not differ in the levels of pain and fatigue. So it is unlikely 
that there is a systematic bias in our study. Secondly, the data were cross-sectional, which affected 
the ability to make any definite conclusions about the cause and effect relationships between 
variables. A longitudinal study of such variables might reveal which variables are causally related 
to pain and fatigue. 
Awareness of pain and fatigue in these disorders is crucial to recognize important issues such as 
the impact on daily life, and the need for possibilities to reduce pain. 
In conclusion, pain and fatigue are only poor related in FSHD and HMSN and unrelated in MD. 
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ABSTRACT 
 
Objectives 
Experienced fatigue is a common symptom experienced by patients with various neuromuscular 
disorders. The purpose of this study was to assess the influence of relatives on fatigue 
experienced by patients with various neuromuscular disorders. 
Methods 
In total, 106 close relatives of patients with Facioscapulohumeral Dystrophy (FSHD), adult-onset 
Myotonic Dystrophy (MD), and Hereditary Motor and Sensory Neuropathy type I (HMSN), 
completed the Checklist Individual Strength (CIS) for themselves, and how they thought their 
relatives filled in this questionnaire. We studied at the agreement between the two. The reaction 
of the relative to the fatigue and to the neuromuscular disorder of the patient was assessed by the 
Family Response Questionnaire. Marital dissatisfaction was also measured. The influence of the 
relative’s response to the patients’ fatigue and the relatives’ fatigue on the fatigue of the patient 
was tested in linear regression models. 
Results 
In all three patient groups, the responses of the relatives to fatigue and disease were characterized 
by sympathetic-empathic responses. Low agreement existed between relatives and MD patients 
(r=0.26) over the patients’ level of fatigue but higher agreement between relatives and FSHD 
(r=0.67) and HMSN (r=0.73) patients. The spouses of MD patients reported less marital 
satisfaction. The sympathetic-empathic responses of relatives of FSHD and HMSN patients, and 
in FSHD also fatigue experienced by the relative, contributed significantly to higher levels of 
fatigue experienced by the patients.  
Conclusion 
The sympathetic-empathic responses of close relatives to the fatigue of the patient were related 
to higher levels of fatigue experienced by FSHD and HMSN patients, but not in MD patients. 
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INTRODUCTION 
 
Fatigue is a symptom experienced by the majority of patients with relatively common 
neuromuscular disorders (1). Fatigue can have a major impact on patients’ functioning and 
activities of daily living, and on psychological well being (1-4). The effects are not limited to the 
patient, the relatives of the patient can suffer as well (5). 
It is known that chronic diseases might also affect the quality of life of close relatives (6-7). Close 
relatives can provide emotional and instrumental support to the disabled individual in order to 
help the patient cope with the disease. Relatives are also able to reinforce their partners to engage 
in activities in daily life (5). Especially in chronic diseases, the major burden of care falls on the 
spouse and other close family members (8). To our knowledge, there has been no study to date 
that has asked the relatives of patients with neuromuscular disorders about their own level of 
fatigue and neuromuscular disorder of the patient. 
Therefore, we conducted a study of patients and their spouses or close relatives in three 
genetically well-defined neuromuscular disorders: facioscapulohumeral muscular dystrophy 
(FSHD), a myogenic disorder; myotonic dystrophy (MD), a multisystem disorder; and hereditary 
motor and sensory neuropathy type Ia (HMSN), a neurogenic disorder. 
The purpose of this study was three-fold: 1) to investigate the level of fatigue experienced by the 
close relatives and their responses to the fatigue and the neuromuscular disorder of the patient, 2) 
to determine if the close relatives are able to correctly perceive the level of fatigue experienced by 
the patient, and 3) to determine the influence of the relatives’ responses and level of fatigue on 
the level of fatigue experienced by the patient. 
 
 
METHODS 
 
Patients and close relatives  
Adult patients with a definite diagnosis of a neuromuscular disorder who could be classified into 
one of the following three diagnostic categories were asked to participate: (1) 
facioscapulohumeral muscular dystrophy (FSHD), (2) adult-onset myotonic dystrophy (MD) or 
(3) hereditary motor and sensory neuropathy type I (HMSN-I). They were recruited from the 
outpatient clinic of the Neuromuscular Centre, based at the Institute of Neurology of the 
Radboud University Nijmegen Medical Centre, and from the Dutch Neuromuscular Diseases 
Association (Vereniging Spierziekten Nederland, VSN).  
In total, 134 patients were asked for a permission to send a booklet with questionnaires, to their 
closest relative (spouse, parent or other). Written informed consent was obtained from all 
participating patients and their close relatives. The regional ethics committee approved the study. 
 
Experienced fatigue  
The Checklist Individual Strength (CIS) is a 20-item questionnaire and measures the following 
four aspects of fatigue during the previous two weeks: fatigue severity (8 items, range 8-56), 
concentration problems (5 items, range 5-35), reduced motivation (4 items, range 4-28) and 
reduced activity (3 items, range 3-21). Each item was scored on a 7-point Likert scale. High 
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scores indicate high levels of fatigue, high levels of concentration problems, low motivation and 
low levels of physical activity (9,10). CIS-fatigue score equal or higher 35 was used to identify 
severe fatigue (11).  
The CIS was used to assess the fatigue experienced by both the patients and the relatives. The 
CIS-fatigue scores of the relatives were compared with the scores of a reference group of 78 
healthy controls (mean age healthy controls 48.1, sd 6.2) who participated as controls in previous 
studies at the Expert Centre Chronic Fatigue (12). 
 
Experienced fatigue relative over patient 
For use by relatives, the Checklist Individual Strength was rephrased to refer to the patient and 
called Checklist Individual Strength relative over patient (CIS-rop). 
 
Family response 
The Family Response Questionnaire (FRQ) contained 25 questions and scored on four 
dimensions: sympathetic and empathic responses (7 items, range 7-35), active engagement (5 
items, range 5-25), rejecting and hostile responses (7 items, range 7-35), and concern with self (6 
items, range 6-30) (13). Each item was scored on a 5-point Likert scale.  
Sympathetic-empathic responses imply trying to imagine what the patient feels like, making 
positive supportive statements. Active engagement is trying to find out more about the symptom 
or illness by reading, discussing with the patient. Rejecting or hostile responses were disbelieving 
the patient’s complaints or minimizing them. Concern with self means that relatives are 
concerned with the effect of the patient’s illness on his/her own life, e.g., resents having to take 
on extra tasks. 
A higher score indicates more of that response. In this study we used the FRQ for fatigue (FRQ-
f) and the FRQ for neuromuscular disorder (FRQ-nmd). In the FRQ-f all questions are referring 
to fatigue of the patient and in the FRQ-nmd the same questions are referring to the 
neuromuscular disorder. 
 
Marital satisfaction 
The subscale marital satisfaction of the Maudsley Marital Questionnaire (MMQ) was used as a 
measure of marital quality (14-15). This scale marital satisfaction contains 10 questions on a 9-
point Likert scale (range 0-80), with a higher score indicating more problems in the relation or 
lower marital satisfaction. 
  
Statistics 
Data analysis was performed using SPSS (version 12.0). Descriptive statistics were used for 
description of the sample. T-tests, chi-square, analyses of variance (ANOVA) with correction 
according to Bonferroni multiple-comparison test and general linear model (GLM)-general 
factorial were performed to test differences between groups. We used a Wilcoxon’s t-test for 
dependent samples to compare the relatives over patients and patient’s fatigue scores. P values < 
0.05 were regarded as statistically significant. Correlations were calculated with the Spearman 
correlation coefficient (r). Furthermore, regression analyses were performed to examine the 
relationship between responses of the relative and the level of fatigue experienced by the relative 
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self to the level of fatigue experienced by of the patients. The dependent variable was the CIS-
fatigue score of the patient, and the independent variables were the responses of the close relative 
and the CIS-fatigue score of the relative. 
 
 
RESULTS 
 
Patient-relative couples 
From the 112 close relatives (84%) who returned the questionnaires, 6 relatives were excluded 
because they did not complete the questionnaire booklet.. 
One hundred and six relative and patient couples participated in this study (33 couples of FSHD 
patients, 32 of MD patients and 41 couples of HMSN patients). Demographic characteristics of 
the three groups of relatives are listed in Table 9.1. No significant differences were found in age 
and sex between the groups. In the MD couples, the percentage of spouses is the lowest of the 
three groups.  
 
 
TABLE 9.1. Demographic characteristics of relatives of patient with three types of neuromuscular 
disorders 
 Relatives of FSHD 
N=33 
Relatives of MD    
N=32 
Relatives of HMSN 
N=41 
Age 46.7 (9.7) 48.5 (10.7) 46.7 (13.2) 
M/F (%) 36% / 64% 34% / 66% 44% / 56% 
Relation of patient (N)    
Spouse  31 19 31 
Years of living together 21.0 (10.4) 21.8 (11.3) 18.1 (12.0) 
    
Mother/father  7 4 
Sister/brother  2 1 
Daughter/son 1  2 
Good friend 1 4 3 
 
TABLE 9.2. Demographic characteristics of patients with three types of neuromuscular disorders 
 FSHD patients 
N=33 
MD patients 
N=32 
HMSN patients 
N=41 
Age 48.9 (13.7) 41.8 (9.5) 43.7 (10.7) 
M/F (%) 61% / 39% 56% / 44% 42% / 58% 
Marital status    
  married/living together 31  19 31 
  divorced  2 2 
  widowed 1   
  living independently 1 6 5 
  living with parents  5 2 
Higher education 
 (>= 12 years) 
9 (27%) 7 (22%) 11 (27%) 
Employment  
 (paid job) 
23 (70 %) 23 (72%) 28 (69%) 
CIS-fatigue 33.5 (12.2) 37.7 (10.8) 33.6 (12.6) 
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Table 9.2 shows the demographic characteristics of the patients. No significant differences were 
found in age, sex, level of education, and employment between the three neuromuscular 
disorders. We found no differences in age between relatives and patients. 
Patients dropped out mostly because they did not have a partner (n=17). The patients who 
refused to take part in this study did not differ from the participating subjects with regard to age, 
gender, marital status, level of education, employment status, and fatigue severity.  
 
 
Experienced fatigue and family responses of relatives 
There was no difference between the relatives of the different patient groups with regard to the 
fatigue they experienced. Eighteen % of the relatives of FSHD patients experienced severe 
fatigue (CIS-fatigue >=35), 16% of the relatives of the MD patients, and 22% of the family 
members of the HMSN patients (Table 9.3). The mean value for CIS-fatigue was higher for the 
relatives than for the healthy reference group (mean healthy controls 19.4, sd 11.0). 
 
TABLE 9. 3. Experienced fatigue and responses to fatigue and neuromuscular disorder of relatives of 
patients with three types of neuromuscular disorders 
 Relatives of 
FSHD 
N=33 
Relatives of 
MD 
N=32 
Relatives of 
HMSN 
N=41 
p-value 
CIS-relatives     
CIS-fatigue 22.6 (11.3) 22.8 (12.3) 25.1 (12.9) ns 
CIS-concentration 11.8 (6.8) 12.7 (6.7) 10.3 (5.3) ns 
CIS-motivation  9.7  (4.5) 11.3 (5.9) 9.79 (4.5) ns 
CIS-activity  5.9  (2.9)  5.9 (3.0)  6.7 (4.6) ns 
FRQ-fatigue     
FRQ-f-sympathetic -empathic 16.8 (4.4) 17.8 (4.5) c 15.2 (3.5) b ns 
FRQ-f-active engagement  9.5  (2.4) 10.3 (3.4) c  8.4 (2.0) b ns 
FRQ-f-rejecting-hostile  9.1  (2.2)  9.6 (2.3)  8.8 (2.1) ns 
FRQ-f-concern with self  8.5  (2.5)  9.3 (3.9) c  7.2 (1.7) b 0.006 
FRQ-neuromuscular disorder     
FRQ-nmd-sympathetic -empathic 16.9 (4.1) 17.6 (4.5) 15.7 (3.8) ns 
FRQ-nmd-active engagement 10.5 (3.1) 10.4 (3.2) 9.2 (2.7) ns 
FRQ-nmd-rejecting-hostile 8.7  (1.8) 9.4 (2.2) 8.7 (2.1) ns 
FRQ-nmd-concern with self 8.4  (2.4) c 9.2 (2.9) c 6.7 (1.4) ab 0.000 
a Significantly different from relatives of FSHD patients, Bonferonni p<0.05 
b Significantly different from relatives of MD patients, Bonferonni p<0.05 
c Significantly different from relatives of HMSN patients, Bonferonni p<0.05 
 
In all three patient groups family responses were characterized by sympathetic-empathic 
responses. We found no differences in responses to fatigue and to the neuromuscular disorder. 
The relatives of HMSN patients had the lowest scores on the subscale  “concern with self”. 
(Table 9.3). The subscales of the FRQ-fatigue were strongly correlated to the subscales of the 
FRQ-neuromuscular disorder (range r=0.76 to r=0.91). 
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Agreement of experienced fatigue and marital satisfaction 
In MD couples no significant correlation between patients fatigue and the perception of patients’ 
fatigue by the relative was found (Table 9.4). In FSHD and HMSN couples high and significant 
correlation was found between patients’ fatigue and the perception of patients fatigue by the 
relative. In HMSN couples no correlation was found between patients reduced concentration and 
the perception of the relative. 
The relatives of the MD patients reported lower marital satisfaction than the other relatives, and 
there was lower agreement in marital satisfaction of the MD couples than the two other groups. 
 
 
TABLE 9.4. Correlations between relatives over patients and patient’s experienced fatigue of three types 
of neuromuscular disorders and in couples who lived together the marital satisfaction. 
 Relative over patient (CIS-rop)  
 CIS-rop- 
fatigue 
CIS-rop-
concentration 
CIS-rop- 
motivation 
CIS-rop- 
activity 
MMQ-marital 
satisfaction 
Patients:      
CIS-fatigue      
   FSHD 0.627**     
   MD 0.260     
   HMSN 0.728**     
CIS-concentration      
   FSHD  0.409*    
   MD  0.432*    
   HMSN  0.230    
CIS-motivation      
   FSHD   0.635**   
   MD   0.409*   
   HMSN   0.437**   
CIS-activity      
   FSHD    0.653**  
   MD    0.490*  
   HMSN    0.439**  
MMQ-marital satisfaction 1)            
   FSHD      0.765** 
   MD      0.402* 
   HMSN     0.814** 
*  correlation is significant at the 0.05 level (2-tailed) **correlation is significant at the 0.01 level (2-tailed) 
1) MMQ-marital satisfaction was only filled out by couples who lived together (31 FSHD couples, 19 MD couples, HMSN 31 
couples) 
 
 
 
Influence of the response and the level of experienced fatigue of relatives to patients’ 
fatigue 
Regression analyses showed that sympathetic-empathic responses (FRQ-f) of the relatives 
contributed significantly to the level of fatigue experienced by the patient in FSHD and HMSN 
couples. In the FSHD couples also the level of fatigue by the relative himself contributed 
significantly. In the MD couples, none of the various responses of the relatives contributed 
significantly to the level of fatigue experienced by the patients (Table 9.5 ). 
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TABLE 9.5. Linear regression analyis to predict experienced fatigue of the patient of each neuromuscular 
disorder 
 Dependent variable 
CIS-fatigue of the patient 
 FSHD MD HMSN 
Relatives Beta p Beta p Beta p 
FRQ-f-sympathetic-empathic 0.461 0.025 0.058 0.822 0.467 0.021 
FRQ-f-active engagement -0.073 0.725 0.374 0.207 -0.142 0.468 
FRQ-f-rejecting-hostile -0.155 0.339 0.067 0.775 -0.291 0.287 
FRQ-f-concern with self 0.288 0.132 -0.227 0.399 0.229 0.423 
CIS-fatigue of the relative -0.480 0.008 -0.133 0.575 0.175 0.308 
Total R2 (adjusted) 0.384  0.064  0.120  
 
 
 
DISCUSSION 
 
As far as we know this is the first study in which the responses of close relatives to patients’ 
experienced fatigue and disease were studied in neuromuscular disorders. Most studies of close 
relatives are focussed on caregivers of patients with cancer, Alzheimer’s disease and Parkinson’s 
disease (8,16-17). These studies showed that spouses and other relatives commonly respond in an 
unsupportive manner. As a relative becomes increasingly disabled by the patients’ disease, the 
role of the significant other is altered, and the relative may be required to relinquish social, 
leisure, and family activities outside the home, as well as restrict time on their own, in order to 
assist in the medical care and household responsibilities. Studies have shown that the greater the 
disability imposed by an illness, the more likely significant others are to respond negatively (8,17). 
In this study we investigated relatives of patients with slowly progressive neuromuscular 
disorders.  
 
The mean fatigue severity of the relatives was significantly higher compared to the scores of a 
reference group of healthy controls. We found no differences in the severity of fatigue 
experienced by the relatives of patients with various neuromuscular disorders. Although the 
patients in this study were mildly affected by their disorder, one could see the heightened level of 
fatigue experienced by the close relatives in relation to or as a burden of the disease of their 
partner. It is possible that the heightened fatigue of the relatives is caused by the disease and/or 
fatigue of the partner. Probably, the relatives were not fulltime caregivers of the patients in this 
study because all patients were ambulant and in all three groups more than 69% of the patients 
were employed. On the other hand, we know that at least about half of the patients suffer from 
severe fatigue, resulting in impairment in several domains. Therefore, some care will be given by 
the relative. However, we do not have specific information of the health status of the relatives, 
we do not know the influence of the health status on fatigue. 
 
The responses of the relatives to both the fatigue and neuromuscular disorder of the patients 
were mainly sympathetic-empathic responses and similar within relatives of patients with the 
various disorders. The relatives reported that they were trying to imagine what the patient feels, 
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making positive supportive statements. Relatives of MD patients reported the highest score on 
the subscale ‘concern with self’ of the Family Response Questionnaire. The relatives were 
concerned about the effect of the patients’ disease on their own life, e.g., resented taking on extra 
tasks. Besides, the relatives of MD patients reported the highest marital dissatisfaction. An 
explanation could be that the MD patient may not understand the impact of his/her disorder on 
the life of the relative, and/or the relative is frustrated about the practical limitations of the 
disorder. We found  a lower percentage of MD patients living with a partner than in the other 
two groups. This was also found in another study (20). 
 
Overall, the relatives rated the level of fatigue experienced by the patient lower than the patient 
did himself. The least agreement was found in MD couples. In spouses living together we found 
more disagreement in marital satisfaction within MD couples than within FSHD and HMSN 
couples. Possibly, disease-specific problems associated with a multisystem disorder like MD, such 
as apathy, lack of expressiveness, and inability to anticipate pleasure, contribute to more marital 
dissatisfaction (18-19). We found that relatives of patients with MD had difficulty in estimating 
the level of fatigue experienced by the patient. The same reaction can be supposed for the 
doctors of patients with MD and may influence their relationship. 
 
We found that the responses of the relatives led to higher levels of fatigue experienced by the 
patients in FSHD and HMSN couples. In FSHD couples also the level of fatigue experienced by 
the relative contributed to the level of fatigue in the patient. Receiving higher levels of 
sympathetic support from the relatives, such as getting help, was associated with higher reports 
of fatigue in patients with FSHD and HMSN. The sympathetic-empathic responses were 
reinforcing the fatigue of the patient. 
This study has some methodological limitations. Firstly, the data were cross-sectional, which 
affected our ability to make any definite conclusions about the cause and effect relationships 
between variables. Secondly, a selection bias is possible, because we only investigated ambulant 
patients. Thirdly, the patients were asked for a permission to send questionnaires to their closest 
relative. Patients dropped out mostly for the reason of not have a partner. In this study we found 
that the fatigue scores of patients with a spouse did not differ from those of the patients with 
another relative. However, we don’t know whether the relatives of the non-investigated group are 
different in their reaction to the patient from the relatives in this study.  
To date, there is very little information about the impact of patients with slowly progressive 
neuromuscular disorders on close relatives. This study reveals that a chronic neuromuscular 
disorder can have an effect on close relatives and vice versa. Especially the responses of close 
relatives influenced the level of fatigue experienced by the patient.  
One important point in clinical practice for the doctor of patients with neuromuscular disorders 
is to try to identify relatives who are at high risk of burden by their partner’ disease. Furthermore, 
these findings emphasise the importance that not only the patient, but also the relative should be 
target of information, this meaning that the close relative should also visit the physician together 
with the patient in order to reduce and manage the consequences of the disorder in both.  
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ABSTRACT 
 
Background  
Severe fatigue is reported by the majority of patients with three relatively common types of 
neuromuscular disorders.  
Objective 
To identify predictors of fatigue in a longitudinal study and to develop a model of experienced 
fatigue in patients with three neuromuscular disorders.  
Methods 
198 patients (60 Facioscapulohumeral Dystrophy (FSHD), 70 adult-onset Myotonic Dystrophy 
(MD) and 68 Hereditary Motor and Sensory Neuropathy type I (HMSN) patients) were studied 
twice during an 18-months period. Fatigue severity was assessed with the Checklist Individual 
Strength (CIS-fatigue). A multidimensional assessment method was used including self-report 
questionnaires, a daily Self Observation List, and a measure of physical activity (actometer). 
Muscle strength was determined using the Medical Research Council (MRC) scale. Structural 
equation modelling was used to develop and test a model of factors contributing to the 
persistence of experienced fatigue. 
Results 
Muscle strength, self-reported physical activity, sleep disturbances and pain at baseline 
contributed directly or indirectly to experienced fatigue and impairment at follow-up. Lower 
muscle strength contributed to lower levels of physical activity, which in turn contributed to 
experienced fatigue severity. The model showed excellent fit for the whole group of 
neuromuscular disorders. In FSHD, also pain contributed to physical activity. A model with the 
actometer as measurement for actual physical activity in stead of self-report showed an excellent 
model fit in FSHD and HMSN, but an insufficient fit in MD. 
Conclusion 
The model of perpetuating factors for fatigue in FSHD and HMSN is different from the model 
in MD. The main difference is in physical (in)activity. These differences have implications for 
interventions based on these models. 
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INTRODUCTION 
 
Neuromuscular disorders include a variety of conditions that affect  the peripheral nervous 
system (1,2). The peripheral nervous system includes peripheral nerves, the motor-nerve cells in 
the spinal cord, and the nerve-muscle (neuromuscular) junction. There are different types of 
neuromuscular disorders. Despite the many different neuromuscular disorders, only a limited 
number of symptoms occur: muscle weakness is the most typical.  
This study concerns three genetically well defined, homogeneous, and large populations of 
patients with relatively common neuromuscular disorders, namely facioscapulohumeral muscular 
dystrophy (FSHD), adult-onset myotonic dystrophy (MD) and hereditary motor and sensory 
neuropathy type I (HMSN). FSHD is an autosomal dominantly inherited myopathy, initially 
characterized by weakness and atrophy in facial, upper arm, and shoulder girdle muscles often 
progressing to affect peroneal and pelvic girdle muscles (3). 
MD is the most common form of muscular dystrophy and is also an autosomal dominant 
hereditary multisystemic disease characterized by myotonia, muscle weakness and atrophy, 
cataracts, cardiac abnormalities, excessive daytime sleepiness, and disorders of other systems such 
as the endocrine system, gastrointestinal tract, skin and bone (4). HMSN, also known as Charcot-
Marie-Tooth disease, forms a heterogeneous group of slowly progressive heritable disorders of 
the peripheral nervous system (5).The most common form is type I. The clinical features of 
HMSN type I include a symmetrical distal muscle weakness and atrophy, and areflexia and 
sensory impairment with distal loss of touch, pain, vibration and joint position sense. Thus, this 
study compares patients with three different neuromuscular disorders, including a myopathy, a 
multisystem disorder and a neuropathy. 
Fatigue is a common symptom of various neurological disorders and is mostly studied in multiple 
sclerosis, Parkinson’s disease, after stroke but less in neuromuscular disorders (6-11).  Within the 
group of neuromuscular disorders, fatigue has mostly been described in patients with post-
poliomyelitis syndrome, myasthenia gravis, and immune mediated neuropathies like Guillain-
Barré syndrome (12-15). In a previous cross-sectional study we concluded that severe fatigue was 
a complaint in more than 60% of a large sample of patients with relatively common 
neuromuscular disorders like FSHD, adult-onset MD and HMSN-I (16). In addition, severe 
fatigue appeared to be related to functional impairment in daily life.  
Until now, no longitudinal studies have been performed in which fatigue is examined in patients 
with neuromuscular disorders. Therefore it is not known which factors prospectively predict the 
level of fatigue.  
Our research group has developed a multidimensional assessment method to determine fatigue in 
several chronic disorders (17-20). This multidimensional assessment method identifies various 
dimensions relevant for fatigue: functional impairment in daily life, physical activity, psychological 
distress, sleep disturbances, concentration problems, social functioning, social support, self-
efficacy, and causal attribution. In chronic disorders like neuromuscular disorders also pain and 
muscle strength are assessed. 
This study presents the longitudinal data of a cohort of patients with three different 
neuromuscular disorders during an 18-month period. Furthermore, we develop a longitudinal 
model to predict fatigue. Based on relations between baseline variables at follow-up, we will 
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formulate a model of predicting factors of fatigue. This model is possible by using the statistical 
technique “structural equation modelling”, also referred to as “causal modelling”. This technique 
makes it not only possible to test different relationships simultaneously but also to compare the 
data fit of two or more proposed models. Such a model can be a basis for treatment interventions 
for fatigue. Therefore, the aim of this study is (1) to identify factors that predict fatigue in various 
neuromuscular disorders, and (2) to develop a model of factors contributing to the persistence of 
fatigue in these disorders. 
 
 
METHODS 
 
Patients 
Adult patients in the age of 18 to 60 years with a definite diagnosis of a neuromuscular disorder 
who could be classified into one of the following three diagnostic categories were asked to 
participate: (1) facioscapulohumeral muscular dystrophy (FSHD), (2) adult-onset myotonic 
dystrophy (MD) or (3) hereditary motor and sensory neuropathy type I (HMSN). Patients were 
recruited from the outpatient clinic of the Neuromuscular Centre of the Radboud University 
Medical Centre and form the Dutch Neuromuscular Diseases Association (Vereniging 
Spierziekten Nederland). Patients are a subgroup of patients described earlier (16). 
Only ambulatory patients were included. From the 527 patients that were eligible 331 patients 
were willing to participate in the research project. We invited 240 patients (for each 
neuromuscular disorder at least 70 patients) and 217 patients (65 FSHD, 79 MD, and 73 HMSN 
patients) complete data could be collected. Patients dropped out (n=23) for several reasons: high 
travel distance, inability to take a day off or personal reasons. Written informed consent was 
obtained from all participating patients. The following demographic features were collected: age, 
gender, marital status, and highest level of education and current status of employment. The 
regional ethics committee approved the study. 
 
Procedure 
The patients who agreed to take part in the study were invited to the Radboud University 
Nijmegen Medical Centre for the assessments. Within the multidimensional assessment method 
different modalities of assessment were used. These include self-report questionnaires,  
standardised sleep- and complaint diaries, neuropsychological tests, and actography (actometer).  
On the first day patients endure a physical examination including the MRC grading scale. The day 
after the patients start with the daily Self Observation List (SOL) during a period of 12 complete 
days. During this period the patients were wearing an actometer. After this 12-day period, 
patients filled out several computerised questionnaires and neuropsychological tests. At baseline 
and at 18-month follow-up, the same dimensions were used again. 
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Dependent variables 
Fatigue  
The Checklist Individual Strength (CIS) is a 20-item questionnaire and measures the following 
four aspects of fatigue during the previous two weeks: fatigue severity (8 items, range 8-56), 
concentration problems (5 items, range 5-35), reduced motivation (4 items, range 4-28) and 
reduced activity (3 items, range 3-21). Each item was scored on a 7-point Likert scale. High 
scores indicate a high level of experienced fatigue, a high level of concentration problems, low 
motivation and low levels of activity (17,18,21). A CIS-fatigue score equal or higher 35 was used 
to identify severe fatigue (17).  
 
Functional Impairment 
The Sickness Impact Profile (SIP) was used to assess functional impairment. We used a sum 
score of the following subscales: body care and movement, home management,  communication, 
work limitations, recreation and pastimes, and impairments with eating (22-23). Higher score 
indicate a higher level of functional impairment.  
 
 
Independent variables 
Physical activity  
Two self-report measurements, the subscales mobility and ambulation of the Sickness Impact 
Profile, were used to assess physical activity. 
The level of actual physical activity was assessed using an actometer (Actilog V3.0), a device worn 
by the patients around the ankle for 12 consecutive days (24). The actometer measures the 
number of accelerations over each 5-minute period. A general physical activity score is calculated 
by averaging the number of accelerations over the 12-day period (24).  
 
Psychological distress 
Psychological distress was measured with two self-report questionnaires: the Beck Depression 
Inventory for primary care (BDI-pc), and the Symptom Checklist-90 (SCL-90). The BDI-pc was 
used instead of the complete BDI, in order to prevent an overlap between physical aspects of 
fatigue with the somatic symptoms of depression (25,26). This shortened version of the BDI has 
7 items and consists of cognitive and affective symptoms. A score of 4 or more is indicative of 
clinical depression. We also used the subscales anxiety and depression of the SCL-90 (27). Higher 
SCL-subscale scores indicate more distress. 
 
Sleep disturbances 
Self-report sleep disturbances (e.g., light and fragmented sleep, difficulties with sleep initiating)  
were measured with the sleep subscale of the SCL-90 (27). In a dairy, the Self Observation List, 
patients reported perceived sleep disturbances every day (daily general quality of sleep, 
unrestorative sleep, hours of sleep during 24-hours, wake-up time and bed time) (28). Total 
scores range from 0 to 100. Higher score indicates higher daily sleep disturbances. 
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Neuropsychological impairment 
Self-reported concentration problems were measured with the concentration subscale of the CIS 
and the alertness behaviour subscale of the SIP. In order not to rely only on self-report data we 
used neuropsychological tests. The Complex Reaction Time (CRT) Task  measures the speed of 
information processing and is comprised of three successive tasks, each providing a reaction time 
(RT1, RT2, RT3) and movement time (MT1, MT2, MT3) (29). RT reflects speed of information 
processing and MT reflects motor speed. The Symbol Digit subtest (SDT) of the Dutch version 
of the Wechsler Adult Intelligence Scale (WAIS) assesses the ability to concentrate, and consists 
of pairing numbers with nonsense symbols as quickly as possible (30). The higher the score on 
this test, the better a person is able to concentrate. 
 
Social functioning and social support 
Social functioning was measured with the social interaction subscale of the SIP. Social support 
was measured by the Van Sonderen Social Support Inventory (SSL) (31). The SSL was divided 
into the SSL-I (amount of social support interactions), the SSL-D (discrepancies between amount 
of social support and desired amount of social support), and the SSL-N (amount of negative 
interactions). Total scores of SSL-I and SSL-D range from 34-136, total score of SSL-N from 7-
28.  
 
Pain 
Pain intensity was assessed by a 0 – 100 rating Visual Analogue Scale (VAS) of average pain 
intensity on current moment, where 0 = no pain and 100 = pain as bad as could be. In addition, 
pain was measured with the daily-observed pain (DOP) score of the SOL during two weeks. 
Severity of pain was reported four times a day on a 5-point scale (0-4). Mean scores range from 0 
to 16 (17). 
 
Muscle strength 
Muscle strength was determined using the Medical Research Council (MRC) grading scale (MRC; 
0 to 5) investigating the strength of the shoulder abductors, grip force, foot extensors and knee 
extensors (32). In order to characterise the patients, these eight values (both left and right) were 
averaged. 
 
Statistics  
Data analysis was performed using SPSS for Windows (version 12.0). Descriptive statistics were 
used to describe the sample. Normality was tested according to the Kolmogorov-Smirnov test. 
Group differences at baseline were tested using one-way ANOVAs. In case of an overall 
significance, the Bonferonni correction was applied to compare the three patient groups. P values 
< 0.05 were regarded as statistically significant. Non-parametric tests such as the Kruskal-Wallis 
test and Chi2 test were used when appropriate. 
Paired sample T-tests were performed to analyse differences between baseline and follow-up 
scores. Pearson correlations were used to analyse relations between the dependent variables 
(experienced fatigue and impairment at follow-up) and the independent variables (various 
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dimensions at baseline). Significant variables will be selected as predictors for experienced fatigue 
and/or functional impairment and were be put in the model of experienced fatigue.  
The models were tested with structural equation modelling techniques, and the computer 
programme AMOS 5.0 was used to test and modify models (33,34). We tested a measurement 
model with directly observed variables in which the error terms associated with the observed 
variables were left to be estimated and also were assumed to be uncorrelated with each other. Chi 
square statistics and the adjusted goodness-of-fit-index (AGFI) were used to test data fit. 
According to guidelines for structural modelling, the data were considered to fit the model when 
the Chi square statistics was not significant and the AGFI was high (preferably above 0.90). 
Furthermore, the population error of approximation (root mean square error of approximation 
(RMSEA)) was taken into account as a measure of discrepancy per degree of freedom. Values up 
to 0.05 indicate a close fit and values up to 0.08 represent reasonable errors of approximation in 
the population. Preferably, the 90% confidence interval (90% CI) of the RMSEA index would be 
between 0.00 and 0.10 (35,36). 
 
 
RESULTS 
 
From the 217 participating patients at baseline, 19 patients dropped out for several reasons 
during the 18-month period of study (e.g. taking part in research takes too much time, family 
circumstances). In total, 198 patients (60 FSHD, 70 MD and 68 HMSN patients) completed the 
whole study. The patients who refused to take part in the study did not differ from the 
participating subjects with regard to age, gender, marital status, level of education, and 
employment status and level of experienced fatigue in each neuromuscular disorder.  
 
Information on baseline demographic characteristics of the groups are summarized in Table 10.1. 
No statistically significant differences were found in age, gender, marital status and level of 
education between the three groups. The mean time between baseline and follow-up was 18 
months (sd 2.6) for the whole group. 
 
TABLE 10.1. Baseline demographic characteristics of the three neuromuscular patient groups 
 FSHD 
N=60 
mean (sd) 
MD 
N=70 
mean (sd) 
HMSN-I 
N=68 
mean (sd) 
Mean age 44.3 (9.9) 41.3 (9.6) 42.4 (9.7) 
Age range 22-61 22-57 20-59 
Gender (male/female) 58% / 42% 57% / 43% 43% / 57% 
Higher education (>= 12 years) 16   (27%) 16   (23%) 19   (28%) 
 
Fatigue and functional impairment at baseline and follow-up 
For the group of FSHD patients the mean CIS-fatigue score at baseline was 31.8 (11.9), and at 
follow up 33.7 (12.1) (p=0.11); for the MD patients the CIS-fatigue at baseline was 33.8 (10.3), 
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and at follow-up 36.5 (9.8) (p=0.006); and for the HMSN patients the CIS-fatigue at baseline was 
34.4 (13.0), and at follow-up 33.9 (12.4) (p=0.63).   
For the group of FSHD patients the mean functional impairment at baseline was 404.2 (413.5), 
and at follow up 452.0 (469.5) (p=0.14); for the MD patients the functional impairment at 
baseline was 605.6 (484.0), and at follow-up 682.5 (489.6) (p=0.008); and for the HMSN patients 
the functional impairment at baseline was 449.9 (338.3), and at follow-up 434.9 (345.4) (p=0.55).  
 
Correlations between dimensions, fatigue and impairment 
In the whole group, correlations between the two dependent variables (CIS-fatigue and 
impairment at follow-up) and the various dimensions at baseline were calculated (Table 10.2). 
The following dimensions correlated significantly with experienced fatigue at follow-up: physical 
activity, sleep disturbances, neuropsychological impairment, pain, and muscle strength. 
Impairment correlated significantly with the dimensions physical activity, psychological distress, 
sleep disturbances, neuropsychological impairment, social functioning, pain, and muscle strength. 
The development of the model was based on the significant correlations between the  
dimensions and experienced fatigue and/or impairment. The variables of the various dimensions 
that correlated highest with fatigue and/or impairment were put (one by one) in the initial model. 
 
Development of a model of fatigue 
The testing and modification of the model of  fatigue was a multi-stage process. Results for each 
stage are presented in Table 10.3. 
Stage 1 
The cause and effect relationships for the initial model (Figure 10.1) were defined as follows: 
Muscle strength at baseline can be expected to have a direct effect on the level of physical activity 
(r=-0.540, p=0.00); lower level of physical activity at baseline is related to the level of fatigue at 
follow-up. We already know that fatigue is associated with functional impairment in daily life 
(16). In this model, we hypothesized that functional impairment at follow-up was caused by the 
level of fatigue at follow-up and the level of physical activity (SIP-ambulation) at baseline. The 
model was rejected as the Chi2 was significant and the Adjustment Goodness of Fit Index (AGFI) 
was low.  
 
 
 
 
 
 
 
 
 
FIGURE 10.1.  The hypothesized model (initial model) on dimensions to experienced fatigue in patients 
with three neuromuscular disorder 
Muscle strength Physical activity 
Experienced 
fatigue 
Impairment 
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Stage 2 
The next highest correlation with fatigue at follow-up is sleep disturbances at baseline, especially 
the daily general sleep quality (Table 10.2). We expected that sleep disturbances (general quality of 
sleep) would have a direct effect on the level of fatigue. Testing of the new model showed that 
the AGFI increased to 0.90. 
Stage 3 
Pain is a common symptom in patients with neuromuscular disorders. Pain (Daily Observed Pain 
score) at baseline was related to fatigue. We expected that pain would have a direct causal effect 
on the level of fatigue. Testing this new model showed a good fit as the Adjustment Goodness of 
Fit Index was well above 0.90 and the Chi2 statistic was not significant. The Root Mean Square 
Error of Approximation (RMSEA) was less than 0.05 indicating a close fit for the model. 
Stage 4 
Social functioning at baseline (SIP-social interaction) was related with impairment at follow-up. 
We expected that social functioning would have a direct causal effect on impairment. Testing this 
new model showed that the AGFI decreased to 0.87. 
Stage 5 
We deleted social functioning from the model. Neuropsychological impairment at baseline  (SIP-
alertness behaviour) was related to impairment at follow-up. We expected that 
neuropsychological impairment has a direct causal effect on impairment. Testing this model 
showed that the AGFI was 0.86. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10.2.  Adjusted model of perpetuating factors of experienced fatigue in patients with three 
neuromuscular disorder (n=198), error terms have been omitted in the figure. *p<0.001, #p<0.05.  
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Stage 6 
We deleted neuropsychological impairment from the model. Psychological distress at baseline 
(SCL-depression) was related with impairment at follow-up. We expected that psychological 
distress would have a direct causal effect on impairment. Testing of this model showed that the 
AGFI was reduced to 0.92. 
Stage 7 
We deleted psychological distress from the model. Muscle strength (MRC score) at baseline was 
related to impairment at follow-up. We expected that muscle strength would have a direct causal 
effect on impairment. Testing this model showed that the AGFI reduced to 0.93, compared to 
stage 3. 
Stage 8 
The model of stage 3 was chosen as the final model , because it had the best model fit (Figure 
10.2). 
In stead of a self-report measure for physical activity we used the actometer (actual level of 
physical activity) as measure for physical activity in the whole group (n=198). The model fit was 
still acceptable.  
 
 
TABLE 10.3. Stages in AMOS analyses for neuromuscular disorders (n=198): Chi2, degrees of freedom,  
p-value of Chi2 , and Adjusted Goodness of Fit Index (AGFI), and root mean square error of  
approximation (RMSEA). 
Stage Description of the model 
(added or deleted causal relations) 
Chi2 df p AGFI RMSEA, lower 
and upper bound 
Stage 1 Testing of the initial model: rejected 15.27 2 0.000 0.82 0.13, 0.05 – 0.22 
Stage 2 Added: sleep disturbances to fatigue 13.9 4 0.007 0.90 0.11, 0.05 - 0.11  
Stage 3 Added: pain to fatigue 4.75 6 0.576 0.97 0.00, 0.00 – 0.10 
Stage 4 Added: social functioning to impairment 28.77 8 0.000 0.87 0.12, 0.07 – 0.16  
Stage 5 Deleted: social functioning 
Added: neuropsychological impairment 
to impairment 
 
33.1 
 
8 
 
0.000 
 
0.86 
 
0.13, 0.08 – 0.17 
Stage 6 Deleted: neuropsychological impairment 
Added: psychological distress to 
impairment 
 
16.35 
 
8 
 
0.038 
 
0.92 
 
0.07, 0.02 – 0.12 
Stage 7 Deleted: psychological distress 
Added: muscle strength to impairment 
 
9.8 
 
5 
 
0.082 
 
0.93 
 
0.07, 0.00 – 0.14 
Stage 8 Deleted: muscle strength to impairment 
Final Model (stage 3) 
 
4.75 
 
6 
 
0.576 
 
0.97 
 
0.00, 0.00 – 0.10 
 Alternative model: 
Actometer instead of a self-report 
measure for physical activity  
 
14.2 
 
6 
 
0.027 
 
0.92 
 
0.08, 0.02 – 0.14 
 
 
Model fit of final model and alternative model in the various neuromuscular disorders 
The relationships between the various dimensions to fatigue and impairment in daily life might 
vary substantially with the neuromuscular disorder. For that reason the model fit of the final 
model (stage 8) was tested for the three neuromuscular disorders separately.  
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For HMSN patients the model fit was excellent (AGFI 0.98). In the FSHD patients the model fit 
of the final model was lower (AGFI 0.94). In FSHD we found a relationship between pain and 
physical activity (r= 0.499), which was not found in MD and HMSN patients. Therefore, in the 
FSHD group we added a relationship between pain and physical activity in the final model, the 
model fit increased (AGFI 0.97) (Table 10.4). In MD patients the model fit was the lowest 
(AGFI 0.95).  
In the three neuromuscular disorders separately we also tested the alternative model with the 
actometer in stead of the self report measure of physical activity (Table 10.4). In HMSN patients 
(AGFI 0.96) and FSHD patients (AGFI 0.94) the model fit was still excellent. However, in MD 
patients the model fit reduced considerably (AGFI 0.84). 
 
 
TABLE 10.4. The final model for the various neuromuscular disorders: Chi2, degrees of freedom, p-value 
of Chi2 , and Adjusted Goodness of Fit Index (AGFI),and root mean square error of  approximation 
(RMSEA)  
Disorder Description of the model 
(added or deleted causal relations) 
Chi2 df p AGFI RMSEA, lower 
and upper bound 
MD Testing the final model 2.82 6 0.831 0.95 0.000, 0.00 – 0.09 
 Testing the alternative model 10.1 6 0.122 0.84 0.100, 0.00 – 0.20 
HMSN Testing the final model 1.99 6 0.926 0.98 0.000, 0.00 – 0.05 
 Testing the alternative model 3.20 6 0.784 0.96 0.000, 0.00 – 0.11 
FSHD       
Stage 1 Testing the final model 3.73 6 0.714 0.94 0.000, 0.00 – 0.11 
 Testing the alternative model 5.0 6 0.543 0.91 0.000, 0.00 – 0.15 
Stage 2 Added: pain to physical activity 5.21 5 0.390 0.97 0.000, 0.00 – 0.10 
 Testing alternative model 6.84 5 0.341 0.94 0.030, 0.00 – 0.12 
 
 
 
DISCUSSION 
 
As far as we know this is the first longitudinal study in which a model has been developed and 
tested with factors involved in the perpetuating of experienced fatigue in patients with 
neuromuscular disorders.  
The investigated neuromuscular disorders are slowly progressive disorders. These patients had 
perhaps more time to adapt their lifestyle on various dimensions to the daily hassles of their 
disease. In a time lag of 18 months we found that the MD patients reported significant higher 
levels of experienced fatigue and increased functional impairments. In FSHD and HMSN 
patients we found no differences in the level of experienced fatigue and functional impairments. 
Model testing revealed that muscle strength, level of self-reported physical activity, sleep 
disturbances, and pain were significantly associated with the level of experienced fatigue. Level of 
experienced fatigue and level of physical activity were significantly associated with more 
functional impairment in daily life. This model showed an excellent fit for the whole group of 
patients. 
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For the separate neuromuscular disorders, the model fit is excellent for the HMSN, also when 
actual level of physical activity was used. In FSHD patients the relation between pain and activity 
has to be added in order to get an acceptable fit. In MD the model fit reduced considerably after 
replacing self-reported physical activity by actual physical activity.  
Physical activity has an important place in the model of fatigue in neuromuscular disorders. The 
same is found in other conditions, e.g., CFS and fatigue after cancer (18,19). Lower level of actual 
physical activity contributed to higher levels of experienced fatigue and more functional 
impairment in daily life in several diseases.  
Physical activity was measured by self-report in the final model. Self-report instruments do not 
measure actual behaviour. Responses on these instruments appear to be an expression of the 
patients’ view about activity, and may be biased by cognitions concerning illness and disability 
(37). Self-report instruments of physical activity reflect subjective interpretation of the level of 
physical activity, and not the actual level of physical activity (38). Therefore, an actometer was 
used as a reference for actual level of physical activity. Accelerometers, such as the actometer 
used in the present study, are reliable and valid instruments to measure human physical activity 
(38). In general, correlations between the actometer and self-reported measures of physical 
activity are moderate (38,19). 
Our investigations showed that actual physical activity levels by actometer differed considerably 
between the three neuromuscular disorders. In patients with myotonic dystrophy we found no 
difference in actometer scores between severely fatigued patients and non-severely fatigued 
patients, but in FSHD and HMSN patients we found significant differences between severely 
fatigued and non-severely fatigued patients on actometer score. This means that in FSHD and 
HMSN was a relationship between actual level of physical activity and experienced fatigue, but 
not in MD. When we tested the model with the actometer instead of the self-report measure in 
FSHD and HMSN patients the model fit remains excellent. But in MD patients the model fit 
reduced considerably. The discrepancy between self-report and actual behaviour appear to be 
larger in MD compared to FSHD and HMSN. These findings also suggest that factors other than 
physical fitness play a role in MD.  
Psychological distress, social functioning and neuropsychological impairment at baseline could 
not be included in the final model. These factors do no add by the factors already presented in 
the model. 
Some pharmaceutical agents may influence the measurements by changing (neuro)functioning. 
While about a third of our neuromuscular patients used any form of medication, we checked if 
this could explain the higher values of fatigue in our group pf patients. Subgroup analyses, 
however, showed that fatigue values of only medication-free patients were also increased. 
The strengths of this study are the longitudinal character of it and the fact that it concerns a large 
group of patients. A limitation is that the subgroups of patients are rather small. Therefore the 
presence of more differences between the three patient groups could not be tested. The number 
of factors to be tested in the model is limited with a small number of patients. Another point is 
the generality of the results. We only investigated ambulant patients and excluded total 
wheelchair bounded patients, to measure the actual level of physical activity in these disorders. So 
the model is probably not valid for more severe patients. However, fatigue scores from 381 non-
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participating patients with neuromuscular disorders (74 FSHD, 243 MD, and 64 HMSN patient) 
did not differ from the participating patients (1).  
 
The model of perpetuating factors of experienced fatigue in three neuromuscular disorders might 
serve as a basis for treatment approaches to reduce fatigue in these disorders. The model of 
perpetuating factors of fatigue in FSHD and HMSN is different from the model of MD. The 
main difference is seen in physical (in)activity. These differenced have implications for 
interventions based on these models. Programmes with comprehensive aerobic exercise would be 
maximise the level of actual physical activity and reduce fatigue in patients with FSHD and 
HMSN. Successful treatment of fatigue in FSHD and HMSN should not be directed only at 
encouraging patients to increase physical activity level but, in addition, sleep disturbances and 
pain should also be treated.   
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INTRODUCTION 
 
The aim of this thesis is to investigate fatigue from prevalence to predictors, and to develop a 
model of perpetuating factors of fatigue in three homogeneous groups of patients with different 
genetically well-defined neuromuscular disorders, using a longitudinal study design. These three 
neuromuscular disorders are the following: facioscapulohumeral muscular dystrophy (FSHD), a 
myogenic disorder; adult-onset myotonic dystrophy (MD), a multisystem disorder; and hereditary 
motor and sensory neuropathy type I (HMSN), a neurogenic disorder.  
In this final chapter we will discuss the main results of this thesis and place them into 
perspective, as well as describe the limitations of our investigations. In Part 1 we will discuss the 
prevalence of experienced fatigue in patients with the three neuromuscular disorders (FSHD, 
MD, and HMSN), factors related to experienced fatigue, the lack of a connection between 
psychiatric comorbidity and fatigue, the relationship between ambulatory disabilities, walking 
aids, and fatigue, and finally, the various types of fatigue (experienced fatigue and physiological 
fatigue). Our model of perpetuating factors of fatigue in neuromuscular disorders will be 
discussed in Part 2 and suggestions for clinical implications and future research will be made in 
Part 3. 
 
 
PART 1 
 
1.1 Prevalence of experienced fatigue in patients with neuromuscular disorders 
Fatigue in multiple sclerosis (MS) is much better known and more frequently studied (1-4) than it 
is in neuromuscular disorders. More than 60% of patients with MS report severe experienced 
fatigue and assessments with validated questionnaires in various samples of MS patients have 
consistently confirmed that experienced fatigue is a frequent problem and a problem with a 
serious impact on daily life. Experienced fatigue is considered to be an established clinical 
symptom of MS (1-4).  
Within the group of neuromuscular disorders, fatigue has been described in patients with post-
polio syndrome, myasthenia gravis, and immune-mediated neuropathies like Guillain-Barré 
syndrome (5-9). These studies demonstrate that fatigue is a prominent and highly disabling 
symptom in the neuromuscular disorders investigated. All these studies had a cross-sectional 
design and not one of them investigated the relationship between fatigue and impairment in daily 
life, or the relationship between fatigue and physical activity. To our knowledge, fatigue has never 
been studied in relatively frequent neuromuscular disorders like FSHD, MD or HMSN. 
Our first goal, therefore, was to assess the prevalence of experienced fatigue in these patient 
groups by means of a validated fatigue questionnaire, the Checklist Individual Strength (10-11). 
The Checklist Individual Strength has excellent psychometric properties and it has been used in 
research and in clinical practice in patients with several disorders and in healthy controls (11-13). 
A cut-off score was determined on this scale to assess severe experienced fatigue (11).  
The results of the studies reported in this thesis show that experienced fatigue is a severe 
problem for more than 60% of patients with FSHD, adult-onset MD, and HMSN type I. These 
data confirm the clinical impression that the majority of patients with these types of 
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neuromuscular disorders suffer from severe fatigue, demonstrating that the experience of severe 
fatigue is not only characteristic of multiple sclerosis, but is a frequent complaint in the said 
disorders as well. 
In the case of all three neuromuscular disorders studied, severely fatigued patients reported more 
limitations in daily life than non-severely fatigued patients, in the areas of physical functioning for 
instance, pain, social functioning, mental health, work, and leisure time.  
The conclusion is warranted that fatigue is not only a frequent complaint, but also a relevant, 
clinically important problem with tremendous implications for the quality of life of these patients. 
 
1.2. Factors related to experienced fatigue 
In addition to the prevalence of experienced fatigue, we also studied the factors that are related to 
fatigue in the three different neuromuscular disorders. As indicated in Chapter 1, we used a 
multi-dimensional assessment method that was developed, tested and validated in cross-sectional 
and prospective studies of several chronic disorders (1,11-13). 
We may conclude from the results of our studies that severely fatigued patients with different 
neuromuscular disorders scored significantly higher on all dimensions compared with non-
severely fatigued patients with the same disorder.  
In addition, we found several differences between severely fatigued and non-severely fatigued 
patients in the three investigated neuromuscular disorders. In patients with MD, the severely 
fatigued patients had higher scores on communication problems, sleep disturbances and 
concentration problems, and more difficulties with initiating and planning than the non-severely 
fatigued patients, and these scores were also higher than in FSHD and HMSN.  Patients with 
FSHD or HMSN with severe fatigue appeared to have lower levels of actual physical activity. 
Remarkably, in MD we found no difference in actual physical activity between severely fatigued 
and non-severely fatigued patients.  
Regression analyses were used to study the relationships between the different dimensions and 
fatigue. Although the factors contributing to fatigue differed somewhat among the disorders, the 
most important finding was that the amount of explained variance of fatigue differed 
considerably in the three neuromuscular disorders, with the amount of explained variance being 
the highest for HMSN and the lowest for MD. These data are cross-sectional, however, which 
makes it difficult to draw definite conclusions about the cause and effect relationships between 
variables. 
The longitudinal study of these factors might reveal which factors have predictive value for 
chronic fatigue (Part 2). 
 
1.3. Psychiatric comorbidity is not an explanation for severe fatigue in these disorders 
Experienced fatigue is a symptom in a number of affective disorders, including depression and 
dysthymia. Depression turned out to be a predictor of low health-related quality of life in several 
chronic neurological diseases (14-16) and the studies in question show that symptoms of 
depression have an appreciable effect on quality of life. Depressive symptoms have been linked 
to more functional impairment and increased levels of fatigue (17-20), which led us to study the 
relationship between experienced fatigue and psychiatric disorders (including depressive 
disorders) in FSHD, MD, and HMSN patients. 
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We found that approximately 11% of the patients with these neuromuscular disorders probably 
had a current psychiatric disorder, while more than 60% of the patients reported severe 
experienced fatigue. The presence of current psychiatric disorders in the neuromuscular disorders 
investigated did not differ from the presence of psychiatric disorders in the Dutch population 
(the 1-month prevalence of mood and anxiety disorders is 14%) (21). The most common 
psychiatric disorders in our groups were depression and phobias. No differences were found 
between the three neuromuscular disorders with regard to the presence of psychiatric 
comorbidity. In contrast to studies of patients with Parkinson’s disease (range of psychiatric 
disorders 15-30%) and multiple sclerosis (range 20-35%) (15,19,20), we found a much lower rate 
of psychiatric disorders in our sample of patients with neuromuscular disorders, even in the 
subgroup of adult-onset MD.  
More importantly, psychiatric comorbidity was not associated with the severity of experienced 
fatigue. The prevalence of experienced fatigue appeared to be as high in patients without 
psychiatric comorbidity as in the group with psychiatric comorbidity, and the same was true for 
patients with and without depression. This means that experienced fatigue cannot be considered 
to be part of a depression in these patients. In contrast to other neurological disorders (MS, 
Parkinson’s disease), psychiatric comorbidity is not an explanation for experienced fatigue in 
FSHD, MD, and HMSN.  
 
1.4. Ambulatory disability, walking aids, and fatigue  
Most hereditary neuromuscular disorders have a clinical course characterized by progressive 
muscular weakness and atrophy that – over a period of years - involves general mobility 
problems, the most serious of which are loss of independent walking ability and dependence in 
daily living activities. Patients with HMSN may also develop foot deformities due to muscular 
imbalance (22). Functional disability of ambulation in HMSN patients has been reported 
previously in the literature (22-28) and while ambulation and mobility-related problems were 
investigated in these studies, none of them investigated the relationship between ambulatory 
disability, walking aids, and experienced fatigue. 
HMSN patients are usually not wheelchair-bound and so many young and middle-aged patients 
who walk independently are regarded as non-disabled or mildly- disabled in the literature (24-26). 
In our study, however, we found that ambulation disabilities occur frequently in ambulant 
patients with HMSN type I and that this presence of ambulatory disabilities appeared to be 
associated with experienced fatigue. In addition, the use of walking aids was related to fewer 
ambulatory problems and less fatigue. Half of the patients who reported ambulatory disabilities 
did not use any form of walking aid and had higher fatigue scores, which could mean that the use 
of walking aids is helpful in reducing fatigue, a finding that is of interest in the rehabilitation 
management of the patient. 
 
1.5. Different types of fatigue (experienced fatigue and physiological fatigue) 
It is particularly interesting to study the contribution of physiological factors to experienced 
fatigue in patients with neuromuscular disorders in whom the motor of the body itself (the 
muscles and/or peripheral nervous system) is affected. 
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Physiological fatigue is defined as the loss of force-producing capacity during exercise. This loss 
is called peripheral fatigue if has its origin at the peripheral nerve or in the muscle tissue (29-31), 
and it is called central fatigue if it occurs because of changes in the central nervous system during 
exercise (31-33). Central activation failure is present when voluntary central activation is sub-
optimal and the increase of central activation failure during exercise is called central fatigue 
(figure 11.1).  
Experienced fatigue is the complaint of the patient that can be heard in the physician’s consulting 
room and it can only be assessed by self-report. Physiological fatigue (peripheral fatigue and 
central fatigue) cannot be reported, but only assessed in a laboratory setting and experienced 
fatigue does not necessarily correlate with signs of physiological fatigue (30).  
A main finding for physiological fatigue is that central activation is diminished or decreases faster 
in patients who experience severe fatigue (Chapter 6); sub-optimal activation means that the 
motor unit firing rate or motor unit recruitment is sub-optimal. Figure 11.1 illustrates the 
concepts of fatigue and central activation failure in controls and patients with three different 
neuromuscular disorders during sustained maximal voluntary contraction (MVC). Central 
activation failure is about 15% at the start of contraction in healthy controls (left panel), which 
means that the maximal voluntary contraction is about 15% lower than maximal muscle capacity.  
The amount of central activation failure increases during sustained maximal voluntary 
contraction, implying that central fatigue occurs.  
 
 
FIGURE 11.1. Peripheral fatigue, central fatigue and central activation failure in healthy controls and in 
patients with one of three different neuromuscular disorders (FSHD, MD, and HMSN). Vertical bars on 
the right of every figure show a constant force level in the panels. 
 
 
In contrast, the maximum muscle capacity is reduced in patients with FSHD, MD or HMSN 
(right panel), as a direct consequence of peripheral changes due to the disease. Moreover, high 
values for central activation failure further decrease force production during maximal voluntary 
contraction. Hardly any central fatigue occurred in the neuromuscular disorders studied. 
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The amount of peripheral fatigue or rate of peripheral fatigue development is lower in the three 
neuromuscular disorders than in healthy controls. To a large extent, this is probably caused by 
the fact that patients perform the task at a lower absolute force level. 
The studies presented in this thesis (Chapter 6 and Chapter 7) indicate that central activation 
failure and central fatigue are related to experienced fatigue. Central activation failure explained 6 
to 10% of the variance in the level of experienced fatigue in the three different neuromuscular 
disorders, which means that central activation has a weak relationship with experienced fatigue. 
We also found no relationship between peripheral fatigue and experienced fatigue and we 
therefore consider physiological fatigue (peripheral fatigue and central activation failure) and 
experienced fatigue to be largely separate types of fatigue. 
 
 
PART 2 
 
2.1. The building of a model of experienced fatigue 
The availability of a model of perpetuating factors of fatigue in three different neuromuscular 
disorders may help to develop treatment approaches to reduce fatigue in these disorders, and we 
therefore developed and tested a model of factors involved in the persistence of experienced 
fatigue in these three neuromuscular disorders, using the “structural equation modelling” 
statistical technique. This technique does not only make it possible to test different relationships 
simultaneously, but also to compare the data fit of two or more proposed models. The 
longitudinal study enabled us to investigate predictors of the natural course of experienced 
fatigue and we examined the relationship possible perpetuating factors at baseline and fatigue at 
follow-up.   The data of the three patient groups had to be combined in order to have enough 
power to test the models, the disadvantage of this procedure being that we focus on the common 
factors instead of the differences.  
 
We found that physical activity, sleep disturbances, pain and muscle strength are predictors of 
experienced fatigue in the combined group of FSHD, MD, and HMSN patients. This means that 
patients who reported lower levels of physical activity, more sleep disturbances, more pain, and 
patients with increased muscle weakness, are the ones that are most likely to experience persistent 
fatigue. In the final model (Chapter 10), physical activity is the most important predictor of 
fatigue, followed by sleep disturbances and pain. 
The following elements for the building of a model of perpetuating factors of fatigue in 
neuromuscular disorders will be discussed in part 2: sleep disturbances and fatigue, pain and 
fatigue, influence of close relatives on fatigue, illness cognitions and fatigue, and finally, 
differences between the three separate neuromuscular disorders. 
 
2.2. Sleep disturbances and fatigue 
Sleep disturbances are common in patients with chronic neurological disorders (34-38), problems 
with sleep maintenance (light and fragmented sleep) and difficulties with sleep initiation being the 
most frequent sleep disorders in neurological disorders. Other common sleep-associated 
complaints include excessive daytime sleepiness and nocturnal pain and cramps (37).  
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Although fatigue is a common finding in a wide range of sleep disorders and has been 
documented in clinical reports, it has not been studied as an independent symptom in the context 
of sleep disturbances (39-41). No studies were found that investigated the relationship between 
sleep disturbances and fatigue in patients with FSHD, MD or HMSN. 
We measured sleep disturbances with validated questionnaires and a standardised sleep complaint 
diary, in which patients reported the perceived sleep disturbances on a daily basis (e.g. quality of 
sleep, unrestorative sleep, hours of sleep, wake-up time and bedtime).  
Sleep disturbances showed an important relationship with experienced fatigue in all three 
disorders and perceived quality of sleep was admitted in the final model of fatigue for the whole 
group. There are some differences in sleep disturbances, however, between the three 
neuromuscular disorders. We found that patients with MD reported more time to sleep and rest 
during the day than patients with FSHD or HMSN, and we also found that one third of the 
participating MD patients reported excessive daytime sleepiness, although the length of sleep 
during the night was similar in FSHD, MD, and HMSN patients.  
HMSN patients reported significantly more sleep problems than the patients in the two other 
groups (Chapter 7). The former reported more problems with falling asleep and maintaining 
sleep and we found a significantly higher standard deviation in the bedtimes of HMSN patients 
than in the two other groups, which means that the bedtimes for HMSN patients vary to a 
greater extent than the bedtimes of the other patient groups. Furthermore, patients with FSHD 
showed greater variability in wake-up time than MD and HMSN patients. 
Previous studies found an association between sleep disturbances, depression and fatigue (42-43), 
but we found a very low rate of depression in the patients investigated and no relationship with 
fatigue, which means that the low prevalence of depression cannot explain the high rate of sleep 
disturbances in these disorders. Even if we see depression as a continuum, using the Beck 
depression inventory, the correlation between depression and different kinds of sleep parameters 
is low. In conclusion, sleep disturbances had a direct relationship with fatigue, which was not 
affected by depression. 
 
2.3. Pain and fatigue 
Pain is a symptom that most clinicians would not typically associate with chronic neuromuscular 
disorders. Clinical experience in our hospital had indicated, however, that many patients with 
FSHD, MD or HMSN report pain and consider it an important problem. Few studies have 
examined pain and the effect of pain on the daily lives of patients with slowly progressive 
neuromuscular disorders (44-47) and these showed considerable variability in the frequency of 
pain in the different disorders. Severe pain appears to be more common among patients with 
muscular dystrophies and post-polio syndrome and less common in patients with other 
neuromuscular disorders (47). Most of these studies investigated pain in heterogeneous groups of 
neuromuscular disorders and had a cross-sectional design; none of them investigated the 
relationship between pain and physical activity, and pain and fatigue in neuromuscular disorders. 
Our first goal was to assess the prevalence of pain in patients with FSHD, MD or HMSN, by 
means of validated pain questionnaires and a standardised pain complaint diary.  
We found that about three-quarters of the FSHD and HMSN patients and nearly half of the MD 
patients report pain (Chapter 8). In all three neuromuscular disorders, the pain scores were higher 
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than the scores of a reference group of healthy people, which means that pain is a clinically 
relevant complaint in these patients. The localization of pain was specific for each neuromuscular 
disorder, with pain being most frequently localized in body regions mostly affected by the 
neuromuscular disorder, so that localization differed among the three disorders. In the three 
groups, we found no differences in functional impairment and in muscle strength between 
patients with and without pain, signifying that pain is not related to impairment and muscle 
strength in the whole group of patients. Only in FSHD patients did we find a relationship 
between pain and physical activity, whereby FSHD patients with higher pain levels showed lower 
levels of physical activity. In contrast to the findings relating to pain, however, higher levels of 
fatigue in all patient groups were consistently associated with higher levels of functional 
impairment and lower levels of physical activity. Pain and experienced fatigue were related in 
FSHD and HMSN patients, but unrelated in MD patients. Pain is an important feature in the 
neuromuscular disorders investigated, therefore, although fatigue has more implications for daily 
functioning. 
 
2.4. Influence of close relatives on fatigue 
The emphasis in research has been primarily on the person with the disease and the disease 
process itself, rather than on the system that includes the close relatives. It is well known that 
patients with chronic disorders may often disorganize the lives of close relatives and change the 
family’s lifestyle, with  recent evidence supporting the concept that close relatives influence the 
mental and physical status of patients with chronic disorders, e.g. in patients with Parkinson’s 
disease (48-53). 
The partner relationship is generally thought to be one of the most important sources of social 
support, because the partner is the main provider of emotional and instrumental support for the 
patient. Rhommessen et al investigated spouse responses to behaviours that patients exhibit as a 
result of their disability (e.g. activity limitations, difficult ambulation, or discomfort) (49) and their 
study shows that some spouses may unwittingly encourage decreased patient functioning by 
being overly solicitous or attentive to patient disability behaviour. Research on individuals with 
chronic pain demonstrates that negative spouse responses to disability are associated with greater 
discomfort and emotional distress in the patient (54), so that the reaction of the spouse to the 
patient’s disability may affect physical and psychological adjustment in the patient. This finding 
for the spouse may also apply to close relatives of the patient, especially in cases where a spouse 
is lacking. 
Although spouses and close relatives are important resources for the patient with a chronic 
disorder (53), the role of spouses or close relatives of patients with neuromuscular disorders has 
received no attention as yet.   
As a consequence, we investigated the responses of close relatives to experienced fatigue of 
patients with FSHD, MD or HMSN (Chapter 9) and found that sympathetic-empathic responses 
by the relative to the fatigue of the patient, such as getting help or attention and advising the 
patient to rest, contributed to higher levels of experienced fatigue in the patients; many close 
relatives advised the severely fatigued patient to rest, for example. This means that such 
sympathetic-empathic responses by the close relatives may reinforce behaviour that increases the 
chances of higher levels of fatigue in the patient. It has also been suggested that social processes 
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in the family system of patients increased their dependency on others and decreased the self-
efficacy of the patient (54).  
We did not include the responses of close relatives in our model of fatigue in neuromuscular 
disorders, because the responses of the relatives were collected exclusively in the follow-up study 
and we only wanted to include factors assessed at baseline in our model of fatigue. Furthermore, 
the sample size in a model assessing responses of close relatives would have been much smaller 
than in our final model, due to the fact that not every patient had a close relative who was willing 
to fill in the relatives’ questionnaires. 
 
 
 
FIGURE 11.2. The model of perpetuating factors of fatigue including the sympathetic-empathic 
responses of close relatives. (N=106: FSHD, n=33; MD, n=32; HMSN, n=41). *p<0.001, #p<0.05. 
 
 
The model fit is 0.88 if we only include patients from the close relatives study (n=106) in our 
final model. If the sympathetic-empathic responses of the close relatives are added to the model 
as a direct influence on the experienced fatigue of the patient, the model fit increases to 0.92 
(Figure 11.2), which means that the responses of close relatives are one of the perpetuating 
factors of fatigue in the neuromuscular disorders. The implications of these findings indicate the 
importance of including close relatives in treatment and of teaching close relatives to reinforce 
healthy behaviour. 
 
2.5. lllness cognitions and fatigue 
Illness cognitions are seen as a risk factor for an unfavourable physical and psychological health 
status in patients with various chronic diseases (55), but have never been studied in 
neuromuscular disorders before. Illness cognitions reflect the way patients perceive and think 
about their disease and are considered important mediators between disease and the well-being of 
the patient. These illness cognitions relate to different aspects of the disease, such as beliefs about 
the cause of the disease, the consequences of the disease, and the sense of control over 
Experienced 
fatigue 
Muscle strength Physical activity 
Pain 
Sleep 
disturbances 
Impairment 
Responses of 
close relatives 
ß=-0.49* 
ß=0.29# 
ß=0.23# 
ß=-0.21# ß=0.22# 
ß=0.15# 
ß=0.28# 
General Discussion       133 
 
 
 
 
 
symptoms (self-efficacy). In addition, illness cognitions can also affect disease-related behaviour, 
such as the perception of symptoms, coping with complaints, seeking help and compliance with 
treatment (56). According to Bandura’s social learning theory, people’s behaviour is strongly 
influenced by self-efficacy expectations (57) and it has been demonstrated that illness cognitions 
also play an important role in the models of persistence of fatigue in chronic fatigue syndrome 
and multiple sclerosis (58). In these models, self-efficacy was directly and independently related 
to fatigue severity.  
We also found for all three disorders that the severely fatigued patients reported a lower sense of 
control over fatigue than the non-severely fatigued patients (Chapter 7). Our model of 
perpetuating factors of fatigue in neuromuscular disorders did not include illness cognitions in 
the final model, however, for the following reason. Those patients who reported that they did not 
experience fatigue as a symptom did not fill out the self-efficacy and causal attribution 
questionnaires, thereby considerably reducing the number of patients in whom we could test the 
model. The model fit is excellent (AGFI 0.94) if we test our model in severely fatigued patients 
alone (n=109) and there is only a small increase in model fit (AGFI 0.95) if the model includes 
self-efficacy at baseline associated with experienced fatigue at follow-up. Lower self-efficacy 
expectations are moderately associated, therefore, with higher levels of experienced fatigue in 
neuromuscular disorders.  
 
2.6. Differences between the three neuromuscular disorders 
In this thesis we have found that the majority of patients with FSHD, MD or HMSN 
experienced severe fatigue and the longitudinal study enabled us to investigate predictors of 
experienced fatigue. We combined the data of the three patient groups in order to have enough 
power to test the models, but we wanted to know the specific perpetuating factors for fatigue in 
each neuromuscular disorder (FSHD, MD, and HMSN), which is why the model comprising the 
factors of the final model was tested for the three neuromuscular disorders separately. The model 
fit remained excellent for HMSN, but was lower in FSHD, in which we found a significant 
relationship between pain and physical activity that was not found in HMSN and MD, and which 
led us to add a relationship between pain and physical activity in the FSHD model in order to get 
a better fit. The model fit remained the lowest in MD and could not be improved. 
The model of fatigue used self-reported physical activity in all three neuromuscular disorders and 
it is known that there can be a considerable discrepancy between self-reported physical activity and 
actual level of physical activity (actometer). At the same time, the highest levels of self-reported 
physical activity were seen in HMSN and FSHD and the lowest in MD. The model fit remained 
excellent when we tested the model with the actometer instead of the self-report measure in 
FSHD and HMSN (Figure 11.3A and 11.3B), but the already lower model fit in MD decreased 
considerably after replacing self-reported physical activity by actual level of physical activity 
(Figure 11.3C). The actual level of physical activity is the most important predictor of fatigue in 
the models of fatigue for FSHD and HMSN, followed by sleep disturbances, which means that 
the actual level of physical activity was a perpetuating factor in FSHD and HMSN, but not in 
MD.  
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FIGURE 11.3A.  The model of perpetuating factors of fatigue in the FSHD group (N=60).  
 AGFI=0.94, *p<0.001, #p<0.05. 
 
 
FIGURE 11.3B.  The model of perpetuating factors of fatigue in the HMSN group (N=68). 
 AGFI=0.96, *p<0.001, #p<0.05. 
 
 
FIGURE 11.3C.  The model of perpetuating factors of fatigue in the MD group (N=70).  
AGFI=0.84, *p<0.001, #p<0.05. 
 
FIGURE 11.3. The different models of perpetuating factors for the various neuromuscular disorders. 
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These findings suggest that factors other than the actual level of physical activity play a role in 
patients with MD. In Chapter 3, we found that patients with MD have higher levels of reduced 
motivation than FSHD and HMSN patients; reduced motivation, which means the drive to 
initiate and sustain interest in a specific activity, is a well-known problem in MD (58-59). 
Excessive daytime sleepiness is another established clinical manifestation of MD (59) and 
measured with the Epworth Sleepiness Scale, we found that one third of the participating MD 
patients reported excessive daytime sleepiness. Although it could be argued that MD patients may 
confuse the experience of fatigue with daytime sleepiness, previous research (60) and our data as 
well showed that excessive daytime sleepiness was related to reduced motivation, but not to the 
level of experienced fatigue, which is why we could not admit excessive daytime sleepiness into 
the model of fatigue in MD. 
Recent evidence has shown a role for the CNS stimulant Modafinil as a therapeutic agent to help 
control excessive daytime sleepiness in patients with MD (61-65), but  we expect Modafinil to 
have no effect on fatigue severity in these patients, because fatigue exists independently of 
excessive daytime sleepiness in MD. 
The model of perpetuating factors of fatigue in FSHD and HMSN is different from the model in 
MD, the main difference being seen in physical (in)activity. These differences have implications 
for interventions based on these models. 
 
 
PART 3 
 
3.1. Generalizability of the model of fatigue 
We developed a model of fatigue in patients with FSHD, MD, and HMSN, but the question is 
whether this model of fatigue is suitable for treatment approaches to fatigue in all these patient 
groups and there are arguments why this is not the case. The model is based on data from 
ambulant patients. We only investigated ambulant patients and excluded totally wheelchair-bound 
patients in order to be able to use an actometer to measure actual level of physical activity in 
these neuromuscular disorders. No differences in fatigue severity were found between eligible 
and non-eligible patients in the three combined groups of neuromuscular disorders. In the FSHD 
group, however, we found a significant difference in self-reported ambulatory impairments 
between eligible and non-eligible patients, but not in the MD group or HMSN group. It is 
possible, therefore, that the model of fatigue would be different in more severely affected FSHD 
patients in particular, e.g. patients with more ambulatory impairments. 
 
3.2. Clinical implications and future research 
Our findings show that fatigue is a common symptom in patients with FSHD, MD, and HMSN. 
Additionally, we have demonstrated that experienced fatigue is a relevant problem, because it is 
related to more severe impairments in these disorders. We conclude from this that fatigue is an 
important issue to be addressed in the neuromuscular clinic and we would like to draw clinical 
conclusions in this paragraph from the data of this thesis. 
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Firstly, it is important that clinicians actively ask the patient and the close relatives about the 
presence and consequences of fatigue and to distinguish it from depression, sleep disturbances 
and exercise intolerance. The Abbreviated Fatigue Questionnaire (AFQ) could be used in 
addition to the medical history to assess fatigue severity (66); this questionnaire was developed 
for use in clinical practice and has good reliability and validity. A cut-off score on this 
questionnaire was determined to assess severe experienced fatigue.  
Next, the clinician can check the known perpetuating factors of fatigue in the individual patient 
(e.g., physical inactivity, sleep disturbances and pain) and can also consider simple treatment 
approaches, such as prescribing walking aids in order to reduce physical inactivity, since physical 
inactivity is the main factor among the perpetuating factors of fatigue in these neuromuscular 
disorders. Furthermore, it may be worthwhile to involve close relatives in the conversation with 
the patient about fatigue and to stimulate close relatives to reinforce healthy behaviour in the 
patient. 
 
The model of perpetuating factors of fatigue in the three neuromuscular disorders can serve as a 
basis for future studies of treatment approaches to reduce fatigue in these disorders. The model 
shows that different factors affect fatigue, directly or indirectly, which means that treatment 
approaches will have to be multi-factorial. The level of actual physical activity is the most 
important factor to treat in FSHD and HMSN, but not in MD. Other factors are sleep 
disturbances, pain, influence of close relatives, and illness cognitions. All of these factors may be 
contained in treatment approaches to reduce fatigue. 
 
What is already known about influencing physical activity and the effect on fatigue in patients 
with FSHD, MD, and HMSN? 
The literature demonstrates that strength training and aerobic exercise training are well tolerated 
and safe interventions with limited positive effect on muscle strength (67-71). All of these studies 
have substantial (methodological) shortcomings, however, their main shortcoming being the 
absence of fatigue measurements. Furthermore, most published studies grouped the different 
neuromuscular disorders together, while we know that FSHD, HMSN and MD have different 
perpetuating factors of fatigue, which is the reason why conclusions on the effect of training 
derived from mixed populations cannot be readily extrapolated to patients with specific 
neuromuscular disorders. The usefulness of aerobic exercise training to improve the level of 
actual physical activity will be relevant for FSHD and HMSN, but not for MD patients, because 
of differences in predictors of fatigue based on our model of perpetuating factors. 
Interventions to reduce fatigue can be developed and tested for FSHD and HMSN based on the 
model derived from this thesis. Other studies are needed for MD, however,  before interventions 
for fatigue can be developed for this patient group. 
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SUMMARY  
 
 
 
Fatigue is a common symptom in a number of (chronic) neurological disorders such as multiple 
sclerosis, Parkinson’s disease, and stroke. Surprisingly, fatigue in neuromuscular disorders 
received little attention. 
This thesis is the result of cooperation between the Expert Centre Chronic Fatigue and the 
Neuromuscular Centre Nijmegen of the Radboud University Medical Centre in Nijmegen. 
In this thesis we studied patients with three homogeneous groups of genetically well-defined 
neuromuscular disorders: facioscapulohumeral muscular dystrophy (FSHD), a myogenic disorder; 
adult-onset myotonic dystrophy (MD), a multisystem disorder; and hereditary motor and sensory 
neuropathy type I (HMSN), a neurogenic disorder. 
Fatigue is a multidimensional symptom and therefore it is important to find factors that 
perpetuate fatigue. A conceptual model of fatigue as it relates to neuromuscular disorders is 
needed to serve as a framework for research and discourse. The longitudinal design enabled us to 
investigate predictors of fatigue in these disorders. In Chapter 1 a general introduction to the 
studies is give. 
Literature reviewed in Chapter 2 has already shown the presence of chronic severe fatigue in 
several diseases. Though, until recently fatigue was seldom recognized as an important symptom 
of neuromuscular disorders. 
In Chapter 3 a study on the prevalence of experienced fatigue in neuromuscular disorders is 
presented. Severe experienced fatigue is experienced by more than 60% in patients with FSHD, 
MD, and HMSN type I. In addition, being severely fatigued was associated with greater levels of 
functional impairment in daily life. Because severe experienced fatigue is associated with 
problems in physical functioning, social functioning, mental health, bodily pain, and general 
health perception, it is a clinically and socially relevant problem. 
An association between experienced fatigue and psychiatric disorders has been reported in a 
number of neurological disorders, but has received little attention in neuromuscular disorders so 
far. Chapter 4 shows that psychiatric comorbidity occurs equally in patients with adult-onset MD, 
FSHD, HMSN-I, which is comparable to that in the Dutch general population. The most 
common psychiatric disorders were depression and phobias. This chapter shows that current and 
lifetime psychiatric comorbidity is not associated with experienced fatigue and/or muscle 
strength in these disorders. 
Chapter 5 shows that ambulatory related disabilities frequently occur within a large homogeneous 
population of HMSN I patients. Walking aids were used by 49% of the patients. Furthermore, 
ambulatory disabilities are related with age, muscle strength, experienced fatigue, actual level of 
physical activity (actometer), and general perceived health status. Walking aids are generally 
administrated to the more severely affected patients, however, the use of walking aids appears to 
be not completely in accordance with the perceived disability.  
Especially in patients with neuromuscular disorders, affecting the muscles and/or nerves, it is 
interesting to study the contribution of physiological factors to experienced fatigue. Physiological 
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fatigue is defined as the loss of force producing capacity during exercise. Both peripheral and 
central factors contributed to physiological fatigue, indicating that both the muscle tissues and the 
central nervous system may be involved. Chapter 6 describes that in the overall group of patients 
with neuromuscular disorders central activation is reduced. However, the inter-individual 
distribution of the levels of central activation is much larger and a clear overlap exists between 
patients and healthy controls. A significant correlation exists between the value of central 
activation failure at the start of the sustained maximal voluntary contraction and the level of 
experienced fatigue. Again, the amount of peripheral fatigue is reduced, probably because of the 
lower maximal voluntary contraction of patients. 
Chapter 7 shows that experienced fatigue is related to central activation failure, but not to 
peripheral fatigue in a large cohort of patients with FSHD, adult-onset MD, and HMSN type I. 
However, central activation failure explained only a small amount of the variance of experienced 
fatigue. Experienced fatigue, central activation failure, and peripheral fatigue appeared to be 
separate types of fatigue with different determinants. There was no significant difference in 
central activation failure, peripheral fatigue or muscle strength between severely experienced 
fatigued and non-severely experienced fatigued patients. The respective determinants of 
experienced fatigue appear to be quite similar in the three neuromuscular disorders, but the 
amount of explained variance differs.  
Chapter 8 shows that three-quart of the FSHD and HMSN patients, and nearly half of the MD 
patients reported regularly pain. Pain complaints were most frequently localized in body regions 
affected in the course of the neuromuscular disorder and thus differ between the three disorders. 
The most common type of pain was muscle pain. There was no relationship between the 
presence of pain and age, gender, functional disability, actual level of physical activity (actometer), 
and muscle strength in all three disorders. We found a weak relation between pain and 
experienced fatigue. We can conclude that pain and experienced fatigue are different features in 
these neuromuscular disorders. 
Experienced fatigue have a major impact on patients’ functioning and activities of daily living. 
The effects are not limited to the patient, the close relatives of the patient can suffer as well. 
Chapter 9 shows that responses of close relatives to both experienced fatigue and neuromuscular 
disorder of the patient were mainly sympathetic-empathic responses and similar within relatives 
of patients with the three disorders. The relatives reported that they were trying to imagine what 
the patients feels, making supportive statements. Overall, the relatives rated the level of 
experienced fatigue of the patient lower than the patient did himself.  We found low agreement 
between relatives and MD patients over the patients’ experienced fatigue and higher agreement 
between relatives and FSHD and HMSN patients.  
In spouse living together we found more disagreement in marital satisfaction within MD couples 
than within FSHD and HMSN couples. Sympathetic-empathic responses of close relatives to 
fatigue of the patient were related to higher levels of experienced fatigue in FSHD and HMSN 
patients, but not in MD patients. 
Chapter 10 is a sequel of our cross-sectional study of fatigue in neuromuscular disorders of which 
the results were presented in the first chapters. The longitudinal design of this study enabled us 
to investigate the perpetuating factors of fatigue. 
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In all three neuromuscular disorders, muscle strength, self-reported activity, sleep disturbances 
and pain at baseline contributed directly or indirectly, to fatigue and impairment at follow-up. 
Lower muscle strength contributed to lower levels of physical activity, which in turn contributed 
to experienced fatigue severity. The model showed excellent fit for the whole group of 
neuromuscular disorders. In FSHD, also pain contributed to physical activity. A model with the 
actometer as measurement for actual physical activity in stead of self-report showed an excellent 
model fit in FSHD and HMSN, but an insufficient fit in MD. In conclusion, the model of 
perpetuating factors for fatigue in FSHD and HMSN is different from the model in MD. The 
main difference is in physical (in)activity. These differences have implications for interventions 
based on these models. 
The general discussion in chapter 11 mainly concerns the building of a model of experienced 
fatigue in neuromuscular disorders. A model of fatigue is the basis to develop treatment 
interventions to reduce fatigue in these disorders. The differences between the three 
neuromuscular disorders are important for treatment interventions. Future studies will have to 
develop treatment interventions and to determine other factors that may reduce fatigue in these 
disorders. 
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SAMENVATTING  
 
 
 
Vermoeidheid is een veel voorkomend symptoom in een groot aantal (chronische) neurologische  
aandoeningen zoals multiple sclerose, ziekte van Parkinson en  cerebrovasculaire aandoeningen. 
Het is opmerkelijk dat vermoeidheid in neuromusculaire aandoeningen nauwelijks aandacht heeft 
gekregen. 
Dit proefschrift betreft een samenwerking tussen het Nijmeegs Kenniscentrum Chronische 
Vermoeidheid en het Neuromusculaire Centrum Nijmegen van het Universitair Medisch 
Centrum St. Radboud in Nijmegen. 
In dit proefschrift worden patiënten uit drie homogene genetisch neuromusculaire aandoeningen 
onderzocht, te weten facioscapulohumerale dystrofie (FSHD), een spieraandoening; myotone 
dystrofie (MD), een multisysteem aandoening, en hereditaire motore en sensore neuropathie type 
I (HMSN), een zenuwaandoening. 
Vermoeidheid is een multidimensioneel symptoom en daarom is het belangrijk om 
instandhoudende factoren van vermoeidheid in neuromusculaire aandoeningen te vinden. Een 
conceptueel model van vermoeidheid in neuromusculaire aandoeningen is nodig om te komen 
tot een raamwerk dat gebruikt kan worden voor onderzoek en beloopstudies. De longitudinale 
studieopzet maakt het mogelijk om predictoren van vermoeidheid in deze aandoeningen te 
bestuderen. Hoofdstuk 1 behelst een algemene introductie op de verschillende studies. 
Hoofdstuk 2 geeft een samenvatting van de literatuur die ernstige ervaren vermoeidheid bij 
uiteenlopende aandoeningen bespreekt. Bij neuromusculaire aandoeningen wordt vermoeidheid 
zelden als symptoom herkent. 
In Hoofdstuk 3  wordt de prevalentie van ervaren vermoeidheid in neuromusculaire 
aandoeningen beschreven. Extreme ervaren vermoeidheid komt voor bij meer dan 60% van de 
patiënten met FSHD, MD en HMSN. De vermoeidheid gaat gepaard met functionele 
beperkingen, zoals meer problemen op het gebied van fysiek functioneren, sociaal functioneren, 
mentaal welzijn, pijn en perceptie van gezondheid,  in het dagelijks leven en is daarom een 
klinisch en sociaal relevant probleem. 
In verschillende chronische neurologische aandoeningen wordt gevonden dat psychiatrische 
stoornissen en ervaren vermoeidheid samen hangen. In hoofdstuk 4 wordt gevonden dat 
psychiatrische stoornissen niet verschillen tussen de drie neuromusculaire aandoeningen en de 
prevalentie vergelijkbaar is met de prevalentie in de algemene Nederlandse bevolking. De 
psychiatrische stoornissen die het meest voorkomen zijn depressie en fobische angsten. Dit 
hoofdstuk laat zien dat huidige en levensloop psychiatrische comorbiditeit niet samenhangen met 
ervaren vermoeidheid en/of spierzwakte in de onderzochte neuromusculaire aandoeningen. 
Hoofdstuk 5 laat zien dat beperkingen op het gebied van lopen frequent voorkomen bij een grote 
groep patiënten met HMSN type I. Loophulpmiddelen worden door 49% van de patiënten 
gebruikt. Beperkingen op het gebied van lopen zijn gerelateerd aan leeftijd, spierkracht, ervaren 
vermoeidheid, feitelijk beweeggedrag, en aan ervaren gezondheidsbeleving. Loophulpmiddelen 
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worden in het algemeen meer voorgeschreven bij patiënten die meer zijn aangedaan. Echter, het 
gebruik van deze hulpmiddelen is niet geheel in overeenstemming met de ervaren beperkingen. 
Met name in patiënten met neuromusculaire aandoeningen, waarbij de spieren en/of de zenuwen 
zijn aangedaan, is het interessant om de bijdrage van fysiologische aspecten van ervaren 
vermoeidheid te bestuderen. Fysiologische vermoeidheid is gedefinieerd als een vermindering van 
de maximale vrijwillige kracht als gevolg van inspanning. Zowel perifere (spier-) als centrale 
(zenuwstelsel-) aspecten kunnen aan fysiologische vermoeidheid bijdragen.  
Hoofdstuk 6 beschrijft dat bij patiënten met verschillende neuromusculaire aandoeningen de 
centrale aansturing van de spieren sterk is verminderd. Dit verschil bestaat zelfs op individueel 
niveau: de centrale activatie is bij iedere onderzochte patiënt kleiner dan bij elke persoon uit de 
controle groep. Tijdens de meting treedt bij de patiënten minder perifere vermoeidheid op dan bij 
de controle personen. Dit komt waarschijnlijk doordat de spiercapaciteit door de verslechterde 
aansturing tijdens de meting in mindere mate aangesproken wordt. 
Hoofdstuk 7 toont dat ervaren vermoeidheid gerelateerd is aan het gebrek aan centrale 
aansturing, maar niet aan perifere vermoeidheid. Echter, het gebrek aan centrale aansturing 
verklaart slechts een klein gedeelte van de ervaren vermoeidheid. Hieruit concluderen we dat 
ervaren vermoeidheid, gebrek aan centrale aansturing en perifere vermoeidheid drie verschillende 
vormen van vermoeidheid zijn. Er werden geen verschillen gevonden tussen ernstig vermoeide 
patiënten en niet vermoeide patiënten in gebrek aan centrale aansturing, perifere vermoeidheid of 
in spierkracht. De verschillende determinanten van ervaren vermoeidheid komen overeen tussen 
de drie verschillende neuromusculaire aandoeningen, maar de verklaarde variantie verschilt sterk 
tussen de drie aandoeningen. 
Driekwart van de patiënten met FSHD en HMSN en bijna de helft van patiënten met MD 
rapporteren frequent pijn (hoofdstuk 8). Pijnklachten worden met name in die lichaamsdelen 
aangegeven die gedurende het beloop van de betreffende neuromusculaire aandoening aangedaan 
raken. Dit zorgt ervoor dat de pijnlokaties verschillend zijn tussen de drie onderzochte 
aandoeningen. De meest gerapporteerde pijn is spierpijn. Er werd geen relatie gevonden tussen 
pijn en leeftijd, tussen pijn en sexe, tussen pijn en functionele beperkingen in het dagelijks leven, 
tussen pijn en actuele fysieke activiteit, en tussen pijn en spierzwakte in alle drie de aandoeningen. 
Er werd een zwakke relatie gevonden tussen pijn en ervaren vermoeidheid. We concluderen dat 
pijn en vermoeidheid verschillende factoren zijn in deze neuromusculaire aandoeningen. 
Hoofdstuk 9 beschrijft dat partners of andere naaste familieleden met name meevoelend reageren 
op de vermoeidheidsklachten en de neuromusculaire aandoening van de patiënt. Er is sprake van 
een lage overeenstemming over de vermoeidheid van de patiënt door de partner en de patiënt 
zelf in koppels van MD patiënten. Er werd overeenstemming gevonden in koppels van FSHD en 
HMSN patiënten over de vermoeidheid van de patiënt. Levenspartners van patiënten met MD 
rapporteren lage huwelijkssatisfactie in tegenstelling tot levenspartners van FSHD en HMSN 
patiënten. Meevoelende responsen van partners van FSHD en HMSN patiënten hebben invloed 
op de ernst van de ervaren vermoeidheid van de patiënt, maar dit wordt niet gevonden in MD 
koppels. 
Hoofdstuk 10 beschrijft het vervolg op de cross-sectionele studie naar vermoeidheid bij patiënten 
met neuromusculaire aandoeningen, waarvan de resultaten in de vorenstaande hoofdstukken 
worden beschreven. De longitudinale studie van dit onderzoek maakt het mogelijk om 
Samenvatting       149 
 
 
 
 
 
instandhoudende factoren van vermoeidheid te onderzoeken. In alle drie de neuromusculaire 
aandoeningen vinden we dat spierzwakte, zelf gerapporteerde fysieke activiteit, slaapproblemen 
en pijn op baseline direct of indirect bijdragen aan ervaren vermoeidheid en beperkingen op 
follow-up. Toename van spierzwakte draagt bij aan verminderde fysieke activiteit, wat leidt tot 
toename van de ervaren vermoeidheid. In patiënten met FSHD levert ook pijn een bijdrage aan 
fysieke activiteit. Een model met de actometer als meetinstrument voor de feitelijke fysieke 
activiteit in plaats van zelf gerapporteerde fysieke activiteit, toont een goede fit voor patiënten 
met FSHD en HMSN, maar niet in patiënten met MD. In patiënten met MD vinden we geen 
samenhang tussen feitelijke fysieke activiteit op baseline en ervaren vermoeidheid bij follow-up in 
tegenstelling tot patiënten met FSHD en HMSN. Deze bevindingen zijn erg belangrijk voor de 
ontwikkeling van interventies om vermoeidheid te verminderen in patiënten met een 
neuromusculaire aandoening. 
De algemene discussie in hoofdstuk 11 gaat vooral over de ontwikkeling van het model voor 
vermoeidheid in patiënten met een neuromusculaire aandoening. Een model voor vermoeidheid 
is de basis voor de ontwikkeling van behandelingsmogelijkheden om vermoeidheid in deze 
aandoeningen te verminderen. De verschillen tussen de drie neuromusculaire aandoeningen zijn 
daarbij zeer belangrijk om een passende behandeling te ontwikkelen. Toekomstig onderzoek zal 
moeten uitwijzen of behandelingsmogelijkheden  vermoeidheid kunnen reduceren in deze 
aandoeningen. 
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LAATSTE WOORD  
 
 
 
Een laatste (dank) woord aan alle reisgenoten. Het voltooien van een proefschrift is het 
volbrengen van een lange avontuurlijke reis. Een reis die zeer afwisselend is verlopen. Soms over 
geplaveide wegen, soms over nauwelijks begaanbare paden, maar immer door afwisselende 
landschappen met weidse vergezichten. Een reis met veel variatie en onverwachte gebeurtenissen. 
Daarbij altijd de ontmoeting met vele reisgenoten, bestaande uit korte ontmoetingen en anderen 
reisden weer langer mee. 
Gaarne wil ik mijn dank betuigen aan alle reisgenoten die met mij deze reis hebben beleefd en 
doorstaan. 
Een eerste woord aan alle deelnemende patiënten. Van heinde en verre reisde u naar Nijmegen 
om deel te nemen aan het onderzoek. Het belangenloos beschikbaar stellen van uw tijd, inzet en 
openhartigheid heeft dit onderzoek doen slagen! Met veel genoegen denk ik aan deze 
ontmoetingen terug. 
Daarnaast het basisteam dat met elkaar deze reis heeft beleefd: 
De drie promotores, “de hooggeleerde jongens”, Gijs Bleijenberg, Baziel van Engelen en Machiel 
Zwarts. Drie kapiteins op een schip op ontdekkingsreis was soms lastig, maar gaf ook aanleiding 
tot diepgaande discussies en het opstellen van kritische (onderzoeks) vragen.  
Met collega onderzoekers Maartje Schillings en Sieberen van der Werf, aan het begin van de reis, 
was de bemanning compleet. Jarenlang hebben we als basisteam maandelijks overleg gehad met 
betrekking tot het ontrafelen van vermoeidheid bij patiënten met verschillende neuromusculaire 
aandoeningen. Reisplannen werden besproken, logistieke zaken geregeld en als het nodig was 
werd de route gewijzigd en/of aangepast. Ons maandelijks overleg gaf voldoende stof voor 
uitvoerige discussies zodat uiteindelijk een voeten-op-tafel-discussie in het leven werd geroepen. 
Helaas werd de kurk niet uit de fles gehaald, misschien waren de resultaten dan heel anders 
geworden! 
Met promotores en onderzoekers uit verschillende disciplines (psychologie, neurologie, klinische 
neurofysiologie, F.C. Donders centre en revalidatie geneeskunde) vormden we een waar multi-
disciplinair team! 
Collega’s van verschillende afdelingen, met name noem ik de afdeling Medische Psychologie, het 
Nijmeegs Kenniscentrum Chronische Vermoeidheid en de afdeling Klinische Neurofysiologie, 
dank ik voor de steun tijdens deze reis, de gezelligheid en hulp bij het een of ander. 
De reisgenoten die mij geweldig geholpen hebben bij de accurate dataverzameling en 
dataverwerking: ik noem Tiny Fasotti, Danielle van Hout, Henny Janssen, Carel Kruip, Jetske 
Oostelbosch en Harmen Vissers. 
Daar waren altijd “de meisjes” van het secretariaat, Nancy, Helma en Jacintha. Altijd bereid om 
mijn reisverhalen aan te horen, brieven of faxen te verzenden, tot en met de verzending van deze 
boekjes. 
156 Laatste woord 
 
 
 
Ria te Winkel-Slotboom heeft me altijd geweldig geholpen, van stickers plakken in de 1100 
screeningsboekjes (de klokken gingen luiden bij Jacob!), logistiek van actometers, 
patiëntnummering, dataverwerking, tot en met een laatste hand aan dit proefschrift! 
Collega onderzoekers en kamergenoten dank ik voor het aanhoren van mijn dagelijkse 
beslommeringen, discussies over statistische analyses en vooral voor de gezelligheid en voor de 
vele lunches samen. Elke week begon met de briefing op maandagochtend om 9.00 uur. Kort 
voor dit wekelijks gebeuren was een ieder naarstig op zoek naar een vraag, een onbegrijpelijke 
statistische analyse of ander probleem. Mogelijk verhoogt dit de creativiteit onder 
wetenschappelijk onderzoekers! 
 
Tot slot een woord aan enkele dierbaren. Marita en Henk, jullie reisden mee met al mijn 
avonturen. Jullie gaven me twee geweldige neefjes, Koen en Sander, door jullie blijf ik jong en in 
de (hedendaagse) tijd op al mijn reizen! 
 
Het laatste woord is aan mijn ouders. Pap en Mam, jullie hebben als thuishaven en als redders aan 
de wal mijn levensreis gevolgd en gesteund. We hebben ervaren dat het oplopen van averij bij 
deze reis kan horen. Maar we hebben ook geleerd dat deze ballast kan worden omgezet in bagage. 
Met deze bagage zet ik mijn reis voort! 
 
 
 
Arnhem, september 2006  
J.S.K. 
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